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Abstract

Peroxisome Proliferator-Activated Receptors (PPARs) are ligand activated transcription factors that belong to the nuclear hormone receptor family. In this thesis, I have investigated the anti-inflammatory role of PPAR-β/δ in animal models of regional myocardial ischaemia and reperfusion (I/R) injury and multiple organ injury/dysfunction associated with endotoxaemia and septic shock. 
Using a selective PPAR-β/δ agonist, GW0742, I have demonstrated that selective activation of PPAR-β/δ protects the rat heart against injury caused by regional I/R when administered, as late as, on reperfusion of the previously ischaemic myocardium. 
Additionally, I have demonstrated that genetic deletion of PPAR-β/δ greatly exacerbates the multiple organ injury/dysfunction caused by endotoxaemia in the mouse. Moreover, treatment of wild-type mice with GW0742 attenuated the multiple organ injury/dysfunction caused by endotoxaemia. Thus, activation of PPAR-β/δ affords a protective effect against multiple organ injury/dysfunction in endotoxic shock. 
I extended the above study by investigating the effect of PPAR-β/δ activation in a clinically relevant model of caecal ligation and puncture (CLP)-induced polymicrobial sepsis by evaluating survival in mice over 10 days. I demonstrated that treatment with GW0742, several hours after the induction of polymicrobial sepsis, improved survival. Furthermore, I have demonstrated this organ protective effect of PPAR-β/δ activation in a rat model of severe acute endotoxaemia.
	Finally, I have shown that the protective effects of PPAR-β/δ activation in animal models of acute regional myocardial I/R injury and endotoxic shock are secondary to an anti-inflammatory mechanism involving the activation of the phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway, which leads to the inhibition of the activation of glycogen synthase kinase (GSK)-3β and nuclear factor (NF)-B activity, subsequently reducing the expression of NF-B-driven gene transcription of a number of pro-inflammatory mediators. 
	Thus, in this thesis, I have demonstrated an anti-inflammatory protective role for PPAR-β/δ in models of regional myocardial I/R injury, septic shock and systemic inflammation.    
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CHAPTER I
General Introduction



 Acute myocardial infarction (MI) is the leading cause of morbidity and mortality in the industrialised world. There is currently considerable interest in investigating the mechanisms underlying ischaemia and reperfusion (I/R) injury in the hope that novel therapeutic targets may be identified that aid the development of drugs which protect against, or at least minimize the extent of, tissue damage. Preserving the viability of ischaemic myocardium has been recognized as a major therapeutic target.
Likewise, sepsis is also a serious clinical problem as its incidence has risen quite rapidly over recent decades in conjunction with increasing mortalities. The development of an appropriate pharmacological intervention for the treatment of sepsis is proving difficult due to the complexity of the disorder. 
It is well established that there is a large inflammatory response that is associated, and contributes, to the augmentation of these two diseases. In this thesis, I explore the role of Peroxisome Proliferator-Activated Receptor (PPAR)-β/δ, a ligand-activated transcription factor, in animal models of acute myocardial I/R injury, endotoxaemia and sepsis. Specifically, I examine the anti-inflammatory role of PPAR-β/δ in providing the basis for a new therapeutic approach to preventing or ameliorating the degree of tissue injury associated with these two diseases.

1.1      PPARs

PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily, related to retinoid, steroid and thyroid hormone receptors (Evans, 1988). Each member of this superfamily share similar structural and functional features (Fig 1.1.1). The amino-terminal (A/B) domain contains a ligand-independent activation function (AF-1) responsible for the phosphorylation of PPAR. A DNA-binding domain (DBD) (C) promotes the binding of PPAR to the PPAR response element (PPRE) in the promoter region of target genes. The hinge region (D) is a docking domain for co-factors. The carboxyl-terminal (E) domain contains a ligand-binding domain (LBD) responsible for ligand selectivity and activation of PPAR binding to the PPRE, increasing the expression of target genes. The ligand-dependent activation function (AF-2) is located in the E domain and recruits PPAR co-factors to assist gene transcription  ADDIN EN.CITE (Kota et al., 2005; Moras & Gronemeyer, 1998). There are three members of the PPAR subfamily, PPAR-α (also known as NR1C1), PPAR-β/δ (also known as NUC1, NR1C2), and PPAR-γ (also known as NR1C3). These receptors were identified as PPARs as the first member of the PPAR family to be cloned, PPAR-α, resulted in peroxisome proliferation upon activation in rodent hepatocytes (Desvergne & Wahli, 1999). However, activation of PPAR-β/δ or PPAR-γ did not elicit this response. 
The tissue distribution of PPARs in humans (and rodents) does vary considerably. PPAR-α is mainly expressed in the liver, kidney, skeletal and cardiac muscle (Chinetti et al., 2000), in addition to a range of vascular cells and monocytes/macrophages  ADDIN EN.CITE (Inoue et al., 1998). PPAR-γ is mainly expressed in adipocytes and in vascular cells and cells of the immune system such as monocytes/macrophages, B and T cells, and dendritic cells (Rizzo & Fiorucci, 2006). PPAR-β/δ is expressed ubiquitously, however little is known about its ligands and function. 
PPARs have been recognised as fatty acid sensors due to the identification of polyunsaturated fatty acids, and their derivatives, as physiological PPAR ligands (Dreyer et al., 1993). This fatty acid sensing activity regulates a variety of homeostatic functions, such as energy metabolism, cell proliferation/differentiation and inflammation (Das & Chakrabarti, 2006). 












Fig 1.1.1.	Schematic of the structure of the functional domains of the PPAR family. PPARs are composed of four distinct functional domains. The A/B domain located at the N-terminal with AF-1 is responsible for phosphorylation. The C domain is the DNA binding domain. D is the hinge region, a docking domain for co-factors. The E domain is located at the C-terminal and contains the ligand binding domain responsible for ligand selectivity and activation of PPAR to the PPRE, and AF-2 responsible for promoting the recruitment of PPAR co-factors required for gene transcription.   

Transcriptional trans-activation

PPARs regulate gene transcription by forming heterodimers with retinoid X receptors (RXRs). RXRs are members of the nuclear hormone receptor superfamily and are activated by the binding of 9-cis-retinoic acid. Structurally, the PPRE consists of direct repeat (DR)-1 elements of two hexanucleotides with the AGGTCA sequence separated by a single nucleotide spacer. The DR-1 sequence is selective for the PPAR-RXR heterodimer which distinguishes it from other nuclear receptor response elements, thereby allowing the PPAR/RXR heterodimer to bind to specific PPREs in the promoter region of specific target genes. This leads to the activation or suppression of relevant target genes in a cell- and tissue-specific manner, depending on the receptor and combination of co-factors, thus behaving as a transcriptional regulator. 
With no ligand present, high affinity complexes are formed between the PPAR-RXR heterodimer and nuclear receptor co-repressor proteins containing histone deacetylase activity which inhibits transcription, such as nuclear receptor co-repressor (N-CoR) and the silencing mediator for retinoid and thyroid hormone receptor (SMRT). This prevents transcriptional activation by sequestering the PPAR-RXR heterodimer from the PPRE. With a ligand present, the co-repressor proteins are displaced by the ligand, and in some cases a co-activator protein such as histone acetylase activity containing steroid receptor co-activator (SRC)-1 and the PPAR binding protein (PBP), which binds to the heterodimer, thus allowing the binding of the active heterodimer to the PPRE, resulting in the activation or suppression of the relevant target genes (Figure 1.1.2). 

Transcriptional trans-repression

PPARs also have the ability of regulating gene expression independently of DNA-binding via a mechanism termed ligand-dependent trans-repression. There are several potential mechanisms of ligand-dependent trans-repression. 
One such mechanism is the competition for limited amounts of essential shared co-activator proteins, thus reducing the availability of co-activators for other transcriptional factors and effectively shifting the gene expression in favour of the activated transcriptional factor. 
Another mechanism is the direct binding of the PPAR-RXR complex to transcription factors causing its functional inhibition by preventing gene transcription. This mechanism of trans-repression, involving physical interaction, has been reported for protein subunits of the nuclear factor (NF)-B family, such as p50 and p65  ADDIN EN.CITE (Chung et al., 2000). 






Figure 1.1.2.	Activation of the peroxisome proliferator-activated receptor (PPAR). PPAR forms a heterodimer with the retinoic acid receptor (RXR). Binding of the ligand to PPAR results in activation of the heterodimer and the dissociation of co-repressors. This produces an active transcription complex that associates with transcriptional co-activators and binds to sequence specific PPAR response elements (PPREs) located on target genes. Modified from (Abdelrahman et al., 2005).

1.1.1	PPAR-α

PPAR-α is a receptor for a number of structurally diverse ligands including endogenous polyunsaturated, saturated and monounsaturated fatty acids such as, linoleic acid, arachidonic acid, eicosapentaenoic acids, palmitic acid, stearic acid, palmitoleic acid and oleic acid. Activation of PPAR-α has been found to modulate lipid metabolism, involving the transcription of apolipoprotein AI and AII resulting in high levels of high density lipoprotein (HDL) cholesterol and, hence, increased HDL uptake  ADDIN EN.CITE (Vu-Dac et al., 1998). PPAR-α activation also regulates β-oxidation of fatty acids and lipoprotein lipase (LPL) activity. PPAR-α activation reduces the activity of apolipoprotein CIII, which is an inhibitor of LPL, therefore increasing LPL activity and subsequently increasing triglyceride clearance from the blood  ADDIN EN.CITE (Staels et al., 1995). Synthetic exogenous ligands of PPAR-α are utilised in the management of dyslipidaemia and include the hypolipidemic fibrate drug class, such as gemfibrozil, fenofibrate and clofibrate. 

PPAR-α in inflammation

	The role of PPARs in inflammation was first reported for PPAR-α where mice lacking PPAR-α demonstrated a prolonged inflammatory response to treatment with a potent chemoattractant, leukotriene B4 (LTB4)  ADDIN EN.CITE (Devchand et al., 1996). Since then, several studies have demonstrated the anti-inflammatory properties of PPAR-α in vitro and in vivo. For example, aortae from PPAR-α deficient mice have exhibited a strong inflammatory response to lipopolysaccharide (LPS) exposure as indicated by enhanced levels of interleukin (IL)-6. Similarly, splenocytes from PPAR-α deficient mice demonstrated a large production of IL-6 and IL-12 in response to LPS when compared to wild-type (WT) mice  ADDIN EN.CITE (Poynter & Daynes, 1998).  In endothelial cells, PPAR-α ligands attenuate IL-6 release  ADDIN EN.CITE (Delerive et al., 1999), endothelin-1 formation  ADDIN EN.CITE (Martin-Nizard et al., 2002), cytokine/LPS induced inter-cellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 expression (Cuzzocrea et al., 2004a), and cyclo-oxygenase (COX)-2 expression  ADDIN EN.CITE (Staels et al., 1998). PPAR-α activation reduces the expression of inducible nitric oxide synthase (iNOS)  ADDIN EN.CITE (Colville-Nash et al., 1998) and production of matrix metallopeptidase (MMP)-9 and tumour necrosis factor (TNF)-α in macrophages (Chinetti et al., 2000) and the secretion of IL-2 and TNF-α in T lymphocytes  ADDIN EN.CITE (Marx et al., 2002). PPAR-α ligands also inhibit the activation of pro-inflammatory transcription factors, NF-B and activator protein (AP)-1, in a number of cell types. PPAR-α has been shown to interact with the p65 subunit of NF-B and the AP-1 containing N-terminus of c-jun  ADDIN EN.CITE (Delerive et al., 1999). PPAR-α can also repress the NF-B pathway by inducing the expression of IB, the major inhibitor of NF-B in smooth muscle cells and hepatocytes  ADDIN EN.CITE (Delerive et al., 2000). In vivo, PPAR-α ligands increase, the anti-inflammatory cytokine, IL-4 and reduce nitric oxide (NO) production in animal models of autoimmune disease  ADDIN EN.CITE (Lovett-Racke et al., 2004), decrease IL-1 and TNF-α in models of allergic dermatitis  ADDIN EN.CITE (Sheu et al., 2002), reduce the tissure injury (infarct size) associated with myocardial I/R injury  ADDIN EN.CITE (Wayman et al., 2002a; Yue et al., 2003), and reduce the formation of atherosclerotic lesions  ADDIN EN.CITE (Li et al., 2004). A number of PPAR-α ligands such as gemfibrozil and fenofibrate have been used in patients in the treatment of hyperlipidemia, where they reduce the plasma concentrations of IL-6, TNF-α, interferon (IFN)-γ, fibrinogen and C-reactive protein (CRP)  ADDIN EN.CITE (Madej et al., 1998; Staels et al., 1998). 

1.1.2	PPAR- γ

PPAR-γ is a receptor for a number of endogenous ligands including the prostaglandin (PG) metabolite, 15-deoxy-Δ12, 14-PGJ2 (15d-PGJ2), and fatty acids such as linoleic acid, arachidonic acid and eicosapentaenoic acid. Synthetic exogenous ligands of PPAR-γ include the thiazolidinediones (TZD) rosiglitazone and pioglitazone. Activation of PPAR-γ leads to an increased sensitivity to the metabolic actions of insulin. This is reported to occur through various gene-dependent mechanisms that affect the actions of insulin. PPAR-γ activation reduces insulin resistance through the inhibition of TNF-α  ADDIN EN.CITE (Shibasaki et al., 2003), and adipocyte-derived factors such as 11β-hydroxysteroid dehydrogenase 1 and adipocyte-related complement protein (ARCP) 30  ADDIN EN.CITE (Berger et al., 2001; Rangwala et al., 2003). PPAR-γ activation also results in increased expression of the glucose transporter protein GLUT4 in adipocytes which plays an important role in the process of glucose uptake (Shimaya et al., 1997). Activation of PPAR-γ via TZDs results in inhibition of the formation of resistin, a hormone secreted by adipocytes that elevates blood glucose levels  ADDIN EN.CITE (Shojima et al., 2002), and enhances phosphatidylinositol 3-kinase (PI3K) activity and membranous protein kinase (PK)B/Akt Ser473 phosphorylation, which inturn promotes insulin-stimulated glucose disposal in skeletal muscle  ADDIN EN.CITE (Kausch et al., 2001). 
PPAR-γ activation also leads to differentiation of adipocytes that are subsequently more capable of fatty acid uptake (Chawla et al., 1994). Furthermore, PPAR-γ activation promotes apoptosis in mature lipid-filled adipocytes  ADDIN EN.CITE (Okuno et al., 1998). 




PPAR-γ in inflammation

	The finding that PPAR-γ is expressed in endothelial cells, vascular smooth muscle cells and macrophages has stimulated a number of studies aimed at investigating the potential anti-inflammatory properties of PPAR-γ ligands. For instance, in endothelial cells PPAR-γ agonists reduce the expression of TNF-α-induced ICAM-1  ADDIN EN.CITE (Chen & Han, 2001), TNF-α- and C-reactive protein (CRP)-induced expression of chemokines monocyte chemoattractant protein (MCP)-1  ADDIN EN.CITE (Murao et al., 1999; Pasceri et al., 2001), and IFN-γ-induced expression of chemokines CXCL9, CXCL10, and CXCL11  ADDIN EN.CITE (Marx et al., 2000). Studies in macrophages have demonstrated an inhibition of the induction of iNOS and MMP-9  ADDIN EN.CITE (Ricote et al., 1998), and the production of TNF-α, IL-1β and IL-6 upon ligand-induced activation of PPAR-γ (Jiang et al., 1998). Additionally, PPAR-γ activation can inhibit the activation of cytokine-induced pro-inflammatory transcription factors AP-1, NF-κB and signal transducers and activator of transcription (STAT)-1  ADDIN EN.CITE (Ricote et al., 1998). Furthermore, PPAR-γ ligands inhibit T-cell proliferation and reduce the production of IFN-γ and TNF-α, and IL-2 by disrupting the T-cell-specific transcription factor nuclear factor for activated T-cells (NFAT)  ADDIN EN.CITE (Yang et al., 2000). A large number of in vivo studies have demonstrated the effectiveness of PPAR-γ activation in inflammatory models such as intestinal  ADDIN EN.CITE (Nakajima et al., 2001), lung  ADDIN EN.CITE (Okada et al., 2002), and myocardial I/R injury  ADDIN EN.CITE (Khandoudi et al., 2002; Wayman et al., 2002b; Yue et al., 2001), colitis  ADDIN EN.CITE (Lewis et al., 2001), rheumatoid arthritis  ADDIN EN.CITE (Kawahito et al., 2000), sepsis  ADDIN EN.CITE (Lee et al., 2005; Zingarelli et al., 2003), pancreatitis  ADDIN EN.CITE (Cuzzocrea et al., 2004b), atherosclerosis  ADDIN EN.CITE (Li et al., 2000), pulmonary inflammation  ADDIN EN.CITE (Birrell et al., 2004), and Alzheimer’s and Parkinson’s disease  ADDIN EN.CITE (Breidert et al., 2002; Landreth & Heneka, 2001). Several PPAR-γ ligands are being used in clinical scenarios including the treatment of type 2 diabetes and its associated cardiovascular inflammatory disorders. For example rosiglitazone seems to reduce the number of coronary artery events within six months following an angioplasty in patients with type 2 diabetes  ADDIN EN.CITE (Wang et al., 2005). 




1.1.3	PPAR-β/δ in inflammation

PPAR-β/δ is the least understood sub-type of the PPAR family, however it is well recognised that prostacyclin (PGI2) (Lim & Dey, 2000) as well as saturated and polyunsaturated fatty acids do activate PPAR-β/δ  ADDIN EN.CITE (Chawla et al., 2003; Forman et al., 1997; Krey et al., 1997; Xu et al., 1999). Studies involving PPAR-β/δ gene disruption have provided strong evidence for the importance of PPAR-β/δ in multiple biological processes such as placental development  ADDIN EN.CITE (Nadra et al., 2006), growth  ADDIN EN.CITE (Peters et al., 2000), platelet function  ADDIN EN.CITE (Ali et al., 2009), and lipid metabolism involved in cardiac development and function  ADDIN EN.CITE (Cheng et al., 2004; Reilly & Lee, 2008). Additionally, functional studies have also highlighted the role of PPAR-β/δ in epidermal differentiation and skin wound healing  ADDIN EN.CITE (Matsuura et al., 1999; Peters et al., 2000). The development of selective synthetic ligands, such as L-165041, GW0742 and GW501516 which activate PPAR-β/δ at very low concentrations in vitro and in vivo with a 1000-fold selectivity over the other PPAR subtypes  ADDIN EN.CITE (Berger et al., 1999; Sznaidman et al., 2003), has aided in the understanding of the physiological functions of PPAR-β/δ. These selective ligands have helped to identify specific roles for PPAR-β/δ in fatty acid oxidation in several tissues, including skeletal muscle and adipose tissue  ADDIN EN.CITE (Tanaka et al., 2003). Furthermore, PPAR-β/δ agonists have beneficial effects on circulating lipids, insulin resistance and obesity, providing evidence for the role of PPAR-β/δ in glucose metabolism and insulin sensitivity  ADDIN EN.CITE (Lee et al., 2006; Oliver et al., 2001; Wan et al., 2010; Wang et al., 2003b). GW0742-induced PPAR-β/δ activation has recently been shown to exhibit beneficial effects in a number of animal models of disease, including atherosclerosis  ADDIN EN.CITE (Graham et al., 2005; Takata et al., 2008), cardiac hypertrophy (Sheng et al., 2008), and myocardial I/R injury (Yue et al., 2008), gut I/R injury (Di Paola et al., 2010b) and testicular I/R injury  ADDIN EN.CITE (Minutoli et al., 2009), spinal cord injury  ADDIN EN.CITE (Paterniti et al., 2010), acute lung injury (Di Paola et al., 2010a), zymosan-induced non-septic shock associated multiple organ failure (Galuppo et al., 2010), and brain inflammation  ADDIN EN.CITE (Defaux et al., 2009; Kalinin et al., 2009). In addition to this line of evidence, PPAR-β/δ has also been demonstrated to play a protective role against experimental colitis using PPAR-/- mice  ADDIN EN.CITE (Hollingshead et al., 2007). Similar to ligand activation of PPAR-α and PPAR-γ, PPAR-β/δ ligands suppress endothelial cell inflammation by inhibiting the production of TNF-α, and reducing the expression of VCAM-1, ICAM-1, E-selectin, MCP-1, and by preventing the nuclear translocation of NF-B  ADDIN EN.CITE (Fan et al., 2008; Liang et al., 2009; Piqueras et al., 2009; Rival et al., 2002; Rodriguez-Calvo et al., 2008). In particular, inhibition of NF-B activation was mediated by the inhibition of the phosphorylation of mitogen-activated protein kinases (MAPK)-extracellular signal-regulated kinase (ERK)1/2 in adipocytes  ADDIN EN.CITE (Rodriguez-Calvo et al., 2008). In addition, activation of PPAR-β/δ protects against hydrogen peroxide (H2O2)-induced apoptosis through the 14-3-3α protein in endothelial cells  ADDIN EN.CITE (Liou et al., 2006). In support of these anti-oxidant properties of PPAR-β/δ, studies have shown that PPAR-β/δ activation induces superoxide dismutase-1, catalase and thioredoxin  ADDIN EN.CITE (Fan et al., 2008). Furthermore, low levels of non-damaging H2O2 increase the activity of PPAR-β/δ and in doing so protect against subsequent high levels of oxidant stress  ADDIN EN.CITE (Jiang et al., 2009). 
A great deal of understanding of the role of PPAR-β/δ in inflammation has arisen from the ongoing research in monocytes and macrophages. Consequently, it has been found that PPAR-β/δ mediates the inflammatory state in monocytes/macrophages through its association and dissociation with a transcriptional co-repressor B cell lymphoma (Bcl)-6  ADDIN EN.CITE (Lee et al., 2003). In the absence of a ligand, PPAR-β/δ associates with Bcl-6 thus preventing its anti-inflammatory effects, such that levels of MCP-1, MCP-3, and IL-1β are increased. However, in PPAR-β/δ knockout (KO) cells, or macrophages expressing dominant negative PPAR-β/δ, or when a ligand is present, Bcl-6 dissociates from PPAR-β/δ and becomes available to suppress pro-inflammatory pathways preventing levels of IFN-γ, TNF-α, CC-chemokine receptor (CCR)-2, IL-1β and IL-6  ADDIN EN.CITE (Barish et al., 2008; Lee et al., 2003; Takata et al., 2008).  




Fig 1.1.3.	Mechanisms of the anti-inflammatory effects of PPAR-β/δ. Ligands of PPAR-β/δ (i) induce the release of the anti-inflammatory co-repressor Bcl-6, and (ii) inhibit the activation of NF-B, and (iii) MAPK-ERK1/2, causing the induction of anti-inflammatory and anti-oxidant genes in sites of local inflammation: adhesion molecules (VCAM-1, ICAM-1 and E-selectin), proinflammatory cytokines (TNF-a, IL-1b, IL-6 and IFN-y), chemokines (MCP-1, MCP-3), and chemokine receptors (CCR2) are all reduced. Endogenous ligands of PPAR-β/δ are induced during the inflammatory response which promote cell survival and wound healing in keratinocytes (Akt, IL-1ra), and anti-oxidant genes in endothelial cells (SOD, catalase, thioredoxin, 14-3-3α). Purple indicates postive regulation by PPAR-β/δ, blue indicates negative regulation by PPAR-β/δ.


1.2	Myocardial infarction

Acute MI is the leading cause of morbidity and mortality in the industrialised world. There is currently considerable interest in investigating the mechanisms underlying I/R injury in the hope that novel therapeutic targets may be identified that aid the development of drugs which protect against, or at least minimize the extent of, tissue damage. The death of myocardium represents a devastating event due to the fact that heart tissue is not readily regenerated. Thus, preserving the viability of ischaemic myocardium has been recognized as a major therapeutic target.  
  
1.2.1	Myocardial ischaemia

Myocardial ischaemia is characterised by the inadequate flow of blood to the heart, leading to the limited availability of glucose and oxygen. As a result, the clearance of metabolic by-products such as lactic acid and carbon dioxide is delayed. This reduction in myocardium perfusion can often lead to cardiomyocyte death and subsequent loss of function (infarction), ultimately resulting in permanent disability or death. 
The mitochondria are vital in their role as the exclusive site for myocardial energy production via aerobic oxidation of substrates. Mitochondrial oxidative phosphorylation is the only process that can generate sufficient energy to support the continuous contractile function of the heart, and when this is compromised, due to inadequate supply of oxygen to the mitochondria, the metabolism of the myocardium is greatly affected (Rouslin & Broge, 1990). The main source of energy under normal aerobic conditions are fatty acids, supplying approximately 50-70 % of the energy (Lopaschuk, 1997). The remaining energy comes from glucose and lactate oxidation. During ischaemia, both fatty acid and carbohydrate oxidation decrease and adenosine triphosphate (ATP) formation is impaired. Glycolysis becomes the main source of ATP in the anaerobic heart (Oliver & Opie, 1994). The decline in oxidative phosphorylation during ischaemia results in the accumulation of reduced nicotinamide adenine dinucleotide (NAD+) and inhibition of the enzyme pyruvate dehydrogenase. Consequently, due to its limited entry into the citric acid cycle, pyruvate is then converted into lactate, which is a marker of ischaemia  ADDIN EN.CITE (Zemgulis et al., 2001). Furthermore, due to the lack of H+ uptake by the mitochondria, glycolysis-induced H+ accumulation leads to a decline in intracellular pH  ADDIN EN.CITE (Liu et al., 2002). During reperfusion, increased fatty acid oxidation inhibits glucose oxidation without affecting the elevated levels of glycolysis.  This results in further uncoupling of glycolysis from glucose oxidation, resulting in continued H+ accumulation.  This accumulation of H+ results in the increased activity of the Na+/H+ exchanger which, in combination with the reduced activity of the Na+/K+ pump, leads to an increase in intracellular Na+ during ischaemia. The increase in intracellular Na+ causes a compensatory activation of the Na+/Ca2+ exchanger, thus resulting in an increase in intracellular Ca2+ (Hoffman et al., 2004).  Increased intracellular Ca2+ levels lead to an excessive mitochondrial Ca2+ influx characterised by intra-mitochondrial Ca2+ deposits and mitochondrial swelling (Shen & Jennings, 1972).  This increase in mitochondrial Ca2+ levels induces mitochondrial permeability transition pore (mPTP) opening, allowing the release of Ca2+, cytochrome c and other apoptogenic factors  ADDIN EN.CITE (Crompton, 1999; Heiskanen et al., 1999). Mitochondrial Ca2+ release leads to elevated cytosolic Ca2+ levels which activate a family of cysteine proteases, known as calpains that are involved in the cleavage and activation of pro-apoptotic proteins.  
Therefore, it is crucial that myocardial blood flow is restored as quickly as possible to the previously ischaemic myocardium to remove metabolic waste and to re-establish oxygen and nutrient supply.

1.2.2	Reperfusion injury 
          
Reperfusion of the previously ischaemic myocardium is required for tissue survival. However, reperfusion itself can lead to accelerated and further myocardial injury beyond that generated by ischaemia alone.  This paradox is now widely known as ‘reperfusion injury’ (Hearse et al., 1975). Myocardial reperfusion injury is a complex process that is mediated by reactive oxygen species (ROS), H+ build-up, intracellular Ca2+ overload, and apoptosis. 
Reperfusion causes the flushing of H+ from the extracellular space, which leads to an overload of intracellular Ca2+ via the increased activity of the Na+/Ca2+ exchanger. In addition to intracellular Ca2+ overload, reperfusion causes cell oedema in cardiomyocytes as a result of osmotic loading during ischaemia. The re-supply of oxygen prompts resumed production of ATP which, in swollen Ca2+ overloaded myocytes with fragile sarcolemma, induces necrosis by hypercontraction and sarcolemmal rupture. Furthermore, I/R injury results in the activation of pro-apoptotic proteins such as, caspase-3, -8, -9 and the translocation of Bax and Bcl-2 in the myocardium. Recent studies have shown that the process of apoptosis can be converted to necrotic processes when co-factors for apoptosis, such as ATP, are deficient  ADDIN EN.CITE (Leist et al., 1999; Single et al., 2001). 
Another major mechanism involved in the development of myocardial reperfusion injury is the opening of the mPTP at the time of reperfusion. The mPTP is a non-selective large conductance channel in the mitochondrial inner membrane which is closed under physiological conditions. Conditions during reperfusion such as, intracellular Ca2+ overload, accumulated ROS and inorganic phosphates, and depletion of ATP promote the opening of mPTPs subsequently leading to cell necrosis and apoptosis. 
Additionally, the inflammatory response following reperfusion of the ischaemic heart also has a significant involvement in the development of myocardial injury. During myocardial I/R injury, inflammatory stimuli are generated by the endothelial cells and cardiomyocytes. This triggers a cytokine cascade, including TNF-, IL-1β, IL-6 and/or IL-8, and the upregulation of adhesion molecules and chemokines, enhanced neutrophil and monocyte infiltration into the myocardium, leading to further cardiac injury  ADDIN EN.CITE (Frangogiannis et al., 2002). 

1.2.3	Reactive oxygen species 

It is well understood that the production of ROS during both ischaemia and reperfusion is an important contributor to I/R-induced myocardial injury  ADDIN EN.CITE (Bolli et al., 1988; Downey, 1990; Li & Jackson, 2002; Zweier et al., 1987; Zweier & Talukder, 2006). Furthermore, it has been noted that low to moderate levels of free radicals are produced during the ischaemic phase, followed by an explosive burst of ROS production during the first two minutes of reperfusion and constant release for at least two hours after the start of reperfusion (Zweier et al., 1987). Although there is a significant reduction in the supply of oxygen during the ischaemic phase, ROS generation is said to occur from the remaining molecular oxygen still present in cardiac cells. This supply of molecular oxygen takes on electrons leaked from ischaemia-induced redox reduced respiratory cytochromes resulting in the formation of superoxide radicals  ADDIN EN.CITE (Becker, 2004; Nohl & Jordan, 1986). 
There are a number of different cell types in cardiac tissue that are capable of producing ROS during I/R such as cardiac myocytes, endothelial cells and neutrophils. In these cells, ROS are being produced during I/R by mitochondria, xanthine oxidase, and NADPH oxidase (Li & Jackson, 2002). Of these potential sources, the mitochondrial electron transport chain is well established as the major intracellular source of ROS  ADDIN EN.CITE (Becker, 2004; Li & Jackson, 2002; Powell et al., 2001). Mitochondria contain antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase and glutathione reductase, and non-enzymatic substances, such as glutathione, α-tocopherol and coenzyme Q which, under physiological conditions, scavenge oxidative agents and their precursors. Oxidative stress during I/R occurs as a result of an imbalance between oxidants and antioxidants. 
The inflammatory response following myocardial I/R results in the activation of neutrophils which also generate large amounts of superoxide through the oxidation of the soluble co-enzyme NADPH via NADPH oxidase (Hoffmeyer et al., 2000). Endothelial cells can also generate ROS during I/R injury from sources such as xanthine oxidase, endothelial nitric oxide synthase (eNOS) and NADPH oxidase. During I/R, eNOS can produce superoxide when there is a deficiency in either its cofactor tetrahydrobiopterin or its substrate L-arginine. Additionally, a phagocyte-type NADPH oxidase complex is expressed in endothelial cells and varies from the neutrophil-expressed NADPH oxidase, in that it produces a significant source of intracellular ROS  ADDIN EN.CITE (Li & Shah, 2002). 
The production of ROS during I/R has many detrimental effects on cardiac tissue due to their highly reactive nature. Membrane lipid components are extremely susceptible to reactions with ROS; this has been demonstrated by enhanced lipid peroxidation reactions of cardiac myocyte membranes in reperfused hearts  ADDIN EN.CITE (Ambrosio et al., 1991; Paradies et al., 1999). This reaction leads to the breakdown of fatty acids and the formation of lipid peroxidation products, both of which are extremely cytotoxic. This oxidant-mediated cellular injury can result in the impairment of proteins that are responsible for the homeostasis of cardiac myocytes and cause damage to the cell membrane by altering membrane ion channel permeability. Ion pumps such as, Na+/K+-ATPase, Ca2+-ATPase or sarcolemmal Ca2+-ATPase decrease their activities during oxidative stress. Furthermore, contractile proteins can also become impaired during oxidative stress resulting in haemodynamic failure  ADDIN EN.CITE (Powell et al., 2001). 
In addition to large amounts of ROS production, during the early phase of reperfusion, NO is also generated in large quantities. The abundance of NO and superoxide during early reperfusion, results in a reaction that leads to the formation of peroxynitrite (OONO-) (Yasmin et al., 1997). The presence of OONO- in the myocardium results in the inhibition of SOD and the oxidation of mitochondrial membrane proteins leading to cellular injury.  

1.2.4	Cardiac cell death 

Cardiac cell death induced by I/R injury mainly occurs by either necrosis or apoptosis. Necrosis is associated with irreversible changes such as organelle/cellular swelling and membrane rupture, and is often characterised as a form of ‘accidental cell death’. Apoptosis is characterised as a form of programmed cell death from either a caspase-dependent or caspase-independent chromatin condensation and is associated with membrane blebbing and cell shrinkage. Apoptosis occurs via two main pathways; the extrinsic (death receptor) pathway and the intrinsic (mitochondrial) pathway (Fig 1.1.4) (Danial & Korsmeyer, 2004). 

Death receptor pathway

	The death receptor pathway is initiated by the binding of an apoptotic signal (ligand) to its relevant death receptor on a target cell (Fig 1.1.4). Death receptors contain an intracellular death domain (DD). Upon ligand binding, adaptor molecules associate with the DD forming a multiprotein complex described as the death-inducing signalling complex (DISC) which subsequently results in the recruitment of inactive procaspase-8. Once procaspase-8 is recruited into the DISC, it is cleaved to activated caspase-8 which continues to cleave and activate downstream procaspase-3 and BH3 (B cell lymphoma-2 [Bcl-2] homology domain 3) interacting domain death agonist (Bid), a proapoptotic Bcl-2 protein, which connects the death receptor and mitochondrial pathway  ADDIN EN.CITE (Crow et al., 2004). 


Mitochondrial pathway 

As mentioned previously, the mitochondria play an important role in triggering necrosis and apoptosis (Fig 1.1.4). In particular, opening of the mPTP is a key contributor to cell death. Opening of the mPTP is associated with the entry of water into the mitochondrial matrix, leading to mitochondrial swelling and rupture of the outer mitochondrial membrane. Mitochondrial rupture results in the release of a number of pro-apoptotic factors that activate the mitochondrial apoptotic cascade, such as cytochrome C and apoptosis-inducing factor (AIF). In particular, cytochrome C, a component of the electron transport chain, is an essential factor in the initiation of apoptosis. Once in the cytosol and in the presence of ATP, cytochrome C binds to apoptosis protease activating factor (Apaf-1) which leads to the recruitment and activation of procaspase-9, subsequently resulting in the activation of downstream caspase-3, and, hence, apoptotic cell death (Adrain & Martin, 2001).      
	Most apoptotic stimuli are eventually directed into the apoptotic Bcl-2 mitochondrial protein family. The Bcl-2 family is divided into anti- and pro-apoptotic proteins. The anti-apoptotic proteins consist of Bcl-xL, Bcl-w, A1, Mc11 and Bcl-2, while the pro-apoptotic proteins consist of Bax and Bad. Under physiological conditions, Bcl-2 is an essential protein that maintains the integrity of the mitochondrial membrane, whereas the other protective proteins only interact with the mitochondrial membrane following cellular injury. Following an apoptotic signal, Bax and Bad migrate from the cytoplasm to the mitochondrial membrane where they induce the release of cytochrome C initiating the apoptosis cascade, which culminates in the activation of caspase-3  ADDIN EN.CITE (Crow et al., 2004). 


Fig 1.2.1.	Central apoptosis pathways. Death receptor pathway and mitochondrial pathway. Modified from  ADDIN EN.CITE (Crow et al., 2004).







1.2.5	Preconditioning of the heart

In 1986, Murry and colleagues discovered that four cycles of 5 min I/R prior to 40 min occlusion of the coronary artery caused a significant reduction in infarct size in a canine model (Murry et al., 1986). This phenomenon, in which short periods of I/R increase the resistance of the heart to the damaging effects of prolonged I/R, was given the term ischaemic preconditioning (IPC) and is well established as the ‘strongest form of in vivo protection against myocardial ischaemic injury other than early reperfusion’ (Kloner et al., 1998). Moreover, this ‘conditioning’ effect of non-lethal I/R can also afford cardioprotection after the onset of myocardial ischaemia (ischaemic perconditioning)  ADDIN EN.CITE (Schmidt et al., 2007) and even after the onset of myocardial reperfusion (ischaemic postconditioning)  ADDIN EN.CITE (Kerendi et al., 2005; Zhao et al., 2003a; Zhao et al., 2003b). Furthemore, it has been reported that similar levels of cardioprotection can be achieved when short periods of non-lethal I/R is applied to organs or tissues distant from the heart before or after the onset of myocardial ischaemia (remote ischaemic preconditioning/postconditioning)  ADDIN EN.CITE (Gho et al., 1996; Kerendi et al., 2005; Pell et al., 1998).
It is well established that IPC induces two distinct windows of cardioprotection against subsequent lethal ischaemic injury. The first window of protection is commonly referred to as ‘classical preconditioning’ which appears immediately and disappears after 2-3 h. This is followed by the second window of protection (SWOP) which is evident 12-24 h later and lasts for 2-3 days (Marber et al., 1993). To date, IPC has been reported in a variety of species and organs (Yellon & Downey, 2003). Consequently, it has become apparent that the cardioprotective process of IPC alters events occurring in the first few minutes of myocardial reperfusion and, hence, protects the heart from myocardial reperfusion injury. There are a number of mediators and signalling pathways underlying the endogenous cardioprotective effect of conditioning, including cell surface receptors to adenosine, bradykinin and opioids, signalling kinases such as PI3K/Akt, ERK1/2, p38, c-jun N-terminal kinase (JNK)-MAPK, janus kinase-signal transduction and transcription-3 (JAK-STAT-3), PKC and PKG, and mitochondrial components such as the K+-ATPase pump, mPTP, PKC and ROS (Hausenloy & Yellon, 2009) (Fig 2.1.2). Furthermore, this powerful phenomenon of IPC has also been reported in clinical settings of coronary artery by-pass surgery  ADDIN EN.CITE (Jenkins et al., 1997; Yellon et al., 1993) and coronary angioplasty (Deutsch et al., 1990).  


Figure 1.2.2.	Signalling pathways underlying the endogenous cardioprotective phenomenon of conditioning. Modified from (Hausenloy & Yellon, 2009).
 
1.3	Sepsis

Sepsis is defined as a systemic inflammatory response syndrome (SIRS) resulting from a severe infection. SIRS has been defined by the American College of Chest Physicians (Bone et al., 1992) as resulting in two or more of the following clinical conditions:
1.	Temperature  (> 38.4oC or < 35.6oC)
2.	Tachycardia (Heart rate > 90 beats per minute)
3.	Tachypnea (Respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg)
4.	White blood cell count (> 12000/µL or < 4000/µL, or > 10 % immature neutrophils 
Sepsis is a serious clinical problem as its incidence has risen quite rapidly over recent decades with average annual increases of 8.7 % reported between 1979 and 2000 in the United States (Martin et al., 2003). Sepsis has a mortality rate of 20-50 %, leading to approximately 200,000 deaths per year in the United States. Subsequently, this creates a large financial burden on health care costing an estimated $16.7 billion on treatment each year  ADDIN EN.CITE (Angus et al., 2001). 
Most patients with sepsis go on to develop severe sepsis which is characterised by changes in organ function or perfusion (Balk, 2000). Patients with severe sepsis can further deteriorate, leading to the onset of septic shock which is defined by the development of pronounced hypotension (systolic blood pressure < 90 mmHg, mean arterial pressure < 60mmHg or a reduction of 40 mmHg from baseline) resulting in inadequate tissue perfusion, despite adequate fluid resuscitation  ADDIN EN.CITE (Bone et al., 1992; Levy et al., 2003). The development of hypotension occurs from a progressive endothelial dysfunction which results in an enhanced formation of NO by iNOS leading to excessive vasodilatation resulting in a reduced response of the vasculature to vasopressors (vascular hyporeactivity)  ADDIN EN.CITE (Fleming et al., 1990; Gray et al., 1990; Julou-Schaeffer et al., 1990; Kilbourn et al., 1990; Szabo et al., 1993; Thiemermann & Vane, 1990). Furthermore, increased microvascular permeability results with the build up of fluid in the organs. Platelet activation and excessive coagulation together with activation and adhesion of neutrophils to the endothelium blocks the microcirculation and reduces blood flow, resulting in ischaemia. Subsequently, this all leads to the dysfunction of at least one organ which results in a mortality rate of approximately 40 %  ADDIN EN.CITE (Hardaway, 1999; Padkin et al., 2003; Parrillo et al., 1990). Approximately 75 % of deaths due to sepsis occur within hours to days after the onset of shock due to therapy-resistant hypotension, suggesting that peripheral vascular failure is the major determining factor with regards to outcome (Groeneveld et al., 1988). The remaining deaths occur days or weeks after the patient has recovered from hypotension, and the cause of death is multiple organ failure (Dal Nogare, 1991). The multiple organ failure associated with sepsis and septic shock has been suggested to be the result of an excessive inflammatory response rather than directly from an infection (Bone et al., 2009). 

1.3.1	Mediators of sepsis

Various components of an invading bacterial, viral or fungal infection may initiate SIRS. Gram-negative and Gram-positive bacteria are commonly associated with most cases of sepsis, 94.4 % of documented cases in the USA in 2000 were attributed to bacterial infection (Martin et al., 2003). Bacterial endotoxin has been found to be localised on the outer membrane of the cell wall and is a unique component of Gram negative bacteria. Extraction and purification techniques have isolated a LPS-protein-phospholipid complex, of which LPS was identified as the active component of ‘endotoxins’  ADDIN EN.CITE (Raetz & Whitfield, 2002). LPS has been isolated from the serum of patients with sepsis and similar septic responses have been observed after injection of LPS into a host. For instance, when low doses of LPS are injected into humans, cardiac output increases and peripheral vasodilatation is observed, in the same way as in patients with sepsis (Fink & Heard, 1990). Furthermore, in patients with Gram-negative infections, plasma levels of LPS have been shown to correlate with the development of organ dysfunction (Brandtzaeg et al., 1989). The cell wall of Gram-positive bacteria contain large quantitites of peptidoglycan (PepG) which, like LPS, has been reported to cause systemic inflammation (Wang et al., 2004). Furthermore, the cell walls of Gram-positive bacteria also contain lipoteichoic acid (LTA) which is considered to be the Gram-positive counterpart of LPS, however not as potent  ADDIN EN.CITE (Wang et al., 2003a).        
The systemic response to infection is mediated through the activation of Toll like receptors (TLR) which induce the release of important local or systemic cytokines that target end-organ receptors. TLRs are a family of pattern recognition receptors (PRR) whose function is to initiate an innate immune response by recognising molecules that are shared by pathogens, termed pathogen-associated molecular proteins (PAMP), such as LPS. To date, ten TLRs have been identified in humans and 12 in mice, of which TLR4 is the recognition receptor for LPS and TL2 is the recognition receptor for PepG and LTA  ADDIN EN.CITE (Poltorak et al., 1998; Schwandner et al., 1999). 
LPS binds to LPS-binding protein (LBP) and is transported to the CD14 receptor on the macrophage  ADDIN EN.CITE (Tobias et al., 1993; Wright et al., 1990). This CD14/LPS complex then interacts with TLR4, and a secreted glycoprotein, MD-2. After TLR4 dimerisation, Toll/Interleukin-1 receptor (TIR) domain containing adaptor protein (TIRAP) and myeloid differentiation (MyD)88 are recruited to the intracellular TIR domain. TLR4 activation results in the transcription of a number of immune and inflammatory response genes through NF-B-mediated mechanisms via a MyD88 dependent or MyD88 independent pathway  ADDIN EN.CITE (Akira & Takeda, 2004; Faure et al., 2001; Zhang & Ghosh, 2000).
In the MyD88 dependent pathway, MyD88 binds to an interleukin-1 receptor-associated kinase (IRAK)4, which phosphorylates IRAK1. IRAK1 binds to the TNF-α receptor associated factor (TRAF)6 and this dimer associates with a membrane bound complex consisting of tumour growth factor (TGF)- activated kinase (TAK)1 and two TAK1 binding proteins (TAB), TAB1 and TAB2. Ubiquitination of TRAF6 and TAK1 activates the complex and phosphorylates TAK1 and TAB2, subsequently releasing the activated protein complex from the membrane. Activated TAK1 phosphorylates the inhibitor B kinase (IKK) which phosphorylates inhibitor of B (IB) for degradation. This causes the release of NF-B subunits, including p50 and p65. IKK in the IKK complexes also phosphorylates p65 on Ser536. NF-B is then free to translocate to the nucleus, where it binds to NF-B binding sites on target genes, resulting in the up-regulation of inflammatory genes  ADDIN EN.CITE (Doyle & O'Neill, 2006; Van Amersfoort et al., 2003).
The MyD88 independent pathway has also been shown to play an important role in the activation of inflammatory genes by TLR4. TIR domain containing adaptor inducing IFN- (TRIF) and TRIF-related adaptor molecule (TRAM) associate with the intracellular region of TLR4. TRIF then associates with receptor interacting protein (RIP)1 which can activate NF-B by either a TRAF6 dependent or independent pathway. TRIF and TRAM can also mediate the activation of interferon regulatory factor (IRF3) through an interaction with IKK and TRAF family member associated NF-B activator. This leads to enhanced gene and protein expression of IFN- and TNF-. Secreted TNF- then activates TNF- receptors which subsequently enhances additional NF-B activation  ADDIN EN.CITE (Akira & Takeda, 2004; Doyle & O'Neill, 2006).
Compared to LPS-induced TLR4 signalling, ligand binding to TLR2 results in the formation of a heterodimer with either TLR1 or 6 depending on the ligand that is bound to TLR2  ADDIN EN.CITE (Schwandner et al., 1999). Nevertheless, TIRAP and MyD88 are recruited to the intracellular TLR TIR domains. MyD88 binds to IRAK4 which phosphorylates IRAK1, resulting in the subsequent dimerisation with TRAF6 and activation of the TAB1/2-TAK1/TRAF6/IRAK1 complex and IKK complex in a similar manner to TLR4 signalling. 
In addition to NF-B, another transcription factor that is involved in host response to infection is AP-1. AP-1 is activated by a TAB1/2-TAK1/TRAF6/IRAK1 complex by activation of the JNK-MAPK pathways which lead to the formation of a heterodimer of the AP-1 subunits c-jun and c-fos. This results in the nuclear translocation of AP-1 where it binds to promoter regions of target genes (Doyle & O'Neill, 2006).



Fig 1.3.1.	Summary of the TLR signalling pathway. On TLR ligand binding, TLR4 dimers recruit Mal (TIRAP) and MyD88. MyD88 binds to IRAK4 which phosphorylates IRAK1. IRAK1 binds to TRAF6 and a TAB1/TAK1/TAB2 complex. This complex eventually leads to the nuclear translocation and, hence, activation of NF-B in a MyD88 dependent manner. MyD88 independent pathway involves the activation of NF-B through TRAM/TRIF via RIP1 and also regulates the activation of IRF3. Activated TLR2 receptors form heterodimers with TLR1 or 6 subsequently resulting in NF-κB activation via the TAB1/2-TAK1 complex. (Doyle & O'Neill, 2006). 



The inflammatory response involves the release of cytokines from macrophages near the site of infection. Cytokines are capable of producing more than one effect, depending on the local hormonal surroundings. Furthermore, the variability of the effects of cytokines is tightly regulated by the complex network of receptor antagonists and other regulatory mediators that are present in the body. The cytokines involved are often categorised into two groups; primary and secondary mediators. Primary mediators can include TNF-α, IL-1, IL-6, IL-8 and interferon (IFN)-γ. These mediators stimulate the release of secondary mediators such as arachidonic acid-derived PGE2, thromboxane A2, platelet-activating factor (PAF), and TF which, in particular, activates the extrinsic system of coagulation resulting in the conversion of prothrombin to thrombin. The IL-1 family consists of IL-1α, IL-1β and the IL-1 receptor antagonist (IL-1ra) (Dinarello, 1988). IL-1β is the main type found in the circulation during critical illness and can cause fever within minutes of reaching the hypothalamus (Dinarello, 1984). TNF-α is synthesised by activated monocytes and macrophages, T- and natural killer (NK) cells and a range of other cells in response to an infection  ADDIN EN.CITE (Kunkel et al., 1986; Moreno et al., 1989). Intravenous administration of TNF-α in dogs results in pathological changes similar to those observed in patients with sepsis. Additionally, vasoactive peptides such as bradykinin, angiotensin and vasoactive intestinal peptide, and amines such as histamine and serotonin are also stimulated (Natanson et al., 1989b). 
These mediators are important as they are involved in fighting pathogenic organisms and promoting wound healing. Under physiological conditions, the cytokine response is regulated in order to keep the initial inflammatory response under control by down-regulating its production and countering its effects. During sepsis, this maintained level of homeostasis can break down, resulting in a complete loss of control and the beginning of a systemic reaction. This compensatory response against the pro-inflammatory state involves the production of many anti-inflammatory mediators such as IL-4, IL-10, IL-13 and TNF-α receptors. It is this sustained elevation of pro- and anti-inflammatory cytokines that results in poor prognosis. This overwhelming inflammatory response eventually leads to septic shock and multiple organ failure. 



1.3.2	Multiple organ dysfunction syndrome 

The excessive inflammatory response and hypoperfusion, resulting from hypotension, microcirculatory alterations and coagulopathy, results in extensive tissue injury and, ultimately, the multiple organ dysfunction syndrome (MODS). MODS can involve the following physiological systems: respiratory, renal, hepatic, gastrointestinal, neurological, pancreatic, haematological and, importantly, the cardiovascular system. MODS occurs when organ dysfunction occurs to such an extent that homeostasis cannot be maintained without clinical intervention. This ultimately leads to the inevitable admission to the intensive care unit (ICU), where patients rapidly undergo fluid volume resuscitation procedures and treatment, which is often supportive, rather than therapeutic in nature. The degree of organ dysfunction and number of failing organs differs among patients and over time. It is generally accepted that the risk of death increases with the number of organs that become dysfunctional, as each failing organ intensifies the injury occurring to the other. Indeed, mortality of septic patients increases from 20 % to almost 100 %, when a single organ failure progresses to the failure of four or more organs (Fry et al., 1980). Furthermore, renal failure has been found to be a significant factor in patient prognosis, as 70 % of patients with sepsis and acute kidney injury going on to die (Schrier & Wang, 2004). The severity of sepsis can also be determined by the extent of organ dysfunction as 19 % and 3 % of septic patients develop acute kidney injury and acute respiratory distress syndrome, respectively, compared to 51 % and 18 % of patients with septic shock. Taking the importance of organ dysfunction as a variable into account, a number of scoring systems have been developed to consider prognosis and tailor effective treatment, such as the sequential organ failure assessment (SOFA) (Vincent et al., 1996) score, which is based on the following, clinical parameters:

1.	Ventilation - partial pressure of oxygen:fraction of inspired oxygen ratio;
2.	Coagulation - platelet count;
3.	Liver - bilirubin levels;
4.	Cardiovascular – degree of hypotension and type and dose of vasopressor;
5.	Central nervous system – degree of consciousness according to the Glasgow coma scale; and
6.	Renal – plasma creatinine levels/glomerular filtration rate
1.3.3	Treatment of sepsis

The development of an appropriate pharmacological intervention for the treatment of sepsis is proving difficult due to the complexity of the disorder. Currently, the strategy for treatment consists of administration of fluids and vasopressors to restore blood pressure and organ perfusion, ventilation and/or oxygenation, and administration of antibiotics  ADDIN EN.CITE (Cohen & Glauser, 1991; Glauser et al., 1991; Rackow & Astiz, 1991; Wheeler & Bernard, 1999). 
Most therapeutic strategies for the treatment of sepsis have targeted pro-inflammatory mediators, however a large number of clinical trials have been unsuccessful in reducing mortality. LPS, TNF-α and IL-1β have been targeted for the treatment of septic shock having previously shown positive results in animal and cell models  ADDIN EN.CITE (Beutler et al., 1985; Davis et al., 1969; Ohlsson et al., 1990; Tracey et al., 1987), however clinical trials demonstrated no beneficial effects in human sepsis  ADDIN EN.CITE (Bone et al., 1995; Cohen, 1999; Fisher et al., 1994; Opal et al., 1997; Reinhart & Karzai, 2001). 
The coagulation system has also been targeted for the treatment of sepsis due to its close involvement with the inflammatory pathway. Under physiological conditions, the body has a number of inhibitors capable of localising coagulation and maintaining haemostasis, such as antithrombin (AT), tissue factor pathway inhibitor (TFPI) and activated protein C (APC). These factors have been targeted as anticoagulation strategies in clinical sepsis trials. AT and TFPI did not demonstrate any beneficial effects  ADDIN EN.CITE (Warren et al., 2001), however APC did provide an improved outcome  ADDIN EN.CITE (Bernard et al., 2001; Healy, 2002). This led to the production of the first drug for treatment of patients with septic shock; however restrictions were later introduced due to an increased risk of bleeding (Warren et al., 2002). 

1.3.4	Cardiac dysfunction

Cardiac dysfunction has been consistently reported during the progression of sepsis in patients; approximately 40 % of patients with sepsis have been reported to develop cardiac dysfunction. As a result, mortality (in this patient group) has been shown to increase from 20 % to 70-90 %  ADDIN EN.CITE (Grocott-Mason & Shah, 1998; Parrillo et al., 1990).
Historically, sepsis-induced cardiac dysfunction had often been understood and clinically presented in two ways. Patients in a hyperdynamic state after sufficient volume resuscitation present with peripheral vasodilatation and a high cardiac output. Patients in a hypodynamic state present with an increased vascular tone and a low cardiac output. These two clinical perspectives were then later reported to be involved in a biphasic response, in that a hyperdynamic phase occurred early and was later followed by a hypodynamic phase and ultimately death of the patient (Clowes et al., 1966). However, this understanding of cardiac dysfunction was dismissed due to the use of poor experimental models that failed to take into account the adequacy of volume resuscitation in some patients. Therefore, the introduction of the pulmonary artery catheter, which can measure left ventricular preload with great accuracy, enabled a more reliable definition of cardiac dysfunction. Subsequently, a number of studies have shown that with adequate volume resuscitation, patients consistently present in a hyperdynamic state until death  ADDIN EN.CITE (Parker et al., 1987; Suffredini et al., 1989). Although an increase in cardiac output is observed during the hyperdynamic state of sepsis, the heart has been reported to be in a dysfunctional state  ADDIN EN.CITE (Kumar et al., 2000; Weisel et al., 1977). 
Using radionuclide cineangiography in septic patients, a study demonstrated a reduced left ventricular ejection fraction (LVEF) and an increased left ventricular end-diastolic volume index (LVEDVI), which returned to normal over 7-10 days in survivors (Parker et al., 1987). This experimental method allowed to measure contractile function, independent of cardiac load, but a more accurate measure of left ventricular systolic dysfunction is demonstrated by a decreased left ventricular stroke work index. Furthermore, another study demonstrated reduced cardiac function when plotting the relationship between left ventricular stroke work index and LVEDVI in septic patients when compared to controls (Ognibene et al., 1988). Additional studies have also demonstrated significant left ventricular systolic dysfunction in septic patients  ADDIN EN.CITE (Ellrodt et al., 1985; Poelaert et al., 1997), further supporting the presence of cardiac dysfunction induced by sepsis, independent of cardiac load.  





Aetiology of cardiac dysfunction in sepsis

	Despite numerous studies investigating cardiac dysfunction in sepsis, its aetiology remains unclear. However, there are a number of potential aetiologies that are commonly investigated in sepsis-related experimental models. A much supported theory for a number of years was that the tissue hypoperfusion associated with sepsis, subsequently decreases cardiac perfusion. Consequently, there is an inadequate O2 delivery to the heart leading to ischaemic injury and cardiac dysfunction (see below). However, two key studies that assessed coronary haemodynamics disproved this theory. Coronary blood flow was measured in septic patients and normal or increased coronary blood flow was found in comparison to normal controls (Cunnion et al., 1986). Furthermore, no difference was displayed in blood flow between patients who developed cardiac dysfunction and those who did not (Dhainaut et al., 1987).
 	Furthermore, a number of studies have displayed preserved cardiac O2 metabolism and levels of high-energy phosphates  ADDIN EN.CITE (Solomon et al., 1994), in contrast to what is observed with ischaemic injury. However, a small degree of cardiac cellular injury has been demonstrated by increased troponin I levels in septic patients (Turner et al., 1999). Hence, there is uncertainty in regards to whether direct cardiac injury is involved in sepsis-induced cardiac dysfunction or if another factor, such as a myocardial depressant factor (MDF) has any role. 

MDF

	Another potential aetiology of sepsis-induced cardiac dysfunction is the presence of a circulating MDF. This theory has been supported by various studies including one in particular which suggested the presence of a MDF in the serum of a septic patient  ADDIN EN.CITE (Parrillo et al., 1985). The patient’s serum exhibited a concentration-dependent depressant effect on in vitro contractility. Furthermore, a significant correlation was observed in terms of the timing and degree of sepsis-induced reduction in LVEF in vivo and in vitro to serum from the same patients. Additionally, higher mortality was demonstrated in patients with high levels of myocardial depressant activity (36 %) in comparison with patients with a lower or absent activity (10 %)  ADDIN EN.CITE (Reilly et al., 1989). Therefore, there is strong evidence in support of a MDF, compared to hypoperfusion, as the cause of sepsis-induced cardiac dysfunction; however the identity of a MDF is unclear. 

MDF candidates

	The substance has been demonstrated to be heat stable, water soluble, and infiltration studies reported the presence of a 10-25 kDa fraction  ADDIN EN.CITE (Pathan et al., 2002; Reilly et al., 1989). These characteristics were similar to either a polypeptide or a protein. There are a vast number of potential candidates as a mediator of cardiac dysfunction, of which the cytokine, TNF- has been suggested to have an important role. TNF- has been implicated to have various mechanisms by which it can cause cardiac dysfunction including calcium dyshomeostasis, disruption of excitation-contraction coupling, direct cytotoxicity, myocyte apoptosis, oxidant stress, and the induction of other cardiac depressants, such as IL-1, IL-2, and IL-6 (Meldrum, 1998).

1.3.5	A role for glyogen synthase kinase-3β in inflammation

Glycogen synthase kinase (GSK)-3β is a 47-kDa serine/threonine kinase that was originally identified as an enzyme that phosphorylates glycogen synthase, the rate-limiting enzyme of glycogen metabolism. Since then, it is now regarded as a multifunctional kinase with more than 40 substrates and is involved in cell membrane-to-nucleus signalling, gene transcription, translation, cell cycle progression and survival  ADDIN EN.CITE (Cohen & Goedert, 2004; Jope & Johnson, 2004; Jope et al., 2007; Woodgett, 2001). In contrast to most kinases, GSK-3β is highly active in a resting cell state and subsequently exerts a negative inhibitory effect on its downstream pathways. Upon stimulation via upstream pathways, GSK-3β becomes serine-phosphorylated at Ser9 residue resulting in enzyme inactivation of GSK-3β and, consequently, inactivation of downstream pathways due to release of the inhibitory effect. A number of upstream pathways that can phosphorylate and, hence, inhibit GSK-3β include PI3K/Akt, AGC kinase and p38 MAP kinase (Cohen & Frame, 2001). 
Recently, the role of GSK-3β has been demonstrated in a number of human disorders such as neurodegenerative diseases, cancer and I/R injury  ADDIN EN.CITE (Cohen & Goedert, 2004; Jope & Johnson, 2004; Jope et al., 2007). Moreover, the use of GSK-3β inhibitors have demonstrated cardioprotective effects against myocardial I/R injury  ADDIN EN.CITE (Gross & Lockwood, 2004; Song et al., 2009), and anti-inflammatory effects in acute systemic inflammation indicating its key role in modulating the inflammatory response  ADDIN EN.CITE (Cuzzocrea et al., 2006; Dugo et al., 2006a; Dugo et al., 2005; Martin et al., 2005; Whittle et al., 2006). 






1.4	Aims of the thesis

Currently, ischaemic heart disease is the leading cause of morbidity and mortality in the industrialised world with the World Health Organization predicting it to be one of the main causes of mortality in the world by 2020. Additionally, sepsis is another serious clinical problem with a world-wide yearly incidence estimated at 18 million cases which continues to increase annually. It is well established that there is a large inflammatory response that is associated, and contributes, to the augmentation of these two diseases. Therefore, there is a great deal of interest in exposing the inflammatory mechanisms underlying myocardial I/R injury, and the multiple organ dysfunction, especially cardiac dysfunction, associated with sepsis in the hope that novel therapeutic targets may be identified that protect against, or at least minimize the extent of, tissue damage involved in the two diseases. 
 
The key question to this thesis: 
‘Does PPAR-β/δ have an anti-inflammatory protective role in acute myocardial I/R injury and sepsis?’ 

In order to answer this question I will investigate the following:

	A recent study has shown that a PPAR-β/δ agonist, GW0742, protects the heart from I/R injury in Zucker fatty rats (Yue et al., 2008); however this study was carried out in a rodent model of obesity and dyslipidemia prior to inducing ischaemia, in addition to an extended reperfusion period (24 hours) and utilising a 7 day oral pre-treatment protocol which can raise doubts in terms of the selective accuracy of PPAR-β/δ activation. Therefore, using GW0742, I will investigate whether selective PPAR-β/δactivation, attenuates the injury associated with acute myocardial I/R injury. Furthermore, I will investigate the anti-inflammatory mechanism(s) behind any protective effect of GW0742 (Chapter II).  

	There is some evidence that PPAR-β/δ activation has anti-inflammatory properties, however very little is known regarding the role of PPAR-β/δ in sepsis. I will investigate the role of PPAR-β/δ in murine models of endotoxaemia and polymicrobial sepsis with the use of PPAR-β/δ KO mice, GW0742, and a highly selective PPAR-β/δ antagonist, GSK0660. I will investigate whether PPAR-β/δ activation can attenuate the multiple organ injury and dysfunction, in particular cardiac dysfunction, associated with endotoxaemia, and improve survival in a clinically relevant model of polymicrobial sepsis. Furthermore, I will investigate the anti-inflammatory mechanism(s) behind any protective effect of GW0742 (Chapter III). 

	Based on the findings of chapter III, I will investigate whether the protective effects of PPAR-β/δ can be observed in an acute model of endotoxaemia in a different species (rat) and whether any protective mechanism(s) afforded by GW0742 can be observed in different tissue (liver) (Chapter IV). 
	






















CHAPTER II
Activation of Peroxisome Proliferator-Activated Receptor-β/δ attenuates myocardial ischaemia/reperfusion injury in the rat












2.1	Introduction

PPAR-α in myocardial ischaemia/reperfusion injury 

The expression of PPAR-α is relatively high in the heart and, as a result, has led to a number of studies regarding its role in myocardial I/R injury. Using an in vivo rat model of regional myocardial I/R injury, Wayman and colleagues discovered that pre-treatment with two different ligands of PPAR-α, clofibrate and WY14643, 30 min before the induction of myocardial I/R significantly reduced infarct size  ADDIN EN.CITE (Wayman et al., 2002b). In a similar model, acute pre-treatment of diabetic rats with WY14643 significantly reduced infarct size via the maintained bioactivity of NO mediated by the activation of the PI3K/Akt signalling pathway  ADDIN EN.CITE (Bulhak et al., 2009). Additionally, pre-treatment of mice with a highly selective PPAR-α agonist GW7647 for 2 days, with a third dose 1 h prior to ischaemia, significantly reduced infarct size caused by regional myocardial I/R and improved functional recovery after 24 hours of reperfusion. This cardioprotective effect of GW7647 was completely abolished in PPAR-α KO mice. Furthermore, the cardioprotective effect of GW7647 was associated with the inhibition of neutrophil accumulation, reduction in the release of proinflammatory cytokines, reduced myocardial expression of MMP-9 and -2, and the inhibition of NF-B activation which mediates the transcription of these pro-inflammatory mediators  ADDIN EN.CITE (Yue et al., 2003). In contrast, chronic pre-treatment of fenofibrate in a large animal model of myocardial I/R (pig) did not reduce infarct size or improve contractile function. The absence of any cardioprotective effect of fenofibrate may be due to differences in species and dose in regards to ligand activation and effects of PPAR-α  ADDIN EN.CITE (Xu et al., 2006).  

PPAR-γ in myocardial ischaemia/reperfusion injury

The expression of PPAR-γ in cardiomyocytes also led to a number of studies investigating its role in myocardial I/R injury. One of the earlier studies used isolated perfused hearts from streptozotocin-induced diabetic rats and found that pre-treatment with rosiglitazone for 4 weeks prevented post-ischaemic injury and improved functional recovery. This cardioprotective effect was associated with the inhibition of the JNK/AP-1 pathway  ADDIN EN.CITE (Khandoudi et al., 2002). This tissue protective effect of PPAR-γ activation against injury caused by myocardial I/R is further supported by several in vivo studies. Various chemically distinct PPAR-γ agonists have demonstrated a reduction in infarct size caused by regional myocardial I/R injury. In the rat, pre-treatment with the TZDs rosiglitazone, ciglitazone and pioglitazone, in addition to the prostaglandins 15d-PGJ2 and PGA1, caused a significant reduction in infarct size  ADDIN EN.CITE (Thiemermann & Wayman, 2001; Wayman et al., 2002b). The most marked reduction in infarct size (> 60 %) was afforded by 15d-PGJ2. A number of mechanisms behind this cardioprotective effect were suggested such as, i) the activation of PPAR-α in addition to PPAR-γ, ii) the expression of the anti-oxidant and anti-apoptotic haemoxygenase-1 (HO-1) stress response protein, and iii) the inhibition of the activation of NF-B. Additionally, two other studies utilising rat models of myocardial I/R injury have also demonstrated the cardioprotective effects of rosiglitazone and pioglitazone. Rosiglitazone causes a substantial reduction in myocardial infarct size and improvement in cardiac function. This cardioprotective effect of rosiglitazone was most likely due to inhibition of the inflammatory response as it prevented leukocyte-endothelial cell interaction by reducing the upregulation of CD11b/CD18, and downregulation of L-selectin on neutrophils and monocytes, in addition to attenuating ICAM-1 expression caused by myocardial I/R  ADDIN EN.CITE (Yue et al., 2001). Pre-treatment with pioglitazone for 7 days before I/R caused a significant reduction in myocardial infarct size in addition to reduced mRNA levels of MCP-1 and ICAM-1  ADDIN EN.CITE (Ito et al., 2003). 
PPAR-γ activation using rosiglitazone and pioglitazone have also shown cardioprotective effects in larger animal models of myocardial I/R. For example, chronic pre-treatment with rosiglitazone for 5 weeks in hypercholesterolemic rabbits has demonstrated substantial reductions in contractile dysfunction most likely by preventing cardiac myocyte apoptosis as reported by disrupting the signalling events leading to the activation of caspase-3  ADDIN EN.CITE (Liu et al., 2004). Furthermore, pre-treatment with pioglitazone for 7 days in rabbits significantly reduced the infarct size following myocardial I/R most likely due to the associated activation of the PI3K/Akt and eNOS pathway  ADDIN EN.CITE (Yasuda et al., 2009). 
There is some debate regarding the cardioprotective effects of troglitazone. For instance, Zhu and colleagues demonstrated that pre-treatment with troglitazone for 8 weeks in non-diabetic pigs demonstrated a significant improvement in LV function after myocardial I/R (Zhu et al., 2000). However, the same group later reported that the troglitazone-afforded cardioprotection in pigs was not due to troglitazone, but instead due to the α-tocopherol moiety that is contained within troglitazone and that pre-treatment with rosiglitazone was ineffective against myocardial I/R  ADDIN EN.CITE (Xu et al., 2005). These studies suggest differences in species and dose in response to PPAR-γ activation in the heart. 
Although cardioprotection has been shown with TZDs in animal studies, there is increasing evidence from a number of clinical trials that have demonstrated an increased risk of serious cardiovascular events following treatment with rosiglitazone. A meta-analysis of 42 randomised controlled trials involving rosiglitazone reported a 1.4-fold increased risk of acute myocardial infarction compared with non-TZD therapy (Nissen & Wolski, 2007). Furthermore, rosiglitazone has been shown to increase the risk of heart failure when compared with pioglitazone therapy, which has not been associated with adverse cardiovascular events  ADDIN EN.CITE (Graham et al., 2010; Juurlink et al., 2009; Winkelmayer et al., 2008). Therefore, some controversy remains regarding the cardioprotective effects of TZDs in myocardial ischaemia/reperfusion injury. 

PPAR-β/δ in myocardial ischaemia/reperfusion injury

Little is known about the role of PPAR-β/δ and its endogenous ligands in I/R injury of the heart. PPAR-β/δ is ubiquitously expressed, more specifically, it is expressed in abundance in both adult heart and neonatal rat cardiomyocytes  ADDIN EN.CITE (Cheng et al., 2004; Gilde et al., 2003). Studies involving PPAR-β/δ gene disruption have provided strong evidence for the importance of PPAR-β/δ in multiple biological processes such as lipid metabolism involved in cardiac development and function  ADDIN EN.CITE (Cheng et al., 2004; Reilly & Lee, 2008). 
The recently developed, selective and potent PPAR-β/δ agonist, GW0742, has led to a number of studies investigating its effects in a number of animal disease models. GW0742-induced PPAR-β/δ activation has demonstrated beneficial effects in atherosclerosis by reducing the expression of MCP-1, ICAM-1 and TNF-α in the aortae of treated mice  (Graham et al., 2005), and prevented activation of the pro-inflammatory MAP kinase, p38 and ERK1/2 mechanisms of angiotensin II-accelerated atherosclerosis in mice  ADDIN EN.CITE (Takata et al., 2008). Furthermore, GW0742-induced PPAR-β/δ activation has demonstrated beneficial effects on angiotensin II-induced cardiac hypertrophy by inhibiting the mRNA expression of cytokines such as MMP-9 and MMP-2, and IL-1β in hypertrophic myocytes (Sheng et al., 2008). 
Moreover, Yue and colleagues recently demonstrated the cardioprotective effects of GW0742 against myocardial I/R injury in a model of metabolic syndrome using obese/dyslipidemic Zucker fatty rats (Yue et al., 2008). Pre-treatment with GW0742 for 7 days in Zucker fatty rats significantly reduced infarct size by 32 % and improved LV function. This cardioprotective effect was most likely afforded by several mechansisms. One such mechansism involved the attenuation of lipotoxicity as GW0742 treatment upregulated the gene expression involved in cardiac fatty acid oxidation, increased the use of fat in the heart and reduced serum levels of free fatty acids caused by myocardial I/R. A large anti-inflammatory reaction also contributes to the cardioprotective mechanism as GW0742 significantly attenuated the cardiac expression of IL-6, IL-8, ICAM-1 and MCP-1 caused by myocardial I/R. Additionally, the pro-survival signalling pathway also exerts a cardioprotective effect as GW0742 activated the PI3K/Akt pathway and reduced the presence of apoptotic cardiomyocytes and caspase-3 activity caused by myocardial I/R. The study demonstrated that PPAR-β/δ activation in obese rats protects against myocardial I/R injury by a number of mechanisms. However, this study was carried out in a rodent model of obesity and dyslipidemia prior to inducing ischaemia, in addition to an extended reperfusion period (24 hours). Furthermore, it involved a 7 day oral pre-treatment which can raise doubts in terms of the selective accuracy of PPAR-β/δ activation and not PPAR-α and/or PPAR-γ. 

GW0742

GW0742 (4-[2-(3-Fluoro-4-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy}-acetic acid) is a potent and highly selective PPAR-β/δ agonist. Its EC50 value for murine PPAR-β/δ, PPAR-α and PPAR-γ is 0.03, 8.8 and >10 µM, respectively  ADDIN EN.CITE (Sznaidman et al., 2003).  



Fig 2.1.1	Chemical structure of the PPAR-β/δ agonist GW0742

GW6471

There is evidence that (i) higher concentrations of GW0742 (in vitro) activate PPAR-α  ADDIN EN.CITE (Sznaidman et al., 2003), and ii) that selective ligands of PPAR-α reduce myocardial infarct size (Wayman et al., 2002a). Thus, I used a selective PPAR-α antagonist GW6471 [[(2S)-2-[[(1Z)-1-Methyl-3-oxo-3-[4-(trifluoromethyl)phe nyl]-1-propenyl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxa zolyl)ethoxy]phenyl]propyl]-carbamic acid ethyl ester] to investigate whether GW6471 alters the effects of GW0742 on myocardial infarct size. GW6471 is an irreversible competitive PPAR- antagonist with an IC50 value of 0.24 µM. To my knowledge, GW6471 has not been previously studied following intravenous administration. Therefore, a dose of 1 mg/kg was selected in this investigation based on its calculated IC50 value of 22µM which is adequate to selectively inhibit PPAR-α by recruiting co-repressors such as N-Cor and SMRT to replace co-activators such as SRC-1 or PBP based on previously reported in vitro assays  ADDIN EN.CITE (Xu et al., 2002).




Fig 2.1.2	Chemical structure of the PPAR-α antagonist

Using a PPAR-β/δ agonist, GW0742, I will investigate the effect of varying concentrations and timings of acute, intravenous administration on infarct size in a rat model of acute myocardial I/R injury in vivo. Once I have established the optimum dose and administration of GW0742 that exhibits the most pronounced reduction in infarct size, I will carry out experiments aimed at revealing the mechanism(s) of the cardioprotective effect of GW0742. These studies will consist of investigating the effect of GW0742 on the I/R induced i) expression of PPAR-β/δ, ii) phosphorylation of Akt and GSK-3β, iii) nuclear translocation of NF-κB, and iv) expression of iNOS and COX-2, all by western blot analysis of the heart.  






2.2	Materials and methods

Surgical Procedure

This study was carried out on 61 (including 4 mortalities due to experimental error) male Wistar rats (Charles River, UK) weighing 240-340g, receiving a standard diet and water ad libitum. The investigation was performed in accordance with the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act 1986, published by HMSO, London.
Rats were anaesthetised with thiopentone sodium (Intraval 120 mg/kg i.p.). Anaesthesia was maintained by supplementary injections of thiopentone sodium as required. The trachea was cannulated and the animals were ventilated with a Harvard ventilator (inspiratory oxygen concentration: 30 %; 70 strokes/min, tidal volume: 8-10 ml/kg). Body temperature was maintained at 37±1 oC with the aid of a rectal probe thermometer attached to a homeothermic blanket unit (Harvard Apparatus Ltd., Edenbridge, Kent. U.K.). The right carotid artery was cannulated with a polyethylene catheter and connected to a pressure transducer (Senso-Nor 844, Senso-Nor, Horten, Norway) in order to monitor mean arterial pressure (MAP) and heart rate (HR), which were displayed on a data acquisition system (MacLab 8e, ADI Instruments, Hastings, U.K.) installed on an IBM compatible computer. The right jugular vein was then cannulated for the administration of drugs and saline. A para-sternal thoracotomy was then performed, using an Electrosurgery device to cauterise the intercostal arteries before cutting through three ribs. The chest was retracted and pericardium dissected from the heart. The left anterior descending (LAD) coronary artery was isolated and a snare occluder was placed around the LAD. The retractor was then removed and the animal was allowed to stabilise for 15 min. 

Coronary artery occlusion in the rat in vivo

The occluder was tightened at time 0. Ischaemia-induced arrhythmias were observed approximately 7-12 minutes into LAD-occlusion, as evidenced by transient falls in MAP (Fig 2.2.1A). After 25 min of LAD-occlusion, the occluder was released to allow reperfusion of the previously ischaemic myocardium (2 h). Reperfusion-induced arrhythmias were observed immediately upon reperfusion, as evidenced by transient falls in MAP (Fig 2.2.1B). Haemodynamic parameters were continuously monitored. Baseline readings were taken prior to treatment, and, myocardial I/R injury. The pressure rate index (PRI), a relative indicator of myocardial oxygen consumption was calculated as a product of the MAP (mmHg) and HR [beats/minute (bpm)] and expressed in mm Hg bpm x 10-3 (Baller et al., 1980). Saline was administered immediately after reperfusion and throughout reperfusion at a rate of 2 ml/kg/h.

Figure 2.2.1.	Example of chart traces recording the mean arterial pressure of a rat that underwent transient I/R injury. Chart traces demonstrating the presence of (A) ischaemia-induced arrhythmias and (B) reperfusion-induced arrhythmias as evidenced by transient falls in MAP 7-12 minutes into LAD-occlusion and immediately upon reperfusion, respectively.  

Quantification of myocardial tissue injury

At the end of the 2 h reperfusion period, the LAD was re-occluded and 1 ml of Evans Blue dye (2 % w/v) was injected into the animal, via the jugular vein. The Evans Blue dye stains the tissue it can circulate through, therefore the non-perfused vascular (occluded) tissue remains un-coloured. Each animal was killed with an over-dose of anaesthetic, the heart excised, and excess dye washed off. The heart was then sectioned into slices of 3-4 mm, the right ventricle wall was removed, and the area at risk [(AAR) – the non-perfused and, hence, non-stained myocardium] was separated from the non-ischaemic (blue) tissue. The ischaemic and non-ischaemic tissue were weighed, and the AAR expressed as a percentage of the left ventricle. The tissue from the AAR was cut into small pieces and incubated with p-nitroblue tetrazolium (NBT, 0.5 mg/ml) for 30 min at 37oC. NBT is a reducing agent that reacts with dehydrogenases present in viable (non-infarcted) tissue to produce a dark blue formazan (Nachlas & Shnitka, 1963). Infarcted tissue (non-viable) will not have dehydrogenase activity and will therefore fail to stain. The stained tissue was separated from the infarcted tissue, weighed, and the infarct size expressed as a percentage of the AAR.

Experimental design

Animals were randomised into 8 groups and were either subjected to (i) surgical procedure alone with no LAD-occlusion and reperfusion and treated with vehicle (dimethylsulphoxide [DMSO] 10 % v/v) (Sham Vehicle), or (ii) surgical procedure and LAD-occlusion and reperfusion and treated with either vehicle (‘control’ animals) or GW0742 or GW6471 (‘treated animals’). For positive control experiments an additional group of animals were also subjected to surgical procedure followed by 2 cycles of IPC (IPC – 1 cycle: 5 min ischaemia and 5 min reperfusion) followed by LAD-occlusion and reperfusion and treated with vehicle. The protocols of the 8 study groups have been displayed in Table 2.2.1. 











Table 2.2.1. Experimental design




Group	n	I (min)	R (h)	Treatment
Sham Vehicle	6	N/A	N/A	10 % DMSO (1 ml/kg, i.v. bolus)
MI Vehicle	8	25	2	10 % DMSO (1 ml/kg, i.v. bolus), 30 min prior to LAD-occlusion and at the start of reperfusion.
MI IPC	8	25	2	10 % DMSO (1 ml/kg, i.v. bolus), 30 min prior to 2 x 5 min ischaemia followed by 5 min reperfusion, prior to LAD-occlusion and at the start of reperfusion.
MI + GW0742 - 3	4	25	2	GW0742 (3 µg/kg, i.v. bolus) 30 min prior to LAD-occlusion and at the start of reperfusion.
MI + GW0742 - 30	7	25	2	GW0742 (30 µg/kg, i.v. bolus) 30 min prior to LAD-occlusion and at the start of reperfusion.
MI + GW0742 - 300	4	25	2	GW0742 (300 µg/kg, i.v. bolus) 30 min prior to LAD-occlusion and at the start of reperfusion.
MI + GW6471 + GW0742 - 30	3	25	2	GW6471 (1 mg/kg, i.v. bolus) 45 min prior to LAD-occlusion only, GW0742 (30 µg/kg, i.v. bolus) 30 min prior to LAD-occlusion and at the start of reperfusion.
MI + GW0742 – 30 REP	5	25	2	GW0742 (30 µg/kg, i.v. bolus) at the start of reperfusion only.


I = ischaemia; R = reperfusion.
NA indicates not applicable.





Western blot analysis

Briefly, heart samples were homogenised at 10 % (w/v) in a Potter Elvehjem homogeniser (Wheaton, Millville, NJ, USA) using a homogenisation buffer containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9, 1 mM MgCl2, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 1 % NP-40, 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5 mM phenylmethyl sulphonyl fluoride (PMSF), 5 g/ml aprotinin, 2.5 g/ml leupeptin. Homogenates were centrifuged at 4,000 g for 5 min at 4°C. Supernatants were removed and centrifuged at 15,000 g at 4°C for 40 min to obtain the cytosolic fraction, while pellets were suspended in an extraction buffer and centrifuged at 14,000 g at 4°C for 20 min to obtain the nuclear fraction. The protein contents were determined using a bicinchoninic acid (BCA) Protein Assay kit following the manufacturer’s directions. Samples were stored at -80°C until use.  Sixty µg of total protein was loaded. Proteins were separated by 8 % sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a polyvinyldenedifluoride (PVDF) membrane, which was then incubated with SuperBlock blocking buffer. Membranes were incubated with primary antibody (rabbit anti-PPAR, rabbit anti-total GSK-3, goat anti-pGSK-3 Ser9, rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-COX-2 and rabbit anti-iNOS). Blots were then incubated with secondary antibody conjugated with horseradish peroxidase for 30 min at room temperature and developed with the enhanced chemiluminescence detection system. The immunoreactive bands were visualised by autoradiography and the density of the bands were evaluated densitometrically using the Gel ProAnalyser 4.5, 2000 software (Media Cybernetics, Silver Spring, USA).  The membranes were stripped and incubated with -actin monoclonal antibody for 30 min and subsequently with anti-mouse antibody for 30 min, at room temperature, in order to assess gel-loading homogeneity. Relative band intensity was assessed and normalised against parallel -actin expression. In the sham group, the immunoreactive bands of the gel were respectively measured and normalized against the first immunoreactive band (standard sham sample) and the results of all the bands belonging to the same group were expressed as mean ± S.E.M. This provides S.E.M for the sham group where a value of 1 is relative to the first immunoreactive band. Each group was then adjusted against corresponding Sham-Control data to establish relative protein expression when compared to Sham-Control animals.

Materials

Unless otherwise stated, all compounds utilised in this study were obtained from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). GW0742 and GW6471 were obtained from Tocris Bioscience (Bristol, UK). Thiopentone sodium (Intraval Sodium®) was obtained from Rhône Mérieux Ltd. (Harlow, Essex, UK). All stock solutions were prepared in non-pyrogenic saline (0.9 % NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK). The BCA Protein Assay kit and SuperBlock blocking buffer were from Pierce Biotechnology Inc. (Rockford, IL, USA); PVDF was obtained from the Millipore Corporation (Bedford, Massachusetts, USA). Antibodies against pGSK-3 (Ser9), total GSK-3, ICAM-1, iNOS, PPAR-β/, anti-goat, anti-mouse and anti-rabbit Ig horseradish peroxidase-linked whole antibodies were from Santa Cruz Biotechnology (Santa Cruz, California, USA). Rabbit polyclonal antibodies against COX-2 were obtained from Cayman Chemicals (Ann Arbor, MI, USA). Antibodies against pAkt (Ser473) and total Akt were from Cell-Signalling Technology (Beverly, MA, USA). Luminol ECL detection reagents were from Amersham (Buckinghamshire, UK).

Statistical analysis

All data are presented as mean  S.E.M of n observations, where n represents the number of animals or samples studied. Haemodynamic parameters were analysed via a two-way analysis of variance (ANOVA) followed by a Bonferroni post-test. Data without repeated measurements were analysed by one-way ANOVA, followed by a Dunnett’s post hoc test for multiple comparisons. P < 0.05 was considered statistically significant. All statistical analysis was performed using GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego California USA.





2.3	Results

PPAR-β/δ expression in the rat heart

When compared to sham-operated animals, myocardial I/R (treatment with vehicle) resulted in a significant increase in the expression of PPAR-β/δ expression (P < 0.05, Fig. 2.3.1). This increase in the expression of PPAR-β/δ caused by regional myocardial I/R was not affected by treatment of I/R-animals with GW0742 (P > 0.05, Fig. 2.3.1).




Figure 2.3.1.	Western blot analysis of PPAR-/ expression in the hearts of rats that underwent transient I/R injury. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4), or 25 min ischaemia (I) and 120 min reperfusion (R) and treated with either vehicle (MI Vehicle, 10 % DMSO, n=4), or GW0742 (GW0742, 30 µg/kg, n=4) on reperfusion only. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin and normalised using the related sham-operated band.  P < 0.05 versus I/R.

Effect of regional MI and GW0742 on haemodynamic parameters

The mean baseline values of MAP in all groups of animals ranged from 119 ± 20 to 131 ± 23 mmHg, and were not significantly different between groups (P > 0.05, Table 2.3.1). When compared with sham-operated animals treated with vehicle, MI-animals treated with vehicle did not exhibit any significant changes in MAP (P > 0.05, Table 2.3.1). Pre-treatment of animals with 2 cycles of IPC before occlusion of the LAD did not exhibit any significant changes in MAP (P > 0.05, Table 2.3.1).  When compared to MI-animals treated with vehicle, MI-animals treated with GW0742 or GW6471 did also not exhibit any significant changes in MAP (P > 0.05, Table 2.3.1). 
The mean baseline values for HR in all groups of animals ranged from 406 ± 31 to 482 ± 26 bpm. When compared with the baseline values of MI-animals treated with vehicle, the baseline values of HR were significantly elevated in the MI-animals treated with GW6471 and GW0742 (P < 0.05, Table 2.3.1). However, there were no differences in HR between any of the groups studied prior to occlusion of the LAD and throughout the later part of the experiment (P > 0.05, Table 2.3.1). 
PRI, a relative indicator of myocardial oxygen consumption, was calculated as the product of MAP and HR. The mean baseline values of PRI in all groups of animals ranged from 49 ± 7 to 58 ± 8 mmHg bpm x 10-3 and were not significantly different between groups (P > 0.05, Table 2.3.1). When compared to the sham-operated animals treated with vehicle, MI-animals treated with vehicle did not exhibit any significant change in mean baseline PRI value prior to LAD-occlusion (P > 0.05, Table 2.3.1). Pre-treatment of animals with 2 cycles of IPC before occlusion of the LAD did not exhibit any significant changes in PRI (P > 0.05, Table 2.3.1). When compared to MI-animals treated with vehicle, MI-animals treated with GW0742 or GW6471 did not show any significant differences in PRI (P > 0.05, Table 2.3.1). 



Table 2.3.1. Alterations in MAP, HR and PRI

Group	-30	0	Occlusion	Reperfusion
			5	15	30	60	120
Sham Vehicle (n = 6)
MAP	131 ± 23	127 ± 21	127 ± 22	123 ± 22	114 ± 16	113 ± 19	109 ± 15
HR	442 ± 27	443 ± 13	439 ± 10	439 ± 14	418 ± 13	418 ± 29	419 ± 15 
PRI	58 ± 8	56 ± 8	56 ± 9	54 ± 9	48 ± 7	47 ± 8	45 ± 6
MI Vehicle (n = 8)
MAP	121 ± 11	111 ± 11	114 ± 12	110 ± 7	105 ± 19	93 ± 23	91 ± 16
HR	406 ± 31	414 ± 34	450 ± 47	441 ± 46 	416 ± 35	419 ± 45	419 ± 39
PRI	49 ± 7	46 ± 7	51 ± 8	48 ± 6	43 ± 8	39 ± 10	38 ± 8
MI IPC (n = 8)						
MAP	115 ± 6 	105 ± 6	115 ± 6	111 ± 7	95 ± 7	97 ± 6	101 ± 5
HR	409 ± 13	394 ± 10	415 ± 11	399 ± 12	417 ± 13	415 ± 10	419 ± 12
PRI	47 ± 2	41 ± 3	48 ± 3	44 ± 3	39 ± 3	40 ± 3	42 ± 2
MI + GW0742 – 3 (n = 4)
MAP	126 ± 20	117 ± 11	112 ± 10	116 ± 14	106 ± 7	98 ± 10	100 ± 14
HR	452 ± 15	438 ± 17	485 ± 19	463 ± 13	443 ± 25	447 ± 21	436 ± 23
PRI	57 ± 10 	51 ± 6	55 ± 6	54 ± 7	47 ± 5	44 ± 6	44 ± 8
MI + GW0742 – 30 (n = 7)
MAP	128 ± 15	121 ± 11	124 ± 10	122 ± 10	114 ± 13	105 ± 14	105 ± 11
HR	420 ± 38	415 ± 26	443 ± 29	435 ± 24	388 ± 59	414 ± 26 	427 ± 42
PRI	54 ± 11	50 ± 7	55 ± 5	53 ± 4	44 ± 8	44 ± 7	45 ± 8
MI + GW0742 – 300 (n = 4)
MAP	125 ± 14	116 ± 10	118 ± 14	116 ± 12	96 ± 21	93 ± 20	96 ± 10
HR	431 ± 21	439 ± 19	452 ± 24	442 ± 11	428 ± 8	427 ± 26	428 ± 18
PRI	54 ± 9	51 ± 6	53 ± 9	51 ± 6	41 ± 10	40 ± 11	41 ± 6
MI + GW6471 + GW0742 – 30 (n = 3)
MAP	119 ± 20	119 ± 13	120 ± 4	118 ± 4	104 ± 9	83 ± 13	65 ± 18
HR	482 ± 26	448 ± 30	476 ± 18	461 ± 21	440 ± 7	475 ± 36	428 ± 27
PRI	57 ± 8 	53 ± 4	57 ± 4	54 ± 4	46 ± 3	39 ± 9	28 ± 7
MI + GW0742 - 30 REP (n = 5)
MAP	123 ± 14	118 ± 21 	118 ± 9	103 ± 14	102 ± 17	98 ± 19	118 ± 15
 HR	434 ± 42	442 ± 52	465 ± 34	428 ± 39	406 ± 44	412 ± 59	432 ± 53
PRI	54 ± 9	52 ± 11	55 ± 5	44 ± 6	42 ± 10	41 ± 13	51 ± 11



Alterations in MAP (mmHg), HR (bpm), and PRI (mmHg bpm 10-3) in rats subjected to surgical procedure alone and treated with vehicle (Sham Vehicle, 10 % DMSO), or 25 min ischaemia and 120 min reperfusion and treated with either vehicle (MI Vehicle, 10 % DMSO), or 2 cycles of preconditioning followed by 25 min ischaemia and 120 min reperfusion and treated with vehicle (MI – IPC, 10 % DMSO), or 25 min ischaemia and 120 min reperfusion and treated with either GW0742 (MI + GW0742 - 3, 3 µg/kg), (MI + GW0742 – 30, 30 µg/kg), (MI + GW0742 – 300, 300 µg/kg), and (MI + GW6471, 1mg/kg, + GW0742 - 30, 30 µg/kg), or treated at the start of reperfusion only with GW0742 (MI + GW0742 - 30 REP, 30 µg/kg).  P < 0.05 versus MI Vehicle. 

 






















Effect on area at risk

	There was no significant difference in AAR between any of the groups studied (Table 2.3.2). 

Table 2.3.2.	List of all the experimental groups with their respective areas at risk, expressed as a percentage of the left ventricle

Group	n	Area at risk (% Left ventricle)
Sham Vehicle	6	58 ±  7
MI Vehicle	8	53 ± 6
MI IPC	8	51 ± 3
MI + GW0742 - 3	4	54 ± 7
MI + GW0742 - 30	7	51 ± 9
MI + GW0742 - 300	4	  56 ± 10
MI + GW6471 + GW0742 - 30	3	51 ± 4
MI + GW0742 - 30 REP 	5	50 ± 4


Area at risk (% of the left ventricle) in rats subjected to surgical procedure alone and treated with vehicle (Sham Vehicle, 10 % DMSO), or 25 min ischaemia and 120 min reperfusion and treated with either vehicle (MI Vehicle, 10 % DMSO), or 2 cycles of preconditioning followed by 25 min ischaemia and 120 min reperfusion and treated with vehicle (MI – IPC, 10 % DMSO), or 25 min ischaemia and 120 min reperfusion and treated with either GW0742 (MI + GW0742 - 3, 3 µg/kg), (MI + GW0742 – 30, 30 µg/kg), (MI + GW0742 – 300, 300 µg/kg), and (MI + GW6471, 1mg/kg, + GW0742 - 30, 30 µg/kg), or treated at the start of reperfusion only with GW0742 (MI + GW0742 - 30 REP, 30 µg/kg).  



Effect on infarct size

Sham-operated animals demonstrated an infarct size of approximately 6 % of AAR, this degree of injury was due to the surgical procedure of isolating and positioning the snare occluder around the LAD coronary artery. When compared with sham-operated animals treated with vehicle, MI-animals treated with vehicle demonstrated a significant increase in infarct size (P < 0.05, Fig. 2.3.2). When compared with MI-animals treated with vehicle, pre-treatment of animals with 2 cycles of IPC before occlusion of the LAD resulted in a significant reduction in infarct size of 50 % (P < 0.05, Fig 2.3.2). When compared with MI-animals treated with vehicle, administration of the low dose of the PPAR-β/δ agonist GW0742 (3 µg/kg at 30 minutes before the onset of myocardial ischaemia and on reperfusion) had no significant effect on infarct size, while a higher dose of 30 µg/kg of GW0742 caused a significant reduction in infarct size of approximately 47 % (P < 0.05, Fig 2.3.2). When compared with MI-animals treated with vehicle, administration of the highest dose of GW0742 (300 µg/kg) also caused a significant reduction in infarct size (P < 0.05, Fig 2.3.2), but the effect observed was not greater than the one afforded by 30 µg/kg of GW0742. 
Pre-treatment of rats with a selective PPAR-α antagonist GW6471 did not abolish the cardioprotective effect afforded by GW0742. Most notably, administration of GW0742 on reperfusion (no pre-treatment) resulted in a significant (approximately 53 %) reduction in infarct size when compared with MI-animals treated with vehicle (P < 0.05, Fig 2.3.2). The reduction in infarct size afforded by the administration of GW0742 on reperfusion alone was not different from the reduction in infarct size afforded by the administration of this PPAR-β/δ agonist as a pre-treatment followed by an administration on reperfusion, or with pre-treatment of animals with 2 cycles of IPC before occlusion of the LAD. Thus, a dose of 30 µg/kg of GW0742 administered on reperfusion alone was used for all mechanistic experiments.











Figure 2.3.2.	Infarct size in rats that underwent transient I/R injury. Rats were subjected to surgical procedure alone and treated with vehicle (Sham Vehicle, 10 % DMSO, n=6), or 25 min ischaemia and 120 min reperfusion and treated with either vehicle (MI Vehicle, 10 % DMSO), or 2 cycles of preconditioning followed by 25 min ischaemia and 120 min reperfusion and treated with vehicle (MI – IPC, 10 % DMSO), or 25 min ischaemia and 120 min reperfusion and treated with either GW0742 (MI + GW0742 - 3, 3 µg/kg), (MI + GW0742 – 30, 30 µg/kg), (MI + GW0742 – 300, 300 µg/kg), and (MI + GW6471, 1mg/kg, + GW0742 - 30, 30 µg/kg), or treated at the start of reperfusion only with GW0742 (MI + GW0742 - 30 REP, 30 µg/kg).  * P < 0.05 versus MI Vehicle, NS = Not Significant P > 0.05. 

Effect of GW0742 on the phosphorylation of Akt and GSK-3β in the hearts of rats that underwent transient I/R injury

When compared to sham-operated animals, myocardial I/R (treatment with vehicle) resulted in a significant decrease in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 (P < 0.05, Fig. 2.3.3A & B). Interestingly, administration of GW0742 on reperfusion alone significantly attenuated the decrease in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 caused by regional myocardial I/R (P < 0.05, Fig. 2.3.3A & B).    	

	


















Figure 2.3.3.	Effects of GW0742 on phosphorylation of Akt and GSK-3β at Ser473 and Ser9 residue in the hearts of rats that underwent transient I/R injury. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4), or 25 min ischaemia (I) and 120 min reperfusion (R) and treated with either vehicle (MI Vehicle, 10 % DMSO, n=4), or GW0742 (GW0742, 30 µg/kg, n=4) on reperfusion only. Densitometric analysis of the bands are expressed as relative optical density (O.D.) of Akt and GSK-3β phosphorylation at Ser473 and Ser9, corrected for the corresponding total Akt and GSK-3β content, respectively, and normalised using the related sham-operated band.  P < 0.05 versus I/R.






Effect of GW0742 on the nuclear translocation of the p65 NF-κB subunit in the hearts of rats that underwent transient I/R injury

When compared to sham-operated animals, myocardial I/R (treatment with vehicle) resulted in a significant increase in the nuclear translocation of the p65 NF-κB subunit (P < 0.05, Fig. 2.3.4). Interestingly, administration of GW0742 on reperfusion alone significantly attenuated the increase in the nuclear translocation of the p65 NF-κB subunit caused by regional myocardial I/R (P < 0.05, Fig. 2.3.4). 



























Figure 2.3.4.	Effects of GW0742 on NF-κB translocation in the hearts of rats that underwent transient I/R injury. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4), or 25 min ischaemia (I) and 120 min reperfusion (R) and treated with either vehicle (MI Vehicle, 10 % DMSO, n=4), or GW0742 (GW0742, 30 µg/kg, n=4) on reperfusion only. NF-κB translocation from the cytosol to the nucleus was evaluated measuring NF-κB p65 subunit levels in both cytosol and nuclear fractions and expressing the results as nucleus/cytosol ratio.  P < 0.05 versus I/R.


Effect of GW0742 on the expression of iNOS and COX-2 in the hearts of rats that underwent transient I/R injury

	When compared to sham-operated animals, myocardial I/R (treatment with vehicle) resulted in a significant increase in the expression of iNOS and COX-2 (P < 0.05, Figs. 2.3.5A & B). Interestingly, administration of GW0742 on reperfusion alone significantly attenuated the increase in the expression of iNOS and COX-2 caused by regional myocardial I/R (P < 0.05, Figs. 2.3.5A & B). 















Figure 2.3.5.	Effects of GW0742 on the expression of COX-2 and iNOS in the heart of rats that underwent transient I/R injury. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4), or 25 min ischaemia (I) and 120 min reperfusion (R) and treated with either vehicle (MI Vehicle, 10 % DMSO, n=4), or GW0742 (GW0742, 30 µg/kg, n=4) on reperfusion only. Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin contents and normalised using the related sham-operated band.  P < 0.05 versus I/R.









2.4	Discussion

Here I have demonstrated, for the first time, that acute myocardial I/R injury leads to an increase in PPAR-β/δ expression in the rat heart. This suggests a possible endogenous protective mechanism in initiating the expression of PPAR-β/δ, coinciding with a lack of an available ligand to activate the receptor and hence initiate a possible endogenous cardioprotective response. There is good evidence that the chronic, oral administration of the highly selective PPAR-β/δ agonist, GW0742, reduces infarct size in Zucker fatty rats (with obesity and dyslipidemia) when subjected to acute myocardial ischaemia and 24 h of reperfusion (Yue et al., 2008). Although GW0742 is a highly selective PPAR-β/δ agonist within the relevant EC50 range, increases in dose/concentration may result in the activation of other PPAR subtypes, PPAR-α and PPAR-γ. It is well documented that ligands of PPAR-α and -γ reduce myocardial infarct size  ADDIN EN.CITE (Wayman et al., 2002b). 
In this chapter I report that the lowest concentration (3 µg/kg) of GW0742 did not have any effect on myocardial infarct size. This result is somewhat surprising, as a dose of 3 µg/kg of GW0742 (assuming a blood volume of ~17 ml per rat) would result in a plasma concentration of 0.09 µM, which is higher than the calculated EC50 for the activation of PPAR-β/δ by GW0742 (0.03 µM)  ADDIN EN.CITE (Sznaidman et al., 2003). One possible explanation for this is that GW0742 may have a short pharmacodynamic profile which may have resulted in a reduced plasma concentration at the time of reperfusion. Therefore, a 10-fold increase in concentration (30 µg/kg) of GW0742, interestingly, demonstrated a considerable reduction in myocardial infarct size. Based on the above assumptions, this dose would have resulted in an approximate plasma concentration of 0.9 µM, which is sufficiently adequate for the activation of PPAR-β/δ (but not PPAR-α, 8.8 µM; and/or –γ, >10 µM) by GW0742. Although a 10-fold higher dose of GW0742 [e.g. 300 µg/kg; likely to result in a sufficient plasma concentration (9 µM) to activate PPAR-α] also reduced infarct size, the observed effect of this high dose was not greater than the one observed with 30 µg/kg of GW0742. As the reduction in infarct size afforded by GW0742 (30 µg/kg) was not attenuated by the selective PPAR-α antagonist, GW6471 (1 mg/kg dose resulting in a plasma concentration of 22 µM in relation to an IC50 value of 0.24 µM of GW6471), I propose that the cardioprotective effects of the acute, intravenous administration of GW0742 are secondary to the activation of PPAR-β/δ. It should be noted that the magnitude of the cardioprotective effect of GW0742 when given on reperfusion alone was similar to the one observed when GW0742 was given as a pre-treatment and then again on reperfusion. Moreover, the magnitude of the cardioprotective effect of reperfusion-alone administered GW0742 was also similar to the potent cardioprotective effect caused by preconditioning of the heart with two short cycles of regional I/R (2 cycles of 5 min I/R). Taken together, this indicates that a significant reduction in infarct size can be achieved when ligands of PPAR-β/δ are administrated on reperfusion of the previously ischemic myocardium, e.g. after thrombolysis.

What then is the mechanism(s) by which PPAR-β/δ affords this cardioprotective effect? Akt is a member of the PI3K signal transduction enzyme family, which regulate cellular activation, inflammatory responses, chemotaxis and apoptosis (Cantley, 2002). More specifically, when phosphorylated by its upstream regulator, phosphoinositide dependent kinase (PDK), Akt modulates cell survival and growth  ADDIN EN.CITE (Matsui et al., 2001). Recently, Yue and colleagues have found an association between PPAR-β/δ activation and Akt phosphorylation. They reported that chronic GW0742 treatment increased cardiac PDK and Akt phosphorylation after myocardial I/R injury (Yue et al., 2008). Several studies have reported an association between Akt phosphorylation and anti-apoptotic effects  ADDIN EN.CITE (Di-Poi et al., 2002; Letavernier et al., 2005). Moreover, anti-apoptotic effects were demonstrated by Yue and colleagues upon chronic PPAR-β/δ activation (GW0742) in association with reduced myocardial infarct size in the Zucker fatty rats (Yue et al., 2008). Here, I have demonstrated that acute administration of the PPAR-β/δ ligand GW0742 considerably attenuated the reduction in Akt phosphorylation associated with myocardial I/R injury in the rat. Therefore, I propose that PPAR-β/δ activation may afford protection against myocardial I/R injury by preventing apoptosis via activation of the PI3K to Akt signalling pathway. 
What then are the signalling events which mediate/contribute to the beneficial effects of GW0742 downstream from the activation of Akt? I believe that many of the observed beneficial effects of GW0742 in myocardial I/R injury are due to the inhibition (by activated Akt) of GSK-3β and of NF-κB. This hypothesis is based on the following findings: GSK-3β is a serine/threonine kinase that was originally recognised as a kinase that phosphorylates glycogen synthase. In contrast to most other kinases, GSK-3β is active in a resting cell state, however, it is inactivated upon the phosphorylation of Ser9. It is now believed that it is a kinase that has enzymatic activity regulated by multiple signalling pathways including the Akt pathway  ADDIN EN.CITE (Cross et al., 1995). Both in vitro and in vivo studies have established that Akt activation leads to the inactivation of GSK-3β by inducing the phosphorylation of Ser9  ADDIN EN.CITE (Cross et al., 1995; Moule et al., 1997). I report in this chapter that myocardial I/R injury leads to a decrease in the phosphorylation of GSK-3β and that this pro-inflammatory effect is prevented by GW0742. In support of my findings, Park et al. found that the PI3K/Akt signalling pathway was involved in the cardioprotective effect of the adenosine A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5’-N-methylcarboxamide against I/R injury (Park et al., 2006). Moreover, they demonstrated that the PI3K/Akt signalling pathway mediated the inhibition of GSK-3β resulting in the inhibition of the mitochondrial permeability transition pore opening at reperfusion, which is proposed to play an important role in reperfusion injury. Furthermore, Hausenloy and Yellon have also proposed that PI3K/Akt mediated inactivation of GSK-3β is critical for the prevention of myocardial reperfusion injury (Hausenloy & Yellon, 2004). Several other studies have also proposed an Akt-GSK-3β mediated mechanism in protecting against myocardial I/R injury. Nishihara et al. have proposed that Akt mediated phosphorylation of GSK-3β is one of the mechanisms behind the additional reduction in infarct size afforded by erythropoietin in ischaemic preconditioned rats  ADDIN EN.CITE (Nishihara et al., 2006). Kovacs et al. have also proposed the same mechanism responsible for the cardioprotective effects of inhibitors of poly [adenosine diphosphate (ADP)-ribose] polymerase (PARP)  ADDIN EN.CITE (Kovacs et al., 2006). 
Several studies have reported an association between GSK-3β and NF-κB activity  ADDIN EN.CITE (Dugo et al., 2005; Hoeflich et al., 2000; Schwabe & Brenner, 2002; Takada et al., 2004). For example, mice in which the gene for GSK-3β had been deleted exhibited a phenotype similar to that of mice lacking the genes involved in the activation of NF-κB, such as the NF-κB p65 subunit and the IκB kinase. Furthermore, mice with the deleted GSK-3β gene did not have any effect on TNF-α-induced IκBα (inhibitor of NF-κB transcription factors) degradation; however this did prevent NF-κB activation  ADDIN EN.CITE (Hoeflich et al., 2000). Moreover, treatment of TNF-α stimulated hepatocytes with a selective GSK-3β inhibitor resulted in a decrease of the NF-κB-dependent gene transcription  ADDIN EN.CITE (Schwabe & Brenner, 2002). This study also indicated four potential phosphorylation sites for GSK-3β on the NF-κB subunit p65. Most notably, pre-treatment of rats with a number of chemically distinct inhibitors of GSK-3β attenuated the organ injury/dysfunction caused by endotoxaemia in the rat  ADDIN EN.CITE (Dugo et al., 2005). This protective effect was associated with inhibition of the activation of NF-κB and NF-κB-dependent pro-inflammatory genes, and inhibition of GSK-3β resulted in a reduced phosphorylation of Ser536 on the NF-κB p65 subunit. Phosphorylation of Ser536 is one possible mechanism by which GSK-3β may inhibit the activation of NF-κB, however, other possible mechanisms have been suggested. For example, Takada et al. demonstrated that GSK-3β activates NF-κB by phosphorylating, and thus degrading IκBα, which is required to prevent NF-κB translocation. GSK-3β has been suggested to play a key role in NF-κB to DNA binding in the nucleus  ADDIN EN.CITE (Takada et al., 2004). More recently, a study has reported cardioprotective effects of GSK-3β inhibition in rats subjected to acute myocardial I/R injury (Gao et al., 2008). In association with a reduction in infarct size, GSK-3β inhibition suppressed NF-κB and p38 MAPK activation, and subsequent NF-κB-dependent pro-inflammatory gene transcription of TNF-α and IL-6. 
Taken together, these findings support the view that PPAR-β/δ activation (e.g. by GW0742) phosphorylates, and hence, activates the Akt pathway which in turn phosphorylates, and hence, inhibits GSK-3β presumably resulting in the inhibition of NF-κB and NF-κB-dependent pro-inflammatory gene transcription. However, further investigation is required to understand the exact molecular mechanism by which GSK-3β activates NF-κB. NF-κB is a transcriptional factor that plays an important role in regulating the transcription of a number of genes, especially those involved in producing mediators involved in local and systemic inflammation, such as cytokines, chemokines, cell adhesion molecules, apoptotic factors and other mediators (Senftleben & Karin, 2002). I report here that (i) myocardial I/R injury resulted in the nuclear translocation of the p65 NF-κB subunit indicating activation of NF-κB and (ii) that this effect was prevented in rats treated with the PPAR-β/δ ligand GW0742. In addition, myocardial I/R injury resulted in the upregulation of the expression of a number of pro-inflammatory proteins (iNOS, COX-2), the expression of which was attenuated in rats treated with the PPAR-β/δ ligand GW0742. Our hypothesis that the observed beneficial (anti-inflammatory and anti-apoptotic) effects of the PPAR-β/δ ligand GW0742 are secondary to inhibition of the activation of NF-κB (secondary to inhibition of GSK-3β) also finds support in the literature: PPAR-β/δ ligands inhibit the expression or secretion of a number of inflammatory mediators transcribed by NF-κB in a variety of cell types  ADDIN EN.CITE (Ding et al., 2006; Planavila et al., 2005; Rodriguez-Calvo et al., 2008). Furthermore, Yue and colleagues demonstrated that PPAR-β/δ activation (GW0742) substantially reduced the myocardial I/R-induced expression of IL-6, IL-8, ICAM-1 and MCP-1 (Yue et al., 2008).   
Although there is good evidence that PPAR-β/δ activation inhibits the activation of NF-κB, the mechanism(s) underlying this effect is not clear. Planavila et al. reported that L-165041-induced activation of PPAR-β/δ enhances the physical interaction between PPAR-β/δ and the p65 subunit of NF-κB, thus preventing NF-κB activation  ADDIN EN.CITE (Planavila et al., 2005), while Ding et al. reported that GW0742-induced activation of PPAR-β/δ prevented the LPS-induced degradation of IκBs, resulting in the suppression of NF-κB activation  ADDIN EN.CITE (Ding et al., 2006). Furthermore, Rodríguez-Calvo et al. demonstrated that GW501516-induced activation of PPAR-β/δ inhibited NF-κB activation by preventing the phosphorylation of the ERK1/2 pathway  ADDIN EN.CITE (Rodriguez-Calvo et al., 2008). Here I have demonstrated in a rat model of myocardial I/R injury, that GW0742-induced activation of PPAR-β/δ reduces the expression of pro-inflammatory proteins, presumably, secondary to prevention of the nuclear translocation of NF-κB. The variations in PPAR-β/δ ligands, cell types and culture conditions may contribute to the different results reported in these studies. Overall, it appears that PPAR-β/δ may inhibit NF-κB activation through a number of possible mechanisms. 

Conclusions

The results of this chapter show for the first time that when administered on reperfusion (of the previously ischaemic myocardium) the PPAR-β/δ ligand GW0742 reduces myocardial infarct size in the rat. This beneficial effect of GW0742 is associated with the activation of PPAR-β/δ, and Akt, which leads to the (i) inhibition of the activation of GSK-3β and NF-κB activity, and (ii) reduced expression of NF-κB-driven gene transcription of pro-inflammatory mediators (iNOS and COX-2). Thus, the use of selective PPAR-β/δ agonists may represent a novel therapeutic approach for the treatment of myocardial I/R injury, e.g. in patients undergoing thrombolysis or percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction.

















CHAPTER III
Protective role of Peroxisome Proliferator-Activated Receptor-β/δ in septic shock














3.1	Introduction

Septic shock results from the systemic inflammatory response to an infection and is characterised by the development of pronounced hypotension and multiple organ dysfunction. In particular, cardiac dysfunction has been reported in 40 % of patients with sepsis, and the overall mortality in septic patients that develop cardiac dysfunction rises to 70-90 %  ADDIN EN.CITE (Grocott-Mason & Shah, 1998; Parrillo et al., 1990). There is a large, unmet clinical need to find new remedies which reduce the organ (specifically cardiac) injury and dysfunction and ultimately mortality associated with septic shock and sepsis.
 
Role of PPARs in inflammation 

Ligands of PPAR-α have been shown to have anti-inflammatory properties both in vitro  ADDIN EN.CITE (Delerive et al., 1999; Poynter & Daynes, 1998) and in vivo  ADDIN EN.CITE (Cuzzocrea et al., 2004a; Lovett-Racke et al., 2004). Specifically, splenocytes from PPAR-α KO mice demonstrated a large production of IL-6 and IL-12 in association with high levels of NF-B activity in response to the endotoxin LPS  ADDIN EN.CITE (Poynter & Daynes, 1998). Moreover, aortic explants from PPAR-α KO mice have also been shown to induce an exacerbated inflammatory response to LPS as demonstrated by increased IL-6 levels which, incidently, are repressed in WT mice treated with fibrates. Fibrate treatment prevented both c-jun and p65-induced transcription of the IL-6 promoter indicating that PPAR-α activation suppresses the vascular inflammatory response by interfering with AP-1 and NF-B transcription factors  ADDIN EN.CITE (Delerive et al., 1999). 
Ligands of PPAR-γ have also been shown to have anti-inflammatory properties both in vitro  ADDIN EN.CITE (Asada et al., 2004; Jiang et al., 1998) and in vivo  ADDIN EN.CITE (Chima et al., 2008; Collin et al., 2004; Cuzzocrea et al., 2004c; Dugo et al., 2004; Genovese et al., 2005; Haraguchi et al., 2008; Kaplan et al., 2005; Liu et al., 2005b; Marzocco et al., 2005; Murch et al., 2007; Wu et al., 2009; Zingarelli et al., 2003). Specifically, ligands of PPAR-γ have been shown to reduce organ injury in animal models of LPS-induced endotoxaemia  ADDIN EN.CITE (Collin & Thiemermann, 2003; Dugo et al., 2004; Kaplan et al., 2005; Liu et al., 2005a; Wu et al., 2009). Furthermore, ligands of PPAR-γ have been shown to improve survival in rats subjected to CLP-induced polymicrobial sepsis. Moreover, hypotension and cytokine production was attenuated, in addition to the reduction in neutrophil infiltration of the lung, colon and liver. These protective effects of PPAR-γ activation were associated with the reduction in NF-B and AP-1 DNA binding in the lung and thoracic aorta  ADDIN EN.CITE (Zingarelli et al., 2003). 
The use of synthetic PPAR-β/δ agonists such as L-165041 and GW501516 have demonstrated anti-inflammatory effects in reducing renal I/R injury and preventing LPS-induced cytokine production in adipocytes  ADDIN EN.CITE (Letavernier et al., 2005; Rodriguez-Calvo et al., 2008). The recent development of a highly selective PPAR-β/δ agonist, GW0742, has led to an increasing number of studies investigating its effects in a number of inflammatory disease models. The use of GW0742 has demonstrated anti-inflammatory effects in atherosclerosis, myocardial I/R injury, gut I/R injury, acute kidney injury, spinal cord injury, lung injury, zymosan-induced multiple organ failure and brain inflammation  ADDIN EN.CITE (Di Paola et al., 2010a; Di Paola et al., 2010b; Galuppo et al., 2010; Graham et al., 2005; Haskova et al., 2008; Kalinin et al., 2009; Kapoor et al., 2010; Paterniti et al., 2010; Yue et al., 2008). However, little is known about the role of PPAR-β/δ and its endogenous ligands in animal models of septic shock and sepsis.

Models of septic shock and sepsis

LPS has been considered to contribute to, or be, the route cause of the septic shock syndrome and subsequent organ injury/dysfunction and inflammation, and has since been used extensively in many experiments to model endotoxic shock  ADDIN EN.CITE (Murch et al., 2007; Natanson et al., 1989a; Natanson et al., 1989b; Schultz & van der Poll, 2002; Suffredini et al., 1989). In particular, it has become a well recognised and applied model in mice, since i.p. injections of LPS result in significant cardiac dysfunction  ADDIN EN.CITE (Knuefermann et al., 2002; Levy & Deutschman, 2004; Nemoto et al., 2002).
The CLP model of sepsis developed by Wichterman et al. in the 1980s (Wichterman et al., 1980) presents many advantages when compared to other models of sepsis, the main advantage being its ability to closely mimic the human state during sepsis. For instance, survival curves of 6- to 16-week-old mice following CLP correlate with those of 10- to 17-year-old humans with sepsis (Turnbull et al., 2003). Moreover, much like models of peritoneal inoculation, it is a simple procedure which results in cytokine responses similar to septic patients (Remick & Ward, 2005). The CLP procedure involves ligation and subsequent puncture of the caecum, resulting in the leakage of faecal material through the peritoneum, ultimately leading to bacterial contamination and, hence, polymicrobial sepsis. Consequently, CLP is similar to a common cause of sepsis and, hence, is a well recognised and applied model of sepsis as extensively reviewed by Hubbard et al. (Hubbard et al., 2005). 

GW0742

GW0742 is a highly selective ligand for PPAR-β/δ. The dose of 30 µg/kg was selected in this investigation as the plasma concentration of the ligand at 30 µg/kg would be expected to selectively activate PPAR-β/δ without any cross-reactivity with other PPAR isoforms, this is because the plasma concentration at 30 µg/kg (900 nM) is higher than the EC50 for the activation of PPAR-β/δ (300 nM), and importantly, well below the reported EC50 values for PPAR-α (8,900 nM) and PPAR-γ (> 10,000 nM)  ADDIN EN.CITE (Graham et al., 2005; Sznaidman et al., 2003; Takata et al., 2008). In addition, acute administration of this dose of GW0742 reduces the infarct size caused by regional myocardial I/R injury as observed in chapter II (Kapoor et al., 2010). 

GSK0660

	GSK0660 (3-[[[2-Methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-2- thiophenecarboxylic acid methyl ester) is a highly selective PPAR-β/δ antagonist that binds to the LBD. The dose of 100 µg/kg was selected in this investigation based on its calculated IC50 value of (3400 nM) which is adequate to selectively inhibit PPAR-β/δ and none of the other PPAR isoforms as the IC50 values for PPAR-β/δ, PPAR-α and PPAR-γ are 155, > 10,000 and ≥ 10,000 nM, respectively  ADDIN EN.CITE (Shearer et al., 2008).





Fig 3.1.1	Chemical structure of the PPAR-β/δ antagonist GSK0660

In this chapter, I will investigate the role of PPAR-β/δ in murine models of LPS-induced endotoxaemia (leading to multiple organ injury and dysfunction) and caecal ligation and puncture (CLP)-induced polymicrobial sepsis in vivo. Specifically, I will investigate (i) the response to endotoxaemia (endpoints: cardiac and renal dysfunction, hepatic injury, lung inflammation) in PPAR-β/δ KO mice; (ii) the effects of a highly-selective PPAR-β/δ agonist, GW0742, when given alone or in the presence of GSK0660, a newly described selective PPAR-β/δ antagonist, in WT/KO-mice subjected to endotoxaemia; (iii) the effects of GW0742 (in the absence and presence of GSK0660) in a clinically relevant model of CLP-induced polymicrobial sepsis, in which survival will be monitored for 10 days; and (iv) the mechanism(s) underlying the observed beneficial effects of activation of PPAR-β/δ in sepsis [including Akt, GSK-3, ERK1/2, STAT-3, NF-B, iNOS], which are known to mediate some of the key effects of LPS in many organs including the heart.


3.2	Materials and methods 

The animal protocols followed in this study were approved by the local Animal Use and Care Committee in accordance with the derivatives of both the Home Office Guidance on the Operation of Animals (Scientific Procedures Act 1986) published by Her Majesty’s Stationary Office and the Guide for the Care and Use of Laboratory Animals of the National Research Council.

Surgical procedure and quantification of organ injury/dysfunction

This study was carried out on a total of 34 male WT and PPAR-β/δ KO mice on a C57BL/6 genetic background (generous gift from Beatrice Désvergne, University of Lausanne, Switzerland), and 125 (including 5 and 2 mortalities in the LPS-vehicle and LPS-GSK0660 groups, respectively) male C57BL/6 mice (Charles River, UK) weighing 25-30g, receiving a standard diet and water ad libitum. The PPAR-β/δ KO mice exhibited a similar phenotype to the WT mice in regards to appearance and body weight. All mice (except where stated) were anaesthetised with ketamine (100 mg/ml) and xylazine (20 mg/ml) mixture [2:1; 1.5 ml/kg, intraperitoneally (i.p.)] before sacrifice. In relevant mice, 16 h after administration of LPS (9 mg/kg i.p., a dose selected from previous experiments), cardiac function was assessed by echocardiography and/or the isolated Langendorff-perfused heart, 1 ml of blood was collected by cardiac puncture and serum values of creatinine and alanine aminotransferase (ALT) were examined as markers of renal dysfunction and hepatic injury, respectively. Additionally, lung and heart samples were taken and stored at -80oC for further analysis. 

Determination of cardiac dysfunction in vivo (Echocardiography)

At 16 h after administration of LPS, anaesthesia was induced with 3 % isoflurane and maintained at 1 % for the duration of the procedure. Two-dimensional and M-mode echocardiographic images were recorded using a Vevo-770 imaging system by a blinded operator. Two-dimensional images were recorded in parasternal long- and short-axis projections with guided M-mode recordings at the level of the papillary muscles in both views. Left ventricular cavity size and wall thickness were measured from at least three beats from each projection and averaged. Left ventricular wall thickness [interventricular septum (IVS) and posterior wall (PW) thickness], and internal dimensions at diastole and systole (LVIDd and LVIDs, respectively), and internal volumes at diastole and systole (LVVOLd and LVVOLs, respectively) were measured. Left ventricular fractional shortening (FS) [(LVIDd - LVIDs)/LVIDd] x 100, and ejection fraction (EF) [(LVVOLd - LVVOLs)/LVVOLd] x 100 were calculated from the M-mode measurements. Percent fractional area of change (FAC) was assessed with a two dimensional trace at the papillary muscle level. 

Determination of cardiac dysfunction ex vivo (isolated Langendorff-perfused heart)

At 16 h after administration of LPS, mice were anaesthetised and heparinised (heparin sodium, 100 IU/100g, i.p.). Following a thoractomy, the heart was excised and rapidly transferred to ice-cold Krebs-Henseleit buffer (KHB), containing (in mmol/L) NaCl 118, KCL 3.8, MgSO4 1.19, NaHCO3 25, CaCl2 1.25, KH2PO4 1.18, sodium pyruvate 5, and glucose 10; equilibrated with 95 % O2/ 5 % CO2 (pH 7.4). Aortic cannulation was performed (within 1 min of excision), hearts were perfused with filtered KHB, gassed continuously with 95 % O2 / 5 % CO2 and maintained at 37oC. Hearts were retrogradely perfused in a non-recirculating Langendorff mode at a constant flow. Flow was measured and could be adjusted using a flow meter to achieve a coronary perfusion pressure of 75  5 mmHg. A small water-filled polyethylene balloon was carefully inserted into the left ventricle (LV) via a small incision in the left atrium made near the opening for the pulmonary vein. Hearts were electrically paced at ~590 bpm via a silver electrode inserted into the wall of the right atrium. Hearts were allowed to stabilise for at least 10 min before any experimental protocols were carried out. Alterations in isovolumic left ventricular developed pressure (LVDP) in response to 5 μL incremental intraventricular loading of the balloon up to 50 μL (physiological range) was assessed. Pressure volume curves were generated to assess LVDP.



Caecal Ligation and Puncture

This study was carried out on 42 female, genetically heterogenous CD-1 outbred mice (female outbred CD-1 mice were included in the study in order to eliminate gender-related variability and provide a heterogenous immuno-inflammatory response) weighing 25-30g receiving a standard diet and water ad libitum. Based on previous evidence and preliminary data, I used a 20-gauge needle size and double caecal puncture technique in order to generate approximately 50 % mortality during the early phase of sepsis (first five days). The original CLP protocol introduced by Wichterman and co-workers (Wichterman et al., 1980) was followed with modifications including analgesia (buprenorphine 0.05 mg/kg s.c., twice/daily for 2 days) and anti-biotic therapy (Imipenem 0.5 mg/mouse s.c., twice daily for 3 days)  ADDIN EN.CITE (Ebong et al., 1999). Animals were monitored for 10 days for all-cause mortality and a Kaplan-Meier 10-day survival curve was generated. Experimental reproducibility was ensured by performing CLP in small sets of animals (n=5) at a time and combining the data of two separate experiments for the study. In contrast to an acute response by LPS, the CLP-induced sepsis model displays a different (slow and gradually progressing) immuno-inflammatory dynamic. Therefore, two GW0742 i.v. injections were administered to provide optimal coverage for the period of the most severe inflammatory response and mortality (typically between 6-48 h post-CLP). 

Experimental Design

Mice were allocated to the following studies receiving the relevant treatment: 

Study 1 - WT-mice injected with either vehicle (Sham) or LPS (LPS-WT) and PPAR-β/δ KO mice injected with LPS (LPS-KO) and PPAR-β/δ KO mice injected with LPS and treated with either GW0742 (30 µg/kg) 1 h after LPS, GSK0660 (100 µg/kg i.v.) 30 min prior to LPS and GW0742 1 h after LPS, or GSK0660 30 min prior to LPS. 

Study 2 - C57BL/6 mice injected with either vehicle (Sham), GW0742 1 h after LPS, GSK0660 30 min prior to LPS and GW0742 1 h after LPS, or GSK0660 30 min prior to LPS.

Study 3 - C57BL/6 mice injected with either vehicle (Sham) or LPS and treated with either vehicle (‘control’), or GW0742 1 h after LPS, GSK0660 30 min prior to LPS and GW0742 1 h after LPS, or GSK0660 30 min prior to LPS.

Study 4 - CD-1 mice were allocated to the same groups as study 3 however were injected with GW0742 6.5 and 12.5 h after CLP surgery while GSK0660 was injected 30 min prior to CLP surgery and each agonist dose.  

The protocols of the 4 study groups have been displayed in Table 3.2.1.

 































Group	n	Treatment	
1	Sham WT – Vehicle	6	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	LPS – WT	8	LPS (9 mg/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	LPS – KO 	8	LPS (9 mg/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	LPS – KO + GW0742	4	LPS (9 mg/kg, i.p. bolus), GW0742 (30 µg/kg, i.v. bolus) 1 h post LPS
	LPS – KO + GSK0660 + GW0742  	4	LPS (9 mg/kg, i.p. bolus), GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to LPS, GW0742 (30 µg/kg, i.v. bolus) 1 h post LPS
	LPS – KO + GSK0660 	4	LPS (9 mg/kg, i.p. bolus), GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to LPS
2	Sham - Vehicle  	17	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	Sham – GW0742	7	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus), GW0742 (30 µg/kg, i.v. bolus) 1 h post saline
	Sham – GSK0660 + GW0742	6	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus),  GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to saline, GW0742 (30 µg/kg, i.v. bolus) 1 h post saline
	Sham – GSK0660	10	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus),  GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to saline
Table 3.2.1. Experimental design 




Table 3.2.1 Experimental design continued.



Group	n	Treatment	
3	Sham – Vehicle   	24	Saline (vehicle for LPS, 1 ml/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	LPS – Vehicle	19	LPS (9 mg/kg, i.p. bolus),  vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	LPS – GW0742 	16	LPS (9 mg/kg, i.p. bolus),  GW0742 (30 µg/kg, i.v. bolus) 1 h post LPS
	LPS – GSK0660 + GW0742  	9	LPS (9 mg/kg, i.p. bolus), GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to LPS, GW0742 (30 µg/kg, i.v. bolus) 1 h post LPS
	LPS – GSK0660  	10	LPS (9 mg/kg, i.p. bolus), GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to LPS
4	Vehicle	11	CLP with a 20-gauge needle, vehicle (10 % DMSO, 1 ml/kg, i.v. bolus)
	GW0742 	11	CLP with a 20-gauge needle,  GW0742 (30 µg/kg, i.v. bolus) 6.5 and 12.5 h post CLP
	GSK0660 + GW0742  	10	CLP with a 20-gauge needle, GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to CLP and 6 and 12 h post CLP, GW0742 (30 µg/kg, i.v. bolus) 6.5 and 12.5 h post CLP
	GSK0660  	10	CLP with a 20-gauge needle, GSK0660 (100 µg/kg, i.v. bolus) 30 min prior to CLP and 6 and 12 h post CLP



LPS – Lipopolysaccharide, CLP – Caecal ligation and puncture


Western blot analysis

Briefly, mouse heart (left ventricle) samples were homogenised at 10 % (w/v) in a Potter-Elvehjem homogeniser (Wheaton, Millville, NJ, USA) using a homogenisation buffer containing 20 mM HEPES, pH 7.9, 1 mM MgCl2, 0.5 mM EDTA, 1 % NP-40, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, 2.5 µg/ml leupeptin. Homogenates were centrifuged at 1,000 g for 5 min at 4°C. Supernatants were removed and centrifuged at 15,000 g at 4°C for 40 min to obtain the cytosolic fraction, while pellets were suspended in an extraction buffer and centrifuged at 14,000 g at 4°C for 20 min to obtain the nuclear fraction. The protein contents were determined using a bicinchoninic acid (BCA) Protein Assay kit following the manufacturer’s directions. Samples were stored at -80°C until use.  Samples were stored at -80°C until use. Fifteen µg total proteins were loaded for Western blot experiments. Proteins were separated by 8 % sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane, which was then incubated with a primary antibody (rabbit anti-total GSK-3β, goat anti-pGSK-3β Ser9, rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-INOS, rabbit anti-NF-κB p65, rabbit anti-total ERK1/2, mouse anti-pERK1/2, rabbit anti-total STAT-3, mouse anti-pSTAT-3). Blots were then incubated with a secondary antibody conjugated with horseradish peroxidase and developed using the ECL detection system. The immunoreactive bands were visualised by autoradiography and the density of the bands was evaluated densitometrically using Gel Pro®Analyzer 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA) and optical density analysis was expressed as fold-increase versus the sham group. In the sham group, the immunoreactive bands of the gel were respectively measured and normalized against the first immunoreactive band (standard sham sample) and the results of all the bands belonging to the same group were expressed as mean ± S.E.M. This provides S.E.M for the sham group where a value of 1 is relative to the first immunoreactive band. The membranes were stripped and incubated with β-actin monoclonal antibody and subsequently with an anti-mouse antibody to assess gel-loading homogeneity. Relative band intensity was assessed and normalised against parallel β-actin expression. Each group was then adjusted against corresponding Sham-Control data to establish relative protein expression when compared to Sham-Control animals.

Myeloperoxidase (MPO) activity

Lung samples were homogenised in a solution containing 0.5 % (w/v) hexadecyltrimethyl-ammonium bromide dissolved in 10 mM potassium phosphate buffer (pH 7) and centrifuged for 30 min at 20,000g at 4°C. An aliquot of the supernatant was then allowed to react with a solution of 1.6 mM tetramethylbenzidine and 0.1 mM H2O2. The rate of change in absorbance was measured spectrophotometrically at 650 nm. MPO activity was defined as the quantity of enzyme degrading 1 µmol of peroxide per min at 37°C and was expressed in milliunits per gram of wet tissue.

Materials

GW0742 (PPAR-β/δ agonist) and GSK0660 (PPAR-β/δ antagonist) were obtained from Tocris Bioscience (Bristol, UK). E. coli LPS (serotype 0111:B4) was obtained from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). Thiopentone sodium (Intraval Sodium®) was obtained from Rhône Mérieux Ltd. (Harlow, Essex, UK). All stock solutions were prepared in non-pyrogenic saline (0.9 % NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK) or 10 % DMSO (Sigma). The BCA Protein Assay kit and SuperBlock blocking buffer were from Pierce Biotechnology Inc. (Rockford, IL, USA); PVDF was obtained from the Millipore Corporation (Bedford, Massachusetts, USA). Antibodies against pGSK-3 (Ser9), total GSK-3, iNOS, anti-goat, anti-mouse and anti-rabbit Ig horseradish peroxidase-linked whole antibodies were from Santa Cruz Biotechnology (Santa Cruz, California, USA). Antibodies against rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-NF-κB p65, rabbit anti-total ERK1/2, mouse anti-pERK1/2, rabbit anti-total STAT-3, mouse anti-pSTAT-3 were from Cell-Signalling Technology (Beverly, MA, USA). Luminol ECL detection reagents were from Amersham (Buckinghamshire, UK).

Statistical analysis

Values are expressed as mean ± S.E.M. Data without repeated measurements was assessed by one-way ANOVA, followed by a Bonferroni’s test for multiple comparison. Data of more than two groups and recorded over a range of volume (isolated Langendorff-perfused heart) was compared using repeated measures two-way ANOVA, followed by Bonferroni’s test for multiple comparison. All survival comparisons were made by the log-rank test and p values were derived from one-tailed tests. P < 0.05 was considered statistically significant. NS = not significant. All statistical analysis was performed using GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego California USA.






3.3	Results 

	Prior to sacrifice, typical characteristics of endotoxaemia were observed in the LPS-subjected mice such as shivering, ocular discharge, coat staring, diarrhoea and lethargy. Interestingly, LPS-subjected mice treated with the PPAR-β/δ agonist GW0742 demonstrated slightly less severe characteristics of endotoxaemia.   

Study 1 – Effect of PPAR-β/δ deletion on cardiac dysfunction in endotoxaemic mice assessed by echocardiography

	In order to investigate the role of PPAR-β/δ in the cardiac dysfunction caused by LPS, left ventricular structure and function were assessed using echocardiography in PPAR-β/δ WT and KO mice 16 h after injection of vehicle or LPS. Figure 3.3.1A shows representative M-mode echocardiograms of sham, WT, KO, KO + GW0742, KO + GSK0660 + GW0742, and KO + GSK0660 mice. When compared to sham-mice, WT-mice subjected to 16 h of endotoxaemia demonstrated a significant reduction in % FS, EF (P < 0.05, Fig 3.3.1B & C) and a small reduction in % FAC (P > 0.05, Fig 3.3.1D), indicating the development of cardiac dysfunction in vivo. Interestingly, PPAR-β/δ KO mice subjected to 16 h of endotoxaemia demonstrated an even greater reduction in % FS, EF and FAC (P < 0.05 when compared to WT-mice subjected to LPS, Fig 3.3.1B-D), demonstrating that the cardiac dysfunction caused by LPS is exacerbated in PPAR-β/δ KO mice. The alterations in % FS, EF and FAC (cardiac dysfunction) caused by LPS in PPAR-β/δ KO mice were not significantly different from those caused by LPS in PPAR-β/δ KO mice treated with either GW0742 or GSK0660 alone, or a combination of GSK0660 and GW0742 (P > 0.05, Fig 3.3.1B-D).


Figure 3.3.1. Study 1 – Effect of PPAR-β/δ deletion on cardiac dysfunction in endotoxaemic mice assessed by echocardiography. (A) Representative M-mode echocardiograms exhibiting the left ventricular posterior wall (lower wall), intraventricular septum (upper wall), and left ventricular cavity. Percentage (B) fractional shortening, (C) ejection fraction and (D) fractional area of change 16 h after WT mice were subjected to vehicle (Sham, saline, n=6), WT mice were subjected to LPS (WT, LPS, n=8), KO mice were subjected to LPS (KO, LPS, n=8), and KO mice were subjected to LPS and treated with either GW0742 1 h post LPS challenge (KO + GW0742, LPS, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (KO + GSK0660 + GW0742, LPS, n=4), or GSK0660 30 min prior to LPS (KO + GSK0660, LPS, n=4).  P < 0.05 versus sham, # P < 0.05 versus WT (one-way analysis of variance with Bonferroni’s post-test). NS = not significant P > 0.05.


Study 1 – Effect of PPAR-β/δ deletion on organ injury/dysfunction in endotoxaemic mice

	When compared to sham-operated mice, WT-mice subjected to LPS did not develop a significant increase in serum creatinine (Fig 3.3.2A). In contrast, PPAR-β/δ KO mice subjected to LPS demonstrated a large, significant increase in serum creatinine and, hence, renal dysfunction (P < 0.05, Fig 3.3.2A). When compared to sham-operated mice, WT-mice subjected to LPS exhibited no significant alterations in serum ALT (Fig 3.3.2B). In contrast, PPAR-β/δ KO mice subjected to LPS exhibited a significant increase in serum ALT and, hence, liver injury (P < 0.05, Fig 3.3.2B). 




Figure 3.3.2.	Study 1 – Effect of PPAR-β/δ deletion on organ injury/dysfunction in endotoxaemic mice. Serum levels of (A) creatinine and (B) alanine aminotransferase (ALT), 16 h after WT mice were subjected to vehicle (Sham, saline, n=6), WT mice were subjected to LPS (WT, LPS, n=8) and KO mice were subjected to LPS (KO, LPS, n=8).  P < 0.05 versus Sham, # P < 0.05 versus WT (one-way analysis of variance with Bonferroni’s post-test).  





Study 1 – Effect of PPAR-β/δ deletion on neutrophil infiltration in the lungs of endotoxaemic mice

Lung samples were measured for MPO activity as an indicator of polymorphonuclear leukocyte (PMN) infiltration into the lungs of endotoxaemic mice. When compared to sham-operated mice, WT-mice subjected to LPS exhibited a significant increase in lung MPO activity (P < 0.05, Fig 3.3.3). In contrast, PPAR-β/δ KO mice subjected to LPS exhibited a significantly larger increase in lung MPO activity and, hence, lung inflammation (P < 0.05, Fig 3.3.3). The alterations in MPO activity caused by LPS in PPAR-β/δ KO mice were not significantly different from those caused by LPS in PPAR-β/δ KO mice treated with either GW0742 or GSK0660 alone, or a combination of GSK0660 and GW0742 (P > 0.05, Fig 3.3.3).










Figure 3.3.3.	Study 1 – Effect of PPAR-β/δ deletion on organ injury/dysfunction in endotoxaemic mice. Myeloperoxidase (MPO) activity was measured in the lungs 16 h after WT mice were subjected to vehicle (Sham, saline, n=3), WT mice were subjected to LPS (WT, LPS, n=3) and KO mice were subjected to LPS (KO, LPS, n=3), and KO mice were subjected to LPS and treated with either GW0742 1 h post LPS challenge (KO + GW0742, LPS, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (KO + GSK0660 + GW0742, LPS, n=4), or GSK0660 30 min prior to LPS (KO + GSK0660, LPS, n=4).  P < 0.05 versus sham, # P < 0.05 versus WT (one-way analysis of variance with Bonferroni’s post-test). NS = not significant P > 0.05. 
  




Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on cardiac dysfunction in endotoxaemic mice assessed by echocardiography

Having observed the detrimental effect of PPAR-β/δ deletion on organ injury/dysfunction in endotoxaemia, the effects of the selective PPAR-β/δ agonist and antagonist GW0742 and GSK0660, respectively, were investigated in mice subjected to endotoxaemia for 16 h. Additionally, the effects of GW0742 and GSK0660 were investigated in sham-mice in order to evaluate agonist and antagonist effects in non-endotoxaemic conditions (Study 2). Figure 3.3.4A shows representative M-mode echocardiograms of sham-mice treated with vehicle, GW0742, GSK0660, or a combination of GSK0660 and GW0742. When compared to sham mice treated with vehicle, sham-mice treated with GW0742, GSK0660, or a combination of GSK0660 and GW0742 demonstrated no significant changes in % FS, EF and FAC indicating no cardiac effects of the agonist or antagonist in non-endotoxaemic conditions (P > 0.05, Figure 3.3.4B-D).
Figure 3.3.5A shows representative M-mode echocardiograms of sham-mice and LPS-mice treated with vehicle, GW0742, GSK0660, or a combination of GSK0660 and GW0742 (Study 3). When compared to sham-mice, mice subjected to LPS demonstrated a significant decrease in % FS, EF and FAC indicating the development of a significant degree of cardiac dysfunction in vivo (P < 0.05, Fig 3.3.5B-D). Administration of GW0742 significantly attenuated the decrease in FS, EF and FAC and, hence, the cardiac dysfunction caused by endotoxaemia (P < 0.05, Fig 3.3.5B-D). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the beneficial effects of GW0742 were abolished (P < 0.05, Fig 3.3.5B-D).



Figure 3.3.4.	Study 2 – Effect of the PPAR- β/δ agonist GW0742 and antagonist GSK0660 on cardiac function in non-endotoxaemic mice assessed by echocardiography. (A) Representative M-mode echocardiograms exhibiting the left ventricular posterior wall (lower wall), intraventricular septum (upper wall), and left ventricular cavity. Percentage (B) fractional shortening, (C) ejection fraction and (D) fractional area of change in mice 16 h after being treated with vehicle (Sham, Vehicle, n=5), GW0742 1 h post vehicle (GW0742, n=5), GSK0660 30 min prior to vehicle and GW0742 1 h post vehicle (GSK0660 + GW0742, n=6), or GSK0660 30 min prior to vehicle (GSK0660, n=5).







Figure 3.3.5.	Study 3 – Effect of the PPAR- β/δ agonist GW0742 and antagonist GSK0660 on cardiac dysfunction in endotoxaemic mice assessed by echocardiography. (A) Representative M-mode echocardiograms exhibiting the left ventricular posterior wall (lower wall), intraventricular septum (upper wall), and left ventricular cavity. Percentage (B) fractional shortening, (C) ejection fraction and (D) fractional area of change in mice 16 h after being treated with vehicle (Sham, vehicle, n=5), LPS (LPS, vehicle, n=5), GW0742 1 h post LPS challenge (LPS, GW0742, n=5), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=6), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=8).  P < 0.05 versus LPS – vehicle, ● P < 0.05 versus GW0742, ♦ P < 0.05 versus GSK0660 + GW0742 (one-way analysis of variance with Bonferroni’s post-test).








Study 3 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on cardiac dysfunction in endotoxaemic mice assessed by the isolated Langendorff-perfused heart 

To investigate whether the cardiac dysfunction observed in vivo can be confirmed in an isolated, perfused heart ex vivo (in the absence of any influences of cardiac pre- or afterload), the LPS-induced alterations in isovolumic LV developed pressure (LVDP) in response to 5 μL incremental volume-loading of the balloon was assessed 16 h after injection of vehicle or LPS. When compared to sham-mice, mice subjected to LPS demonstrated a significant cardiac dysfunction measured as a reduction in LVDP in response to 20-50 µL volume loading (P < 0.05, Fig 3.3.6). Administration of GW0742 significantly attenuated the cardiac dysfunction caused by endotoxaemia at a volume load of 20-45 µL (P < 0.05, Fig 3.3.6).  In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the beneficial effects of GW0742 were abolished at a volume load of 25-50 µL (P < 0.05, Fig 3.3.6).








Figure 3.3.6.	Study 3 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on cardiac dysfunction in endotoxaemic mice assessed by the isolated Langendorff-perfused heart. Left ventricular developed pressure generated in response to 5 μL incremental increases in balloon volume in mice 16 h after being treated with vehicle (Sham, vehicle, n=7), LPS (LPS, vehicle, n=6), GW0742 1 h post LPS challenge (LPS, GW0742, n=6), or GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=5).  P < 0.05 versus LPS – Vehicle,  P < 0.05 LPS – GW0742 versus LPS – GSK0660 + GW0742, LPS – GSK0660 (Repeated measures two-way analysis of variance with Bonferroni’s post-test).








Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on organ injury/dysfunction in endotoxaemic mice

The effects of the selective PPAR-β/δ agonist and antagonist GW0742 and GSK0660, respectively, on organ injury/dysfunction were investigated in mice subjected to endotoxaemia for 16 h. Additionally, the effects of GW0742 and GSK0660 on organ injury/dysfunction were investigated in sham-mice in order to observe agonist and antagonist effects in non-endotoxaemic conditions (Study 2). When compared to sham mice treated with vehicle, sham-mice treated with GW0742, GSK0660, or a combination of GSK0660 and GW0742 demonstrated no significant changes in serum levels of creatinine (P > 0.05, Figure 3.3.7A) and ALT (P > 0.05, Figure 3.3.7B) indicating no effects of the agonist or antagonist on the kidney and liver, respectively, in non-endotoxaemic conditions. 
When compared to sham-operated mice (Study 3), mice subjected to LPS demonstrated a significant increase in serum levels of creatinine (P < 0.05, Fig 3.3.8A). Administration of GW0742 significantly attenuated the renal dysfunction (P < 0.05, Fig 3.3.8A) caused by endotoxaemia. In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the beneficial effects of GW0742 appeared reduced (P > 0.05, Fig 3.3.8A). When compared to sham-operated mice, mice subjected to LPS and treated with either vehicle, GW0742 or GW0742 together with GSK0660 did not exhibit any significant alterations in serum ALT (Fig 3.3.8B). 










Figure 3.3.7.	Study 2 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on organ injury/dysfunction in non-endotoxaemic mice. Serum levels of (A) creatinine and (B) alanine aminotransferase (ALT) in mice 16 h after being treated with vehicle (Sham, Vehicle, n=17), GW0742 1 h post vehicle (GW0742, n=7), GSK0660 30 min prior to vehicle and GW0742 1 h post vehicle (GSK0660 + GW0742, n=6), or GSK0660 30 min prior to vehicle (GSK0660, n=10). 













Figure 3.3.8.	Study 3 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on organ injury/dysfunction in endotoxaemic mice. Serum levels of (A) creatinine and (B) alanine aminotransferase (ALT) in mice 16 h after being treated with vehicle (Sham, vehicle, n=17), LPS (LPS, vehicle, n=13), GW0742 1 h post LPS challenge (LPS, GW0742, n=10), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=5), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=5).  P < 0.05 versus LPS – Vehicle (one-way analysis of variance with Bonferroni’s post-test).















Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on neutrophil infiltration in the lungs of endotoxaemic mice

The effects of the selective PPAR-β/δ agonist and antagonist GW0742 and GSK0660, respectively, on lung MPO activity were investigated in mice subjected to endotoxaemia for 16 h. Additionally, the effects of GW0742 and GSK0660 on lung MPO activity were investigated in sham-mice in order to observe agonist and antagonist effects in non-endotoxaemic conditions (Study 2). When compared to sham mice treated with vehicle, sham-mice treated with GW0742, GSK0660, or a combination of GSK0660 and GW0742 demonstrated no significant changes in lung MPO activity (P > 0.05, Figure 3.3.9) indicating no effects of the agonist or antagonist on the lung in non-endotoxaemic conditions. 
When compared to sham-operated mice (Study 3), mice subjected to LPS demonstrated a significant increase in lung MPO activity (P < 0.05, Fig 3.3.10). GW0742 significantly attenuated the increase in MPO activity caused by endotoxaemia (P < 0.05, Fig. 3.3.10). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the beneficial effects of GW0742 were abolished (Fig 3.3.10). 



Figure 3.3.9.	Study 2 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on neutrophil infiltration in the lungs of non-endotoxaemic mice. Myeloperoxidase (MPO) activity was measured in the lungs of mice 16 h after being treated with vehicle (Sham, Vehicle, n=4), GW0742 1 h post vehicle (GW0742, n=4), GSK0660 30 min prior to vehicle and GW0742 1 h post vehicle (GSK0660 + GW0742, n=4), or GSK0660 30 min prior to vehicle (GSK0660, n=4).



Figure 3.3.10.	   Study 3 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on neutrophil infiltration in the lungs of endotoxaemic mice. Myeloperoxidase (MPO) activity was measured in the lungs of mice 16 h after being treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4).  P < 0.05 versus LPS – Vehicle, ● P < 0.05 versus GW0742, ♦ P < 0.05 versus GSK0660 + GW0742 (one-way analysis of variance with Bonferroni’s post-test).







Study 4 – Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on survival (10 days) in CLP-induced septic mice

	The murine model of CLP with fluid resuscitation and antibiotics utilised in this study offers the best possible substitute for abdominal polymicrobial human sepsis to date (Hubbard et al., 2005). Upon observation for 10 days, CLP-mice began to exhibit typical characteristics of sepsis, such as shivering, ocular discharge, coat staring, diarrhoea and lethargy, approximately 24-48 h after surgery. Interestingly, CLP-mice treated with the PPAR-β/δ agonist GW0742 demonstrated slightly less severe characteristics of sepsis.
The survival of CLP-mice treated with vehicle was 36 % after 10 days. Administration of GW0742 significantly improved 10 day survival to 82 % (P < 0.05, Fig. 3.3.11). In CLP mice pre-treated with the PPAR-β/δ antagonist GSK0660 prior to the administration of GW0742, the survival benefit of GW0742 was reduced to 60 %, while CLP-mice pre-treated with GSK0660 alone abolished all survival benefit to 40 % (Fig 3.3.11). 











Figure 3.3.11.   Study 4 – Effect of GW0742 and antagonist GSK0660 on survival (10 days) in CLP-induced septic mice. Kaplan-Meier 10-day survival curve of mice subjected to CLP with a 20-gauge needle to produce approximately 50 % mortality during the early phase of sepsis (first 5 days). All animals were analysed based on treatment with either vehicle (10 % DMSO, n=11), GW0742 6.5 and 12.5 h after CLP surgery (GW0742, n=11), GSK0660 30 min prior to CLP surgery and 6 and 12 h after CLP surgery in combination with GW0742 6.5 and 12.5 h after CLP surgery (GSK0660 + GW0742, n=10), or GSK0660 30 min prior to CLP surgery and 6 and 12 h after CLP surgery (GSK0660, n=10).  P < 0.05 versus GW0742 (all survival comparisons were made by the log-rank test and p values were derived from one-tailed tests).






Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on the phosphorylation of Akt and GSK-3β in the hearts of mice that underwent endotoxic shock

The mechanism(s) underlying the tissue and especially the cardioprotective effect of PPAR-β/δ activation was investigated by western blot analysis of the mouse heart (where I observed the most striking protective effects of GW0742). When compared to sham-operated mice, mice subjected to LPS and treated with vehicle demonstrated no change in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 (P > 0.05, Fig. 3.3.12A & B). Interestingly, GW0742 significantly increased the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 when compared to vehicle-treated LPS-mice (P < 0.05, Fig. 3.3.12A & B). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the observed effects of GW0742 on Akt and GSK-3β phosphorylation were abolished (P < 0.05, Fig 3.3.12A & B). When compared to vehicle-treated LPS-mice, PPAR-β/δ KO mice subjected to LPS demonstrated no change in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 (P > 0.05, Fig. 3.3.12A & B).










Figure 3.3.12. Effect of GW0742 and antagonist GSK0660 on the phosphorylation of (A) Akt and (B) GSK-3b on Ser473 and Ser9 residue, respectively, in the hearts of mice that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of six separate experiments in which mice were treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4), and PPAR-β/δ KO mice were treated with LPS (LPS, KO, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of Akt phosphorylation at Ser473 and GSK-3β phosphorylation at Ser9, corrected for the corresponding total Akt and GSK-3β content and normalised using the related sham band.  P < 0.05 versus vehicle, ● P < 0.05 versus GW0742, ♦ P < 0.05 versus GSK0660 + GW0742 (one-way analysis of variance with Bonferroni’s post-test).





Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on the phosphorylation of ERK1/2 in the hearts of mice that underwent endotoxic shock

When compared to sham-operated mice, mice subjected to LPS and treated with vehicle demonstrated a significant increase in the phosphorylation of ERK1/2 (P < 0.05, Fig. 3.3.13). GW0742 significantly attenuated the increase in phosphorylation of ERK1/2 caused by endotoxaemia (P < 0.05, Fig. 3.3.13). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the observed effects of GW0742 on ERK1/2 phosphorylation were abolished (P < 0.05, Fig 3.3.13). When compared to vehicle-treated LPS-mice, PPAR-β/δ KO mice subjected to LPS demonstrated no change in the phosphorylation of ERK1/2 (P > 0.05, Fig. 3.3.13).









Figure 3.3.13. Effect of GW0742 and antagonist GSK0660 on the phosphorylation of ERK1/2 in the hearts of mice that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of six separate experiments in which mice were treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4), and PPAR-β/δ KO mice were treated with LPS (LPS, KO, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of ERK1/2 phosphorylation, corrected for the corresponding total ERK1/2 content and normalised using the related sham band.  P < 0.05 versus vehicle, ● P < 0.05 versus GW0742 (one-way analysis of variance with Bonferroni’s post-test).

Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on the nuclear translocation of the p65 NF-κB subunit in the hearts of mice that underwent endotoxic shock

When compared to sham-operated mice, mice subjected to LPS and treated with vehicle demonstrated a significant increase in the nuclear translocation of the p65 NF-κB subunit (P < 0.05, Fig. 3.3.14) and, hence, activation of NF-κB. GW0742 significantly attenuated the increase in nuclear translocation of the p65 NF-κB subunit caused by endotoxaemia (P < 0.05, Fig. 3.3.14). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the observed effects of GW0742 on nuclear translocation of the p65 NF-κB subunit were abolished (P < 0.05, Fig 3.3.14). When compared to vehicle-treated LPS-mice, PPAR-β/δ KO mice subjected to LPS demonstrated no change in the nuclear translocation of the p65 NF-κB subunit (P > 0.05, Fig. 3.3.14).









Figure 3.3.14. Effect of GW0742 and antagonist GSK0660 on the nuclear translocation of the p65 NF-κB subunit in the hearts of mice that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of six separate experiments in which mice were treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4), and PPAR-β/δ KO mice were treated with LPS (LPS, KO, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of NF-κB p65 subunit levels in both cytosolic and nuclear fractions and expressed as a nucleus/cytosol ratio.  P < 0.05 versus vehicle, ● P < 0.05 versus GW0742 (one-way analysis of variance with Bonferroni’s post-test).




Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on the phosphorylation of STAT-3 in the hearts of mice that underwent endotoxic shock

When compared to sham-operated mice, mice subjected to LPS and treated with vehicle demonstrated a significant increase in the phosphorylation of STAT-3 (P < 0.05, Fig. 3.3.15). GW0742 significantly attenuated the increase in phosphorylation of STAT-3 caused by endotoxaemia (P < 0.05, Fig. 3.3.15). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the observed effects of GW0742 on STAT-3 phosphorylation were abolished (P < 0.05, Fig 3.3.15). When compared to vehicle-treated LPS-mice, PPAR-β/δ KO mice subjected to LPS demonstrated a significant increase in the phosphorylation of STAT-3 (P < 0.05, Fig. 3.3.15).









Figure 3.3.15. Effect of GW0742 and antagonist GSK0660 on the phosphorylation of STAT-3 in the hearts of mice that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of six separate experiments in which mice were treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4), and PPAR-β/δ KO mice were treated with LPS (LPS, KO, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of STAT-3 phosphorylation, corrected for the corresponding total STAT-3 content and normalised using the related sham band.  P < 0.05 versus vehicle, ● P < 0.05 versus GW0742 (one-way analysis of variance with Bonferroni’s post-test).


Effect of the PPAR-β/δ agonist GW0742 and antagonist GSK0660 on the expression of iNOS in the hearts of mice that underwent endotoxic shock

When compared to sham-operated mice, mice subjected to LPS and treated with vehicle demonstrated a significant increase in the expression of iNOS protein (P < 0.05, Fig. 3.3.16). GW0742 significantly attenuated the increase in the expression of iNOS caused by endotoxaemia (P < 0.05, Fig. 3.3.16). In mice pre-treated with the PPAR-β/δ antagonist GSK0660, the observed effects of GW0742 on iNOS expression were abolished (P < 0.05, Fig 3.3.16). When compared to vehicle-treated LPS-mice, PPAR-β/δ KO mice subjected to LPS demonstrated no change in the expression of iNOS protein (P > 0.05, Fig. 3.3.16).








Figure 3.3.16. Effect of GW0742 and antagonist GSK0660 on the expression of iNOS in the hearts of mice that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of six separate experiments in which mice were treated with vehicle (Sham, vehicle, n=4), LPS (LPS, vehicle, n=4), GW0742 1 h post LPS challenge (LPS, GW0742, n=4), GSK0660 30 min prior to LPS and GW0742 1 h post LPS (LPS, GSK0660 + GW0742, n=4), or GSK0660 30 min prior to LPS (LPS, GSK0660, n=4), and PPAR-β/δ KO mice were treated with LPS (LPS, KO, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding β-actin content and normalised using the related sham band.  P < 0.05 versus vehicle, ● P < 0.05 versus GW0742 (one-way analysis of variance with Bonferroni’s post-test).




3.4	Discussion

Sepsis is the primary cause of mortality in critically ill patients  ADDIN EN.CITE (Angus et al., 2001). Septic shock is characterised by the development of pronounced hypotension and multiple organ dysfunction. In particular, cardiac dysfunction has been consistently reported in 40 % of patients with sepsis. As a result, mortality in this patient group increases to 70-90 %  ADDIN EN.CITE (Grocott-Mason & Shah, 1998; Parrillo et al., 1990). The complex pathophysiology of sepsis is yet to be fully understood, however it is well established that it involves a systemic immune response to an infection that may lead to an excessive inflammatory response, and ultimately, multiple organ failure. The development of an appropriate pharmacological intervention for the treatment of sepsis-induced multiple organ dysfunction is proving difficult due to the complexity of the disorder. However, targeting the excessive inflammatory response is thought to be of significant importance in preventing multiple organ dysfunction. 
Chronic ligand activation of PPAR-β/δ exhibits anti-inflammatory effects in experimental models of atherosclerosis, myocardial ischaemia, acute kidney injury and acute lung injury  ADDIN EN.CITE (Graham et al., 2005; Haskova et al., 2008; Letavernier et al., 2005; Rodriguez-Calvo et al., 2008; Yue et al., 2008). However, the selective activation and subsequent role of PPAR-β/δ in experimental models of LPS-induced multiple organ failure and/or sepsis has not been investigated. Therefore, I examined the role of PPAR-β/δ in a murine model of endotoxic shock by utilising PPAR-β/δ KO mice, a selective PPAR-β/δ agonist (GW0742) and a selective PPAR-β/δ antagonist (GSK0660). The work reported in this chapter demonstrates for the first time that PPAR-β/δ deletion considerably exacerbates the cardiac dysfunction, renal dysfunction, hepatic injury and lung inflammation caused by endotoxaemia. Additionally, treatment of the PPAR-β/δ KO mice with GW0742 and GSK0660 did not have any effect on the cardiac dysfunction and lung inflammation caused by endotoxaemia, indicating the high selectivity of these compounds for PPAR-β/δ. Taken together, these findings imply that endogenous PPAR-β/δ limits the extent of organ injury/dysfunction and systemic inflammation. This hypothesis is also supported by our finding that treatment of C57/BL6-mice with the selective PPAR-β/δ agonist GW0742 attenuated the cardiac dysfunction, renal dysfunction and lung inflammation caused by endotoxaemia. These effects of GW0742 were secondary to the activation of PPAR-β/δ, as they were abolished (or significantly reduced) by the selective PPAR-β/δ antagonist GSK0660. 
Although these findings indicate that activation of PPAR-δ may be of benefit in endotoxaemia, I wished to verify this hypothesis by using a more clinically relevant model of (CLP-induced polymicrobial) sepsis in which the treatment is first administered several hours after CLP. I demonstrated that treatment of  female mice subjected to CLP with GW0742 (at 6 h and 12 h after CLP) increased 10-day survival from 36 % (vehicle-control) to 82 %; an effect which was abolished if mice were co-treated with the PPAR-β/δ antagonist GSK0660. These findings support the views that endogenous PPAR-β/δ reduces the injury and inflammation associated with endotoxaemia and, that selective ligands of PPAR-β/δ improve outcome in murine models of endotoxaemia and polymicrobial sepsis (in a gender-independent fashion). 
Notably, in both models, the protective effects of GW0742 were present when given after the onset of endotoxaemia and polymicrobial sepsis. This could be of great clinical importance, as it has been suggested that a number of therapeutic approaches for septic shock have been unsuccessful in clinical trials, as they have been given prophylactically in experimental models rather than therapeutically. Therefore, my findings, that GW0742 given after the induction of endotoxaemia and sepsis protects the organs against the associated injury and dysfunction and improves survival, respectively, suggests a broader window for the therapeutic use of GW0742 in sepsis. 

The release of Bcl-6, a transcription repressor, is considered a central mechanism to the anti-inflammatory effects of PPAR-β/δ in atherosclerosis  ADDIN EN.CITE (Fan et al., 2008; Takata et al., 2008; Wang, 2008). Bcl-6 in the resting cell forms a complex with PPAR-β/δ. When activated by ligand, PPAR-β/δ and Bcl-6 dissociate from each other, allowing the Bcl-6 then to act to suppress inflammatory responses. In this model of action, PPAR-β/δ KO mice counter-intuitively resemble ligand activation of PPAR-β/δ. As there is no PPAR-β/δ in the KO mouse, Bcl-6 remains free to act. As in our model, PPAR-β/δ KO and ligand activation do not mimic each other, and in fact oppose the effects of each other, our results point to additional major anti-inflammatory pathway(s) by which PPAR-β/δ acts. 
Akt is a member of the PI3K signal transduction enzyme family, which regulate cellular activation, inflammatory responses, chemotaxis and apoptosis  ADDIN EN.CITE (Cantley, 2002). When phosphorylated by its upstream regulator, PDK, Akt modulates cell survival and growth  ADDIN EN.CITE (Cantley, 2002). Several studies have reported an association between PPAR-β/δ and Akt phosphorylation in the regulation of cell survival. In human proximal tubular epithelial cells (HK-2) L-165041-induced PPAR-β/δ activation substantially reduced the medullary necrosis, apoptosis and inflammation caused by oxidative stress. This anti-apoptotic effect was abolished upon inhibition of the Akt signalling pathway  ADDIN EN.CITE (Letavernier et al., 2005). Activation of Akt subsequently also mediates the anti-apoptotic effects of PPAR-β/δ ligands in keratinocytes following growth factor withdrawal  ADDIN EN.CITE (Di-Poi et al., 2002). Here I demonstrate that PPAR-β/δ activation caused a pronounced increase in Akt phosphorylation. My hypothesis that the beneficial effects of the PPAR-β/δ ligand GW0742 are secondary to activation of Akt is supported by the recent findings that chronic administration of GW0742 in the rat results in PDK phosphorylation and, hence, increased Akt phosphorylation (Yue et al., 2008). Moreover, GW0742 reversed the enhanced expression of the pro-apoptotic markers, Bax and Bid, and the down-regulation of the anti-apoptotic marker, Bcl-xL, associated with myocardial ischaemia and reperfusion in the rat heart. Additionally, activation of PPAR-β/δ reduces apoptosis in colon carcinoma cells  ADDIN EN.CITE (Gupta et al., 2004), keratinocytes  ADDIN EN.CITE (Di-Poi et al., 2002), and HK-2 cells  ADDIN EN.CITE (Letavernier et al., 2005). Thus, I propose that PPAR-β/δ activation leads to phosphorylation and hence activation of Akt. Furthermore, I believe that downstream of Akt, many of the observed beneficial effects of the PPAR-β/δ agonist GW0742 in endotoxaemia may be due to the inhibition of GSK-3β and of the central pro-inflammatory transcription factor NF-κB. 
GSK-3β is a serine/threonine kinase that was originally recognised as a kinase that phosphorylates glycogen synthase. In contrast to most other kinases, GSK-3β is active in a resting cell state, however, it is inactivated by phosphorylation of Ser9. GSK-3β is regulated by multiple signalling pathways including the Akt pathway which inactivates it by causing Ser9 phosphorylation  ADDIN EN.CITE (Cross et al., 1995; Hurel et al., 1996; Moule et al., 1997). Consistent with the activation of Akt reported here, PPAR-β/δ activation caused a pronounced increase in GSK-3β phosphorylation on the Ser9 residue. Downstream of GSK-3β, several studies have now reported an association between GSK-3β and NF-κB activity in vitro  ADDIN EN.CITE (Hoeflich et al., 2000; Schwabe & Brenner, 2002; Takada et al., 2004) and in vivo  ADDIN EN.CITE (Dugo et al., 2006b; Dugo et al., 2005). NF-κB is a transcriptional factor that plays an important role in regulating the transcription of a number of genes, especially those involved in producing mediators involved in local and systemic inflammation, such as cytokines, chemokines, cell adhesion molecules, apoptotic factors and other mediators (Senftleben & Karin, 2002). Treatment of TNF-α stimulated hepatocytes with a selective GSK-3β inhibitor resulted in a decrease of the NF-κB-dependent gene transcription  ADDIN EN.CITE (Schwabe & Brenner, 2002). This study also indicated four potential phosphorylation sites for GSK-3β on the NF-κB subunit p65. Most notably, pre-treatment with a number of chemically distinct inhibitors of GSK-3β attenuates organ injury/dysfunction caused be endotoxaemia  ADDIN EN.CITE (Dugo et al., 2005; Martin et al., 2005). This protective effect was associated with inhibition of the activation of NF-κB and NF-κB-dependent pro-inflammatory genes, along with a reduced phosphorylation of Ser536 on the NF-κB p65 subunit. In addition, GSK-3β may also inhibit the activation of NF-κB by phosphorylating and, thus, degrading IκBα, which is required to prevent NF-κB translocation  ADDIN EN.CITE (Takada et al., 2004). In the heart, I show that endotoxaemia results in the nuclear translocation of the p65 NF-κB subunit and that this effect was prevented in mice treated with the PPAR-β/δ agonist GW0742. In addition, endotoxaemia resulted in the upregulation of a NF-κB target gene iNOS, and that the expression of this pro-inflammatory protein was attenuated in mice treated with the PPAR-β/δ agonist GW0742. Taken together, these findings support the view that PPAR-β/δ activation (e.g. by GW0742) could possibly phosphorylate, and hence, activate the Akt pathway which in turn could phosphorylate, and hence, inhibit GSK-3β presumably resulting in the inhibition of NF-κB and NF-κB-dependent pro-inflammatory gene transcription. However, further investigation is required to understand the exact molecular mechanism by which GSK-3β activates NF-κB.
PPAR-β/δ agonists inhibit the expression or secretion of a number of pro-inflammatory mediators transcribed by NF-κB in a variety of cell types  ADDIN EN.CITE (Ding et al., 2006; Planavila et al., 2005; Rival et al., 2002; Rodriguez-Calvo et al., 2008). Therefore, additional anti-inflammatory mechanisms may also be in place by which PPAR-β/δ acts. PPAR-β/δ activation inhibits LPS-induced IL-6 expression in adipocytes by preventing NF-κB activation via ERK1/2 activation  ADDIN EN.CITE (Rodriguez-Calvo et al., 2008). Furthermore, PPAR-β/δ activation inhibits VCAM-1 expression and MCP-1 secretion in endothelial cells by inhibiting NF-κB translocation to the nucleus  ADDIN EN.CITE (Rival et al., 2002). In rat cardiomyocytes, GW0742  ADDIN EN.CITE (Ding et al., 2006) and L-165041  ADDIN EN.CITE (Planavila et al., 2005) inhibit the LPS-induced expression of TNF-α and MCP-1; and this effect was associated with the inhibition of NF-κB. In addition to NF-B, another transcription factor, STAT-3 is known to play an important role in cell survival/apoptosis, proliferation, and inflammatory responses  ADDIN EN.CITE (Wang et al., 2007; Welte et al., 2003) in part at least by inducing the suppressor of cytokine signalling (SOC)-3 pathway. I report here that endotoxaemia lead to an increase in the phosphorylation of STAT-3, which was exacerbated in mice lacking PPAR-β/δ, and that this pro-inflammatory effect was subsequently prevented by selective PPAR-β/δ activation in WT-mice. Similarly, the PPAR-β/δ agonist GW501516 inhibits IL-6 mediated inflammatory responses and subsequent acute phase reaction in the liver by preventing the transcriptional activity of STAT-3. Moreover, it was suggested that GW501516-induced activation of PPAR-β/δ leads to a direct protein-protein interaction which inhibits the binding of STAT-3 on its responsive element within an α1-antichymotrypsin promoter (Kino et al., 2007). 
Although PPAR-β/δ activation inhibits the activation of NF-κB, the mechanisms underlying this effect are not completely clear. Planavilla et al. reported that L-165041-induced PPAR-β/δ activation enhances the physical interaction between PPAR-β/δ and the p65 subunit of NF-κB, thus preventing NF-κB activation  ADDIN EN.CITE (Planavila et al., 2005), while Ding et al. reported that GW0742-induced activation of PPAR-β/δ prevented the LPS-induced degradation of IκBs, resulting in the suppression of NF-κB activation  ADDIN EN.CITE (Ding et al., 2006). Furthermore, Rodríguez-Calvo et al. demonstrated that GW501516-induced activation of PPAR-β/δ inhibited NF-κB activation by inhibiting the MAPK-ERK1/2 pathway  ADDIN EN.CITE (Rodriguez-Calvo et al., 2008). Indeed, in a recent review by Bishop-Bailey and Bystrom, suppression of ERK1/2 activation is a common finding for PPAR-β/δ ligands, having been found in human keratinocytes, and in mouse skin, mouse macrophages, 3T3L1 adipocytes, and testicular ischaemia-reperfusion injury (Bishop-Bailey & Bystrom, 2009). Although it is not clear as to how PPAR-β/δ regulates ERK1/2, I report here that endotoxaemia lead to an increase in the phosphorylation of ERK1/2 which was prevented by selective PPAR-β/δ activation. Thus, further supporting the existence of multiple (Bcl-6 independent) anti-inflammatory pathways involved in the activation of PPAR-β/δ. 



Conclusions

The results reported in this chapter suggest for the first time that endogenous PPAR-β/δ limits the extent of organ injury/dysfunction and inflammation associated with endotoxaemia. Moreover, selective activation of PPAR-β/δ attenuated the multiple organ injury/dysfunction and improved survival when administered acutely in rodent models of endotoxaemia and polymicrobial sepsis. A cardiac dysfunction has been consistently reported in 40 % of patients with sepsis and the development of a cardiac dysfunction significantly contributes to the rise in mortality in these patients  ADDIN EN.CITE (Grocott-Mason & Shah, 1998; Parrillo et al., 1990). I demonstrate here that LPS causes a very pronounced cardiac dysfunction (e.g. a reduction of ejection fraction, fractional shortening and fractional area of change) in vivo when measured by echocardiography. The impairment in cardiac function observed by echocardiography is indeed secondary to an impairment in contractility (rather than haemodynamic factors, e.g. reduction in preload) as it can also be demonstrated in an isolated Langendorff-perfused heart ex vivo. This cardiac dysfunction was exacerbated in PPAR-β/δ KO mice and largely reduced by treatment of mice with a selective PPAR-β/δ ligand. These findings indicate for the first time that endogenous PPAR-β/δ limit the impairment in cardiac dysfunction caused by LPS and that ligands of this nuclear receptor may be useful in reducing cardiac dysfunction.
The observed beneficial effects of PPAR-β/δ activation are associated with the activation of the PI3K-Akt signalling pathway and inhibition of the MAPK-ERK1/2 signalling pathway, where Akt activation could lead to the inhibition of the activation of GSK-3β which, in conjunction with the MAPK-ERK1/2 signalling pathway, could subsequently suppress NF-κB activity, leading to reduced expression of the NF-κB-driven gene transcription of the pro-inflammatory mediator iNOS. In parallel, I have shown that PPAR-β/δ activation is also associated with the suppression of the pro-inflammatory transcription factor STAT-3 (Fig 12). However, the signalling pathway described above still require further investigation in order to determine the exact involvement of each pathway subsequent to the activation of PPAR-β/δ. Overall, the use of selective PPAR-β/δ agonists may represent a novel anti-inflammatory therapeutic approach for the treatment of sepsis, shock, and other conditions involving local and systemic inflammation.


Fig 3.4.1.  Anti-inflammatory mechanisms of PPAR-β/δ activation. The Bcl-6 independent anti-inflammatory mechanism of PPAR-β/δ activation is associated with: (i) the activation of the PI3K-Akt signalling pathway which leads to the inhibition of the activation of glycogen synthase kinase (GSK)-3β which subsequently suppresses nuclear factor (NF)-κB activity leading to reduced expression of the NF-κB-driven gene transcription of pro-inflammatory mediators, (ii) inhibition of the mitogen-activated protein kinase (MAPK)- extracellular signal-regulated kinase (ERK)1/2 signalling pathway which subsequently suppresses NF-κB activity leading to reduced expression of the NF-κB-driven gene transcription of pro-inflammatory mediators, and (iii) in parallel, PPAR-β/δ activation is also associated with the suppression of the pro-inflammatory transcription factor signal transducer and activator of transcription (STAT)-3.














CHAPTER IV
Activation of Peroxisome Proliferator-Activated Receptor-β/δ attenuates organ injury/dysfunction caused by endotoxaemia in the rat


4.1	Introduction 

In chapter III, I demonstrated for the first time that PPAR-β/δ deletion considerably exacerbates the multiple organ injury and dysfunction caused by endotoxaemia in mice, implying that endogenous PPAR-β/δ limit the extent of organ injury and dysfunction. In support of this, I demonstrated the therapeutic effect of a selective PPAR-β/δ agonist in attenuating the organ injury and dysfunction associated with endotoxaemia and improving survival in septic mice. In particular, the heart was the focus of the investigation as this is where I observed the most pronounced cardioprotective effect of PPAR-β/δ activation. 
Clinical trials testing novel interventions against septic shock often fail because preclinical studies frequently rely on intervention investigations on specific animal models. Unfortunately, different animal models of septic shock exhibit a variety in regards to disease progression. For example, I have shown that mice enter the hypodynamic phase between 16 and 18 h following an endotoxic challenge (LPS 9 mg/kg), while CLP studies report the induction of a hypodynamic phase after 20 h in mice (Yang et al., 2002). Moreover, each animal species can respond differently to the same experimental challenge. For example, C3H/HeJ mice exhibit a hyporesponsive response to LPS in regards to cardiac output, while larger animal models such as rabbits and Sprague-Dawley rats exhibit various alterations in cardiac output in response to varying doses of LPS (Fink & Heard, 1990). On the whole, investigations based on intervention therapy in septic shock are complicated by the number of different animal models and the inherent variability that occurs between different species. 
Thus, based on the findings of chapter III, I will investigate whether the protective effects of PPAR-β/δ activation can be observed in a severe acute model of endotoxaemia in a different species (rat) and whether any protective mechanism(s) afforded by GW0742 can be observed in different tissue (liver). Hence this study aims to investigate the effect of the selective PPAR-β/δ ligand, GW0742, on the (i) haemodynamic alterations, (ii) renal dysfunction, (iii) liver injury, (v) neuromuscular injury and (v) the lung inflammation caused by severe acute endotoxaemia in the rat. I will also investigate the mechanism(s) underlying any observed beneficial effects of GW0742. Specifically, I will investigate the effects of GW0742 on the endotoxaemia-induced alterations in Akt and GSK-3β phosphorylation, nuclear translocation of NF-κB, expression of the pro-inflammatory proteins iNOS, COX-2 and ICAM-1 expression, neutrophil infiltration, and apoptosis (Bcl-2 and Bid expression) in the liver. 






4.2	Materials and methods 

The animal protocols followed in this study were approved by the local Animal Use and Care Committee in accordance with the derivatives of both the Home Office Guidance on the Operation of Animals (Scientific Procedures Act 1986) published by Her Majesty’s Stationary Office and the Guide for the Care and Use of Laboratory Animals of the National Research Council.

Surgical procedure 

This study was carried out on 30 male Wistar rats (Charles River, UK) weighing 240-340g, receiving a standard diet and water ad libitum. All rats were anaesthetised with thiopentone sodium (Intraval®, 120 mg/kg, i.p.), and anaesthesia was maintained by supplementary injections of thiopentone sodium (~1-2 mg/kg/h i.v.) as required. A tracheostomy was performed to maintain airway patency and rectal temperature was maintained at 371C with a homeothermic blanket (Harvard Apparatus Limited, UK). A polyethylene catheter was positioned in the carotid artery, for measurement MAP and HR using a pressure transducer (Senso-Nor 844, Senso-Nor, Norway) and a data acquisition system (MacLab 8e, ADI instruments, UK). The jugular vein was cannulated for the administration of drugs and saline (1 ml/kg/h i.v.). A cannula was also inserted into the bladder to prevent post renal failure by facilitating urine flow. Upon completion of the surgical procedure, MAP and HR were allowed to stabilise for 20 min. 

Quantification of organ injury and dysfunction

Six h after administration of LPS, 1.5 ml of blood was collected into a serum gel S/1.3 tube from a catheter placed in the carotid artery. Blood was centrifuged for 3 min at 6000 x g at room temperature to separate serum. All serum samples were analysed within 24 h of collection by a contract laboratory for veterinary clinical chemistry (IDEXX Laboratories, UK). Serum markers were measured as indices of multiple organ injury/dysfunction:

1.	Renal dysfunction was assessed by measuring the rise in serum levels of creatinine (indicator of reduced glomerular filtration rate, and hence, renal dysfunction) and urea (indicator of impaired excretory function of the kidney and/or increased catabolism)  ADDIN EN.CITE (Thiemermann et al., 1995). 

2.	Liver injury was determined by measuring the rise in serum levels of AST (a non-specific marker enzyme of hepatocellular injury) and ALT (a specific marker enzyme for the development of cholestasis and development of hepatic parenchymal injury)  ADDIN EN.CITE (Hewett et al., 1993; Thiemermann et al., 1995).

3.	Creatine kinase (CK), an indicator of injury to the brain, heart or skeletal muscle was determined by measuring the rise in serum levels of CK  ADDIN EN.CITE (Ruetten et al., 1996).

Liver samples were excised and immediately frozen in liquid nitrogen, and stored at -80oC for western blot analysis after 90 min or 6 h of endotoxaemia, where appropriate. 

Experimental design

Animals were randomised into 5 groups and were subjected to either (i) surgical procedure alone with no LPS challenge and treated with vehicle (10 % DMSO  v/v) (Sham Vehicle), or (ii) surgical procedure and LPS challenge (6 mg/kg, i.v. bolus over 10 minutes) and treated with either vehicle (‘control’ animals) or GW0742. The protocols of the 5 study groups have been displayed in Table 4.2.1. 








Table 4.2.1	Experimental design

Group	n	Received LPS (6 mg/kg i.v. over 10 min)	Treatment
Sham Vehicle	5	-	10 % DMSO (1 ml/kg, i.v. bolus)
LPS Vehicle	8		10 % DMSO (1 ml/kg, i.v. bolus)
LPS + GW0742-Pre 30 min 	4		GW0742 (30 µg/kg, i.v. bolus), 30 min prior to LPS challenge
LPS + GW0742-Post 30 min	3		GW0742 (30 µg/kg, i.v. bolus), 30 min after LPS challenge
LPS + GW0742-Post 1 h 	7		GW0742 (30 µg/kg, i.v. bolus), 1 hour after LPS challenge

Rats were subjected to either (i) surgical procedure alone with no LPS challenge and treated with vehicle (DMSO 10 % v/v) (Sham Vehicle), or (ii) surgical procedure and LPS challenge (6 mg/kg, i.v. bolus over 10 minutes) and treated with either vehicle or GW0742 at various time points. n is the number of animals per group. 

Western blot analysis

Briefly, rat liver samples were homogenised at 10 % (w/v) in a Potter-Elvehjem homogeniser (Wheaton, Millville, NJ, USA) using a homogenisation buffer containing 20 mM HEPES, pH 7.9, 1 mM MgCl2, 0.5 mM EDTA, 1 % NP-40, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, 2.5 µg/ml leupeptin. Homogenates were centrifuged at 1,000 g for 5 min at 4°C. Supernatants were removed and centrifuged at 15,000 g at 4°C for 40 min to obtain the cytosolic fraction, while pellets were suspended in an extraction buffer and centrifuged at 14,000 g at 4°C for 20 min to obtain the nuclear fraction. The protein contents were determined using a bicinchoninic acid (BCA) Protein Assay kit following the manufacturer’s directions. Samples were stored at -80°C until use. Fifteen µg total proteins were loaded for Western blot experiments. Proteins were separated by 8 % SDS-PAGE and transferred to a PVDF membrane, which was incubated with primary antibody (rabbit anti-PPARδ, rabbit anti-Bcl-2, rabbit anti-Bax, rabbit anti-Bid, rabbit anti-total GSK-3β, goat anti-pGSK-3β Ser9, rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-COX-2, rabbit anti-iNOS and goat anti-ICAM-1). Blots were then incubated with a secondary antibody conjugated with horseradish peroxidase and developed using the ECL detection system. The immunoreactive bands were visualised by autoradiography and the density of the bands was evaluated densitometrically using Gel Pro®Analyzer 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA) and optical density analysis was expressed as fold-increase versus the sham group. In the sham group, the immunoreactive bands of the gel were respectively measured and normalized against the first immunoreactive band (standard sham sample) and the results of all the bands belonging to the same group were expressed as mean ± S.E.M. This provides S.E.M for the sham group where a value of 1 is relative to the first immunoreactive band. The membranes were stripped and incubated with β-actin monoclonal antibody and subsequently with an anti-mouse antibody to assess gel-loading homogeneity.  Relative band intensity was assessed and normalised against parallel β-actin expression. Each group was then adjusted against corresponding Sham-Control data to establish relative protein expression when compared to Sham-Control animals. 

MPO activity

Lung and liver samples were homogenised in a solution containing 0.5 % (w/v) hexadecyltrimethyl-ammonium bromide dissolved in 10 mM potassium phosphate buffer (pH 7) and centrifuged for 30 min at 20,000g at 4°C. An aliquot of the supernatant was then allowed to react with a solution of 1.6 mM tetramethylbenzidine and 0.1 mM H2O2. The rate of change in absorbance was measured spectrophotometrically at 650 nm. MPO activity was defined as the quantity of enzyme degrading 1 µmol of peroxide per min at 37°C and was expressed in milliunits per gram of wet tissue.


Materials

GW0742 (PPAR-β/δ agonist) and GSK0660 (PPAR-β/δ antagonist) were obtained from Tocris Bioscience (Bristol, UK). GW0742 is a highly selective ligand for PPAR-β/δ. The dose of 30 µg/kg was selected in this study as the plasma concentration of the ligand at 30 µg/kg would be expected to selectively activate PPAR-β/δ without any cross-reactivity with other PPAR isoforms, this is because the plasma concentration at 30 µg/kg (900 nM) is higher than the EC50 for the activation of PPAR-β/δ (300 nM), and importantly, well below the reported EC50 values for PPAR-α (8,900 nM) and PPAR-γ (>10,000 nM)  ADDIN EN.CITE (Graham et al., 2005; Sznaidman et al., 2003; Takata et al., 2008). In addition, acute administration of this dose of GW0742 reduces the infarct size caused by regional myocardial ischaemia and reperfusion (see chapter II) (Kapoor et al., 2010). GSK0660 is a highly selective antagonist for PPAR-β/δ. The dose of 1 µg/kg was selected in this study based on its calculated IC50 value of (3400 nM) which is adequate to selectively inhibit PPAR-β/δ and none of the other PPAR isoforms as the IC50 values for PPAR-β/δ, PPAR-α and PPAR-γ are 155, > 10,000 and ≥ 10,000 nM, respectively  ADDIN EN.CITE (Shearer et al., 2008). E. coli LPS (serotype 0111:B4) was obtained from Sigma-Aldrich Company Ltd. (Poole, Dorset, UK). Thiopentone sodium (Intraval Sodium®) was obtained from Rhône Mérieux Ltd. (Harlow, Essex, UK). All stock solutions were prepared in non-pyrogenic saline (0.9 % NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK) or 10 % DMSO (Sigma). The BCA Protein Assay kit and SuperBlock blocking buffer were from Pierce Biotechnology Inc. (Rockford, IL, USA); PVDF was obtained from the Millipore Corporation (Bedford, Massachusetts, USA). Antibodies against pGSK-3 (Ser9), total GSK-3, iNOS, anti-goat, anti-mouse and anti-rabbit Ig horseradish peroxidase-linked whole antibodies were from Santa Cruz Biotechnology (Santa Cruz, California, USA). Antibodies against rabbit anti-total Akt, mouse anti-pAkt Ser473, rabbit anti-NF-κB p65, rabbit anti-total ERK1/2, mouse anti-pERK1/2, rabbit anti-total STAT-3, mouse anti-pSTAT-3 were from Cell-Signalling Technology (Beverly, MA, USA). Luminol ECL detection reagents were from Amersham (Buckinghamshire, UK).

Statistical analysis

All data are presented as means ± S.E.M of n observations, where n represents the number of animals or blood samples studied. Data without repeated measurements (organ injury/dysfunction) was analysed by one-way ANOVA, followed by a Dunnett’s test for multiple comparison. Data of more than two groups and recorded over a range of time were compared using repeated measures two-way ANOVA, followed by Bonferroni’s test for multiple comparison. P < 0.05 was considered statistically significant. All statistical analysis was performed using GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego California USA.




4.3	Results 

Effect of endotoxaemia and GW0742 on haemodynamic parameters

Prior to LPS administration, mean baseline values for MAP were similar in all experimental groups ranging from 125 ± 6 to 134 ± 7 mmHg (P > 0.05, Table 4.3.1). When compared to the sham-operated rats treated with vehicle, endotoxaemic-rats treated with vehicle resulted in a significant, biphasic fall in MAP (P < 0.05, Table 4.3.1). When compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 (30 g/kg) did not cause any significant alterations in the fall in MAP caused by endotoxaemia at any time point (P > 0.05, Table 4.3.1).
Prior to LPS administration, mean baseline values for HR were similar in all experimental groups ranging from 386 ± 17 to 422 ± 14 mmHg (P > 0.05, Table 4.3.1). When compared to the sham-operated rats treated with vehicle, endotoxaemic-rats treated with vehicle resulted in a significant increase in HR at 2-5 hours post LPS (P < 0.05, Table 4.3.1). When compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 (30 g/kg) did not cause any significant alterations in the tachycardia caused by endotoxaemia at any time point (P > 0.05, Table 4.3.1).














Group	Time (min)
	0	LPS		
		20	30	90	150	210	270	330	390
Sham Vehicle (n = 5)	
MAP	134 ± 4	127 ± 6	127 ± 8	123 ± 6	120 ± 4	110 ± 5	108 ± 5	112 ± 6	112 ± 3
HR	412 ± 17	400 ± 18	397 ± 21	402 ± 17	404 ± 14	390 ± 12 	386 ± 14	401 ± 12	404 ± 9 
LPS Vehicle (n = 8)	
MAP	125 ± 6	119 ± 6	117 ± 8	85 ± 3	95 ± 3	98 ± 2	86 ± 2	77 ± 3	71 ± 5
HR	413 ± 10	416 ± 11	416 ± 12 	461 ± 7	481 ± 7	465 ± 14	450 ± 18	462 ± 18	430 ± 26
LPS + GW0742 – Pre 30 mins (n = 4)	
MAP	131 ± 5	123 ± 6	132 ± 4	108 ± 6	116 ± 6	114 ± 8	110 ± 6	104 ± 5	93 ± 8
HR	386 ± 17	406 ± 29	409 ± 30	452 ± 31	460 ± 30	452 ± 23	431 ± 29	437 ± 28	402 ± 1
LPS + GW0742 – Post 30 mins (n = 3)	
MAP	131 ± 9	129 ± 7	133 ± 10	92 ± 14	101 ± 13	107 ± 13	96 ± 13	90 ± 9	88 ± 6
HR	415 ± 12	426 ± 11	427 ± 9	463 ± 14	505 ± 15 	485 ± 28	477 ± 23	473 ± 29 	476 ± 8
LPS + GW0742 – Post 1 hr (n = 5)	
MAP	134 ± 7	131 ± 4	125 ± 6	95 ± 6	108 ± 4	109 ± 5	100 ± 6	92 ± 6	92 ± 7
HR	422 ± 14	426 ± 12	421 ± 12	458 ± 11	479 ± 13	472 ± 8	472 ± 8	480 ± 13	505 ± 10
Table 4.3.1.	Effect of GW0742 on haemodynamic parameters in rats that underwent endotoxic shock


Alterations in MAP and HR in rats subjected to i) surgical procedure alone and treated with vehicle (Sham - Vehicle, 10 % DMSO, 1 ml/kg i.v., n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS - Vehicle, 10 % DMSO, 1 ml/kg i.v., n=8), or GW0742 (30 μg/kg) 30 mins prior to LPS (LPS + GW0742 – Pre 30 mins, i.v., n=4), GW0742 30 mins post LPS (LPS + GW0742 – Post 30 mins, i.v., n=3) or GW0742 1 hour post LPS (LPS + GW0742 – Post 1 hr, i.v., n=5). ( P < 0.05 vs. LPS-Vehicle) (Repeated measures two-way analysis of variance with Bonferroni’s post-test).






PPAR-β/δ expression in the liver of rats that underwent endotoxic shock 

When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant decrease in PPAR-β/δ expression in the liver. Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly attenuated the decrease in PPAR-β/δ expression caused by endotoxaemia (P < 0.05, Fig. 4.3.1). 


Figure 4.3.1. Effects of GW0742 on the expression of PPAR-/ in the liver of rats that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 1 h post LPS (GW0742, n=5). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin and normalised using the related sham-operated band.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test). 
Effect of GW0742 on organ injury/dysfunction in rats that underwent endotoxic shock

	When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated significant increases in the serum levels of urea and creatinine (indicators of renal injury), CK (indicator of neuromuscular injury), AST and ALT (indicators of liver injury) (P < 0.05, Figs 4.3.2A-E). When compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 30 min prior to or after LPS challenge did not cause any significant changes in organ injury parameters (P > 0.05, Fig 4.3.2A-E). However, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h post LPS challenge attenuated the renal dysfunction, liver injury (P < 0.05, Figs 4.3.2A, B, D & E) and neuromuscular injury caused by endotoxaemia, although the latter effect was not significant (P > 0.05, Fig 4.3.2C). 

















Figure 4.3.2. Effects of GW0742 on the organ injury/dysfunction in rats that underwent endotoxic shock. Serum levels of (A) urea, (B) creatinine, (C) creatine kinase (CK), (D) aspartate aminotransferase (AST) and (E) alanine aminotransferase (ALT) in rats subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 (30 μg/kg) 30 mins prior to LPS (LPS + GW0742 – Pre 30 mins, i.v., n=4), GW0742 30 mins post LPS (LPS + GW0742 – Post 30 mins, i.v., n=3) or GW0742 1 hour post LPS (LPS + GW0742 – Post 1 hr, i.v., n=5).  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test).  
Effect of GW0742 on neutrophil infiltration in the lungs of rats that underwent endotoxic shock

	MPO activity was used as an indicator of PMN infiltration into the lungs of rats. When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant increase in MPO activity (P < 0.05, Fig. 4.3.3). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly attenuated the increase in MPO activity caused by endotoxaemia (P < 0.05, Fig. 4.3.3). 

Figure 4.3.3. Effects of GW0742 on myeloperoxidase activity in rats that underwent endotoxic shock. Myeloperoxidase (MPO) activity was measured in the lungs of rats that were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=4), or GW0742 1 h post LPS (GW0742, n=4). P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test). 
Effect of GW0742 on the phosphorylation of Akt and GSK-3β in the liver of rats that underwent endotoxic shock

When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant decrease in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 (P < 0.05, Fig. 4.3.4A & B). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly abolished the decrease in the phosphorylation of Akt on Ser473 and GSK-3β on Ser9 caused by endotoxaemia (P < 0.05, Fig. 4.3.4A & B).    



























Figure 4.3.4. Effects of GW0742 on the phosphorylation of (A) Akt and (B) GSK-3 on Ser473 and Ser9 residue, respectively, in the liver of rats that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 1 h post LPS (GW0742, n=5). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of Akt phosphorylation at Ser473 and GSK-3 phosphorylation at Ser9, corrected for the corresponding total Akt and GSK-3 content and normalised using the related sham-operated band.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test). 
	





Effect of GW0742 on the nuclear translocation of the p65 NF-κB subunit in the liver of rats that underwent endotoxic shock

When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant increase in the nuclear translocation of the p65 NF-κB subunit (P < 0.05, Fig. 4.3.5), and, hence, activation of NF-κB. Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly abolished the increase in the nuclear translocation of the p65 NF-κB subunit caused by endotoxaemia (P < 0.05, Fig. 4.3.5). 



Figure 4.3.5. Effects of GW0742 on the nuclear translocation of the p65 NF-κB subunit in the liver of rats that underwent endotoxic shock.  Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=4) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=4), or GW0742 1 h post LPS (GW0742, n=4). Densitometric analysis of the bands is expressed as relative optical density (O.D.) of NF-κB p65 subunit levels in both cytosolic and nuclear fractions and expressed as a nucleus/cytosol ratio.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test).

Effect of GW0742 on the expression of iNOS and COX-2 in the liver of rats that underwent endotoxic shock

	When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant increase in the expression of iNOS and COX-2 (P < 0.05, Figs. 4.3.6A & B). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly abolished the increase in the expression of iNOS and COX-2 caused by endotoxaemia (P < 0.05, Figs. 4.3.6A & B). 












Figure 4.3.6. Effects of GW0742 on the expression of (A) iNOS and (B) COX-2 expression in the liver of rats that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 1 h post LPS (GW0742, n=5). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin contents and normalised using the related sham-operated band.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test). 








Effect of GW0742 on neutrophil infiltration in the liver of rats that underwent endotoxic shock

	MPO activity was used as an indicator of PMN infiltration into liver. When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant increase in the expression of ICAM-1 (P < 0.05, Fig. 4.3.7A). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly attenuated the increase in the expression of ICAM-1 caused by endotoxaemia (P < 0.05, Fig. 4.3.7A). When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant increase in MPO activity (P < 0.05, Fig. 4.3.7B). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 significantly attenuated the increase in MPO activity caused by endotoxaemia (P < 0.05, Fig. 4.3.7B).  












Figure 4.3.7. Effects of GW0742 on neutrophil infiltration in the liver of rats that underwent endotoxic shock. (A) ICAM-1 expression and (B) MPO activity were measured in liver homogenates. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 1 h post LPS (GW0742, n=5). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin contents and normalised using the related sham-operated band.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test). 








Effect of GW0742 on the expression of Bcl-2 and Bid in the liver of rats that underwent endotoxic shock

	When compared to sham-operated rats, endotoxaemic-rats treated with vehicle demonstrated a significant decrease in the expression of the anti-apoptotic marker Bcl-2 (P < 0.05, Fig. 4.3.8A). Bid is a pro-apoptotic protein, however, unlike others, Bid activation depends on the proteolytic processing of intact Bid into truncated forms of tBid (Yi et al., 2003). Here, I demonstrate that when compared to sham-operated rats, endotoxaemic-rats treated with vehicle resulted in a significant decrease in the expression of the non-truncated form of Bid, thus suggesting its conversion to the pro-apoptotic tBid (P < 0.05, Fig. 4.3.8B). Interestingly, when compared to endotoxaemic-rats treated with vehicle, endotoxaemic-rats treated with GW0742 1 h after LPS significantly attenuated the decrease in expression of Bcl-2, and Bid, thus suggesting its prevented conversion from Bid to tBid, caused by endotoxaemia (P < 0.05, Fig. 4.3.8A & B).







Figure 4.3.8. Effects of GW0742 on the expression of markers of apoptosis, (A) Bcl-2 and (B) Bid in the liver of rats that underwent endotoxic shock. Each immunoblot is from a single experiment and is representative of three separate experiments in which rats were subjected to i) surgical procedure alone and treated with vehicle (Sham, 10 % DMSO, n=5) or ii) LPS (6 mg/kg over 10 min) and treated with either vehicle (LPS, 10 % DMSO, n=8), or GW0742 1 h post LPS (GW0742, n=5). Densitometric analysis of the bands is expressed as relative optical density (O.D.), corrected for the corresponding -actin contents and normalised using the related sham-operated band.  P < 0.05 versus LPS (one-way analysis of variance with Dunnett's post-test).









4.4	Discussion

In this chapter, I have demonstrated that the systemic administration of LPS endotoxin from Gram-negative bacteria results in considerable increases in serum levels of urea and creatinine, indicating the development of acute renal dysfunction. Moreover, administration of LPS also caused substantial increases in serum levels of the transaminases AST and ALT, indicating hepatocellular injury, and increased serum levels of CK, indicating neuromuscular injury. Additionally, administration of LPS also caused an increase in MPO activity in the lung, indicating PMN accumulation. Furthermore, administration of LPS leads to the development of a pronounced circulatory failure (hypotension and tachycardia), indicative of a systemic inflammatory response. Taken together, these findings are indicative of the development of septic shock in a 6 h model of endotoxaemia in the rat. 
I demonstrated for the first time that the acute administration of the selective PPAR-β/δ ligand GW0742 (30 μg/kg) attenuated the (i) down-regulation of PPAR-β/δ in the liver, (ii) renal dysfunction, (iii) liver injury, and (iv) lung inflammation caused by endotoxaemia for 6 h in the rat. Thus, in support of my findings in chapter III, I demonstrate for the first time that treatment with a selective PPAR-β/δ agonist reduces the multiple organ injury and dysfunction caused by endotoxaemia in the rat. Furthermore, the protective effects of GW0742 were dependent on the timing of administration as treatment with GW0742 30 min before and after the onset of endotoxaemia had no effect on organ injury and dysfunction. However, when given 1 h after the onset of endotoxaemia, GW0742 reduced the renal dysfunction, hepatic injury, and lung inflammation caused by endotoxaemia. This could be of great clinical importance, as it has been suggested that a number of therapeutic approaches for septic shock have been unsuccessful in clinical trials, as they have been given prophylactically in experimental models rather than therapeutically. Therefore, my findings, that GW0742 given after the induction of acute severe endotoxaemia protects the organs against the associated injury and dysfunction, suggests a broader window for the therapeutic use of GW0742 against septic shock.
The biphasic fall in blood pressure caused by LPS was not prevented by GW0742. This is not too surprising, as some agents which do not affect the fall in blood pressure in similar models do reduce organ injury and dysfunction  ADDIN EN.CITE (Collin et al., 2005), while others which do attenuate the fall in blood pressure do not reduce organ injury and dysfunction  ADDIN EN.CITE (Wray et al., 1998). Therefore, there is no apparent correlation between haemodynamic effects and organ function in this model.    Moreover, administration of LPS and PepG (Gram-positive bacterial component) has been reported to not result in a fall in blood pressure, but still cause a significant degree of organ injury and dysfunction  ADDIN EN.CITE (Dugo et al., 2005). There is also clinical evidence for a lack of protection against organ injury dysfunction despite improvements in blood pressure. For example, using fluid and norepinephrine to raise MAP from 65 to 85 mm Hg in septic patients does not improve the impairment in either metabolic variables, indicated by oxygen delivery, oxygen consumption or arterial lactate, or renal function, indicated by urine flow, serum creatinine and creatinine clearance  ADDIN EN.CITE (Bourgoin et al., 2005). 

What then is the mechanism by which PPAR-β/δ activation affords this organ protective effect? As mentioned in chapter III, Akt is a member of the PI3K signal transduction enzyme family, which regulate cellular activation, inflammatory responses, chemotaxis and apoptosis  ADDIN EN.CITE (Cantley, 2002). Moreover, it is reported (chapter III) and well-established that there is an association between PPAR-β/δ and Akt phosphorylation  ADDIN EN.CITE (Di-Poi et al., 2002; Letavernier et al., 2005). I report here that endotoxaemia caused a very pronounced decrease in Akt phosphorylation (measured in the liver of the rat), an effect which should drive excessive inflammation and apoptosis. Most notably, the therapeutic administration of the PPAR-β/δ agonist GW0742 abolished the reduction in Akt phosphorylation associated with endotoxaemia in the rat liver. In addition GW0742 prevented the LPS-induced (i) down-regulation of the anti-apoptotic marker, Bcl-2, and (ii) proteolytic processing of Bid to the pro-apoptotic marker tBid. My hypothesis that the beneficial effects of the PPAR-β/δ ligand GW0742 are secondary to activation of Akt finds support in the following findings: (i) Chronic administration (prior to myocardial infarction) of GW0742 in the rat results in PDK phosphorylation and, hence, increased Akt phosphorylation (Yue et al., 2008). (ii) GW0742 reverses the enhanced expression of the pro-apoptotic markers, Bax and Bid, and the down-regulation of the anti-apoptotic marker, Bcl-xL, associated with myocardial I/R injury. (iii) Activation of PPAR-β/δ reduces apoptosis in colon carcinoma cells  ADDIN EN.CITE (Gupta et al., 2004), keratinocytes  ADDIN EN.CITE (Di-Poi et al., 2002), and HK-2 cells  ADDIN EN.CITE (Letavernier et al., 2005). Thus, I propose that PPAR-β/δ activation may afford protection against endotoxaemia by inhibiting apoptosis via activation of the PI-3K to Akt signalling pathway. This is in concurrence with anti-apoptotic effects reported in colon carcinoma cells  ADDIN EN.CITE (Gupta et al., 2004), keratinocytes  ADDIN EN.CITE (Di-Poi et al., 2002), and HK-2 cells  ADDIN EN.CITE (Letavernier et al., 2005) upon the activation of PPAR-β/δ.  
What then are the signalling events which mediate the beneficial effects of GW0742 downstream from the activation of Akt? In support of my findings in chapter III, I believe that many of the observed beneficial effects of the PPAR-β/δ ligand GW0742 in endotoxaemia are due to the inhibition (by activated Akt) of GSK-3β and of NF-κB. GSK-3β is a kinase that has enzymatic activity regulated by multiple signalling pathways including the Akt pathway  ADDIN EN.CITE (Cross et al., 1995). Both in vitro and in vivo studies have established that Akt activation leads to the inactivation of GSK-3β by inducing the phosphorylation of Ser9  ADDIN EN.CITE (Cross et al., 1995; Hurel et al., 1996; Moule et al., 1997). I report here that endotoxaemia leads to a decrease in the phosphorylation of GSK-3β and that this pro-inflammatory effect is prevented by the therapeutic administration of GW0742. 
As mentioned in chapter III, several studies have reported an association between GSK-3β and NF-κB activity  ADDIN EN.CITE (Dugo et al., 2006b; Dugo et al., 2005; Hoeflich et al., 2000; Schwabe & Brenner, 2002; Takada et al., 2004). Most notably, pre-treatment of rats with a number of chemically distinct inhibitors of GSK-3β 1 h after the onset of endotoxaemia attenuates the organ injury/dysfunction caused be endotoxaemia in the rat  ADDIN EN.CITE (Dugo et al., 2005). This protective effect was associated with inhibition of the activation of NF-κB and NF-κB-dependent pro-inflammatory genes, and inhibition of GSK-3β resulted in a reduced phosphorylation of Ser536 on the NF-κB p65 subunit. Phosphorylation of Ser536 is one possible mechanism by which GSK-3β may inhibit the activation of NF-κB, however, other possible mechanisms have been suggested. For example, Takada et al demonstrated that GSK-3β activates NF-κB by phosphorylating, and thus degrading IκBα, which is required to prevent NF-κB translocation. GSK-3β has been suggested to play a key role in NF-κB to DNA binding in the nucleus  ADDIN EN.CITE (Takada et al., 2004). I therefore, investigated whether GW0742 affects the nuclear translocation and, hence, activation of NF-B. The induction of severe acute endotoxaemia resulted in the nuclear translocation of the p65 NF-κB subunit (in the liver) indicating activation of NF-κB. Therapeutic administration of GW0742 prevented the nuclear translocation of the p65 NF-κB subunit indicating the inactivation of NF-B. Taken together, these findings support the view that PPAR-β/δ activation (e.g. by GW0742) phosphorylates, and hence, activates the Akt pathway which in turn phosphorylates, and hence, inhibits GSK-3β presumably resulting in the inhibition of NF-κB and NF-κB-dependent pro-inflammatory gene transcription. However, further investigation is required to understand the exact molecular mechanism by which GSK-3β activates NF-κB. 
As stated in chapter III, PPAR-β/δ agonists inhibit the expression or secretion of a number of pro-inflammatory mediators transcribed by NF-κB in a variety of cell types  ADDIN EN.CITE (Ding et al., 2006; Planavila et al., 2005; Rival et al., 2002; Rodriguez-Calvo et al., 2008). I report here that severe acute endotoxaemia resulted in the upregulation of the expression of a number of pro-inflammatory proteins (iNOS, COX-2, ICAM-1), the expression of which was attenuated in rats treated with the PPAR-β/δ agonist GW0742. The increase in ICAM-1 expression associated with endotoxaemia also resulted in an increase in tissue (liver) MPO activity, which is a reliable indicator of neutrophil recruitment into a target tissue, and this effect was attenuated in rats treated with GW0742. Although there is good evidence that PPAR-β/δ activation inhibits the activation of NF-κB, the mechanisms underlying this effect is not clear. 
 In support of my findings in chapter III, I have demonstrated in a model of severe acute endotoxaemia that GW0742-induced activation of PPAR-β/δ reduces the expression of pro-inflammatory proteins, presumably, secondary to prevention of the nuclear translocation of NF-κB. In addition to the proposed mechanism of action suggested in chapter III, there are a number of studies that report various ways in which PPAR-β/δ can inhibit the activation of NF-B  ADDIN EN.CITE (Bishop-Bailey & Bystrom, 2009; Ding et al., 2006; Planavila et al., 2005; Rodriguez-Calvo et al., 2008). The variations in PPAR-β/δ agonists, cell types, culture conditions and length of LPS exposure may contribute to the different results reported in these studies. Overall, it appears that PPAR-β/δ may inhibit NF-κB activation through a number of possible mechanisms. 

Conclusions

I demonstrate for the first time that when administered therapeutically (after the onset of endotoxaemia), the highly selective PPAR-β/δ agonist GW0742 reduces systemic inflammation, apoptosis and multiple organ injury and dysfunction in a rat model of severe acute endotoxaemia. This beneficial effect of GW0742 is associated with the activation of PPAR-β/δ, and Akt, which leads to the (i) inhibition of the activation of GSK-3β and NF-κB activity, (ii) reduced expression of NF-κB-driven gene transcription of pro-inflammatory mediators (iNOS, COX-2 and ICAM-1), and (iii) reduced expression of apoptotic markers (Bcl-2 and Bid). Thus, the use of selective PPAR-β/δ agonists may represent a novel therapeutic approach for the therapy of sepsis, shock, and other conditions involving local and systemic inflammation.


































CHAPTER V
General discussion


 	In this thesis, I have investigated the role of PPAR-β/δ in animal models of acute myocardial I/R injury, endotoxaemia and sepsis. Specifically, I have investigated the anti-inflammatory role of PPAR-β/δ as it is well established that there is a large inflammatory response that is associated, and contributes, to the augmentation of these two diseases. 

Using a highly selective PPAR-β/δ agonist, GW0742, I have evaluated whether selective PPAR-β/δ activation attenuates the injury caused by regional myocardial I/R injury. Furthermore, I have investigated the anti-inflammatory mechanism(s) involved in the cardioprotection afforded by GW0742.
I have reported that acute myocardial I/R injury leads to an increase in PPAR-β/δ expression in the rat heart suggesting a possible endogenous protective mechanism in initiating the expression of PPAR-β/δ, coinciding with a lack of an available ligand to activate the receptor and, hence, initiate a possible endogenous cardioprotective response. I investigated whether such a PPAR-β/δ ligand could be cardioprotective. Subsequently, I demonstrated that the selective PPAR-β/δ agonist, GW0742 reduces myocardial infarct size substantially at a concentration (30 μg/kg) designed to selectively activate PPAR-β/δ and not PPAR-α (next PPAR isoform on the EC50 activation range). Moreover, the cardioprotective effects of GW0742 were solely due to the activation of PPAR-β/δ as the reduction in infarct size afforded by GW0742 was not attenuated by the selective PPAR-α antagonist, GW6471. Furthermore, the administration of GW0742 on reperfusion alone (of the previously ischaemic myocardium), resulted in the same degree of cardioprotection as when GW0742 was given as a pre-treatment and, notably, when the heart was preconditioned with short cycles of regional I/R (2 cycles of 5 min). Thus, PPAR-β/δ ligands are highly effective in reducing infarct size when administered as a pre-treatment (30 min prior to regional myocardial ischaemia) and on reperfusion, and on reperfusion alone of the previously ischaemic myocardium. This pre-treatment regimen could be of particular interest in clinical situations where the onset of ischaemic insult can be controlled, for instance during heart transplants and by-pass surgery where there is a brief period of zero blood flow to the heart, followed by reperfusion, thus resulting in I/R injury. The benefits of treatment on reperfusion alone can be translated to clinical situations such as after an episode of acute MI, for instance following thrombolysis or PTCA.
Here, I demonstrate that the cardioprotective mechanism afforded by reperfusion-administered GW0742 is associated with the activation of PPAR-β/δ, and Akt, which leads to the (i) inhibition of the activation of GSK-3β and NF-κB activity, and (ii) reduced expression of NF-κB-driven gene transcription of pro-inflammatory mediators (iNOS and COX-2). Thus, the use of selective PPAR-β/δ agonists may represent a novel therapeutic approach for the anti-inflammatory treatment of regional myocardial I/R injury, e.g. in patients undergoing thrombolysis or PTCA after acute myocardial infarction. 

In this thesis, I have also evaluated the role of PPAR-β/δ in murine models of endotoxaemia and polymicrobial sepsis with the use of PPAR-β/δ KO mice, GW0742, and a highly selective PPAR-β/δ antagonist, GSK0660. I investigated whether PPAR-β/δ activation can attenuate the multiple organ injury and dysfunction associated with endotoxaemia and improve survival in a clinically relevant model of polymicrobial sepsis. Furthermore, I have also investigated the anti-inflammatory mechanism(s) behind the protective effect of GW0742. 
I have reported for the first time that the genetic deletion of PPAR-β/δ greatly exacerbates the cardiac dysfunction, renal dysfunction, hepatic injury and lung inflammation caused by endotoxaemia in the mouse. These results imply that endogenous PPAR-β/δ limits the extent of organ injury/dysfunction and systemic inflammation. This hypothesis is supported by the finding (i) that treatment of WT mice with the PPAR-β/δ agonist, GW0742 attenuated the cardiac dysfunction, renal dysfunction and lung inflammation caused by endotoxaemia, and (ii) that the organ protective effects of GW0742 were abolished, or significantly reduced, by the recently developed selective PPAR-β/δ antagonist GSK0660. Thus, activation of PPAR-β/δ affords a protective effect against organ injury/dysfunction in endotoxic shock, in particular against the cardiac dysfunction that develops and is often lethal in septic patients. Furthermore, I also demonstrated for the first time that treatment of female CD-1 mice with GW0742, several hours after the induction of polymicrobial sepsis by CLP surgery, dramatically improved survival over 10 days. Once more, this beneficial effect of GW0742 was abolished by GSK0660 confirming that the protective effect of GW0742 was secondary to PPAR-β/δ activation. These findings demonstrate that selective ligands of PPAR-β/δ improve outcome in a model of polymicrobial sepsis which is clinically relevant as it mimics the human scenario of disease progression in sepsis. 
In this thesis, I have also demonstrated for the first time that treatment of rats with GW0742 limits the renal dysfunction, liver injury and lung inflammation caused by endotoxaemia. This protective effect of GW0742 was independent of haemodynamic effects as GW0742 had no effect on the biphasic fall in blood pressure and tachycardia caused by endotoxaemia in the rat. Instead, the beneficial effects of GW0742 in the mouse and rat model of endotoxaemia share a similar anti-inflammatory mechanism to what was demonstrated in the rat model of regional myocardial I/R injury. Therefore, I demonstrated that PPAR-β/δ activation lead to the activation of Akt, which lead to the (i) inhibition of the activation of GSK-3β and NF-κB activity, and (ii) reduced expression of NF-κB-driven gene transcription of pro-inflammatory mediators in the mouse (iNOS) and rat (iNOS, COX-2 and ICAM-1). In addition to the activation of the PI3K-Akt signalling pathway, I also demonstrated in the mouse that PPAR-β/δ activation was associated with the inhibition of the MAPK-ERK1/2 signalling pathway which can also suppress NF-B activity. Moreover, in parallel, PPAR-β/δ activation in the mouse was also associated with the suppression of another nuclear transcription factor, STAT-3 which can also drive gene transcription of pro-inflammatory mediators. Moreover, in the rat, activation of PPAR-β/δ was associated with a reduction in the expression of the apoptotic markers, Bcl-2 and Bid. Thus, I have provided evidence that GW0742 has both strong anti-inflammatory and anti-apoptotic roles in conditions of severe acute endotoxaemia which warrant further investigation into the exact anti-inflammatory mechanism(s) of PPAR-β/δ activation. In general, the use of selective PPAR-β/δ agonists may represent a novel anti-inflammatory therapeutic approach for the treatment against the systemic inflammatory response.
Notably, the protective effects of GW0742 were present when administered after the onset of endotoxaemia and polymicrobial sepsis. This could be of great clinical importance, as it has been suggested that a number of therapeutic approaches for septic shock have been unsuccessful in clinical trials, as they have been given prophylactically in experimental models rather than therapeutically. Therefore, my findings, that GW0742 given after the induction of endotoxaemia and sepsis protects the organs against the associated injury/dysfunction and improves survival, respectively, suggests a broader window for the therapeutic use of GW0742 in sepsis, shock, and other conditions involving local and systemic inflammation.

Overall, my findings in this thesis have demonstrated convincing protective effects of GW0742-induced PPAR-β/δ activation in different species (rat, mouse), different strains (PPAR-β/δ KO, C57/BL6, CD-1 mice), different gender (male, female mice) and similar signalling effects in different tissue (heart, liver). In particular, male C57/BL6 mice treated with GW0742 demonstrated protective effects against multiple organ injury/dysfunction caused by endotoxaemia. This beneficial effect of GW0742 was also seen in female CD-1 mice where survival was improved following CLP-induced polymicrobial sepsis for 10 days. It is increasingly recognised that gender differences are apparent in response to infection and sepsis. The presence of oestrogen is reported to increase immune function while testosterone is reported to suppress immune function often leading to a worsened outcome after a traumatic injury. In fact, clinical applications of gender differences are starting to occur with the generation of sex hormone-based treatments, although the large scale efficacy of these treatments is yet to be reported (Beery, 2003). Furthermore, as reviewed by Choudhry and colleagues, results collected from trauma-haemorrhage-induced sepsis experimental studies reveal that, post-injury, the suppression of immune and cardiac function is severe in males and ovariectomised females while immune and cardiac function is maintained in proestrus females (Choudhry et al., 2006). Therefore, my finding that GW0742 improves survival in female CD-1 mice following the onset of polymicrobial sepsis adds further weight to the conclusion that GW0742 offers protective effects during sepsis. 

Future work

	In the future, I would like to investigate whether PPAR-β/δ activation has an anti-inflammatory protective effect in a recovery (chronic) model of regional myocardial I/R. I would also like to fully investigate the central anti-inflammatory mechanism associated with PPAR-β/δ activation that has been demonstrated in each chapter. In particular, I would like to elucidate the exact roles of the PI3K-Akt signalling pathway, MAPK-ERK1/2 signalling pathway, GSK-3β and NF-B. I would do so by carrying out experiments, using selective inhibitors, which specifically interfere with each one of these components of the anti-inflammatory mechanism. 
	Furthermore, as I have investigated the role of PPAR-β/δ in mice and rats of various strains and gender, I would also like to investigate the effect of PPAR-β/δ activation in larger animal model of sepsis, such as a faecal peritonitis-induced model of sepsis in the pig, as the pig has inflammatory and cardiodynamic responses that are similar to humans.  
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